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Abstract 
 
Recent data show that 7.6 million Americans have survived a myocardial infarction (MI), and 5.1 
million Americans suffer from severe heart failure. Stem cell therapy has the potential to improve cardiac 
function after MI. Two promising cells for cardiovascular regeneration therapies include human 
mesenchymal stem cells (hMSCs) and pluripotent stem cell derived cardiomyocytes (hPS-CM) each with 
their own unique method for improving cardiac function post-infarct. However, a limiting factor to cell 
therapies is that the methods currently used to deliver cells to the myocardium, including intramyocardial 
injection (considered the gold standard), suffer from low retention rates. To promote localization of 
delivered cells to the infarct and increase retention rates, our lab has developed a fibrin biological suture 
that can deliver human mesenchymal stem cells (hMSCs) with an efficiency of 64% compared to just 11% 
with intramyocardial injection in the normal rat heart.  
 
In this dissertation we sought to examine the functionality of hMSC and hPS-CM seeded sutures and 
their impact on cardiovascular regeneration applications. We began by delivering hMSC seeded fibrin 
sutures to an infarcted rat heart and found that the sutures are an effective method to deliver cells to the 
infarcted myocardium and demonstrated a trend towards improved regional mechanical function in the 
infarct region over infarct alone. Next, we transitioned to using hPS-CM and developed methods to seed 
the sutures, as well as a method to measure hPS-CM contractility with high spatial and temporal 
resolution, while concurrently capturing calcium transients. This technique allowed us to examine the 
contractile behavior in terms of contractile strain and conduction velocity of hPS-CM seeded on fibrin 
microthreads over 21 days in culture. We found that the fibrin microthread is a suitable scaffold for hPS-
CM attachment and contraction and that extended culture promotes cell alignment along the length of 
the suture as well as improvements in contractile function in terms of increases in contractile strain and 
conduction velocity. Finally, we delivered the hPS-CM seeded microthreads to an uninjured rat heart and 
found a delivery efficiency of 67%. Overall, we further demonstrated the technology of the fibrin suture 
to deliver cells to an infarct as well as the ability to support the attachment, contraction and delivery of 
hPS-CM to cardiac tissue.  
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1 Overview 
1.1 Introduction 
The American Heart Association reported in the 2015 update of the heart disease and stroke statistics 
that 85.6 million Americans, over 33% of the population, exhibit a form of cardiovascular disease (CVD)1. 
In 2011, CVD was implicated in 54% of total deaths. The death rates attributable to CVD have decreased 
30% from 2001 to 2011, however there is still a 47% probability at birth of dying from a major 
cardiovascular event, compared to only 22% by cancer1. CVD is estimated to have a total direct cost of 
$320 billion, which is projected to rise to $918 billion by 20301. These statistics and findings indicate a real 
clinical need to continue to decrease the probability of death by CVD through improving treatments and 
understanding of the disease.  
Of the 85.6 million Americans who suffer from CVD, 15.5 million specifically suffer from coronary heart 
disease1. CHD results in myocardial infarction (MI) for 7.6 million Americans causing 5.7 million Americans 
to suffer from heart failure (HF) a condition characterized by the inability of the heart to pump enough 
blood to support other organs1. The number of patients with HF is expected to rise to 8.4 million 
Americans by 20302. Currently, the total cost of care for HF is $31 billion, which is expected to increase to 
$70 billion by 20302.  
The rate of hospitalizations for HF have slightly decreased over time, however, there is still a 50% 
mortality associated with HF 3 years after the first hospitalization2. The only true cure for end stage heart 
failure is a heart transplant; however, due to limited donor availability and the potential for immune 
rejection, a heart transplant is not an ideal treatment option3, 4 
Myocardial infarction occurs due to an occlusion of blood flow, caused by atherosclerosis in the 
coronary arteries. Clinically, MI is treated by resuming blood flow using drugs, catheterization techniques 
to open blocked arteries, or a coronary artery bypass graft. If treatment does not occur within the first 
30-60 minutes after an MI, irreversible damage to the myocardium can occur5. After an MI, an 
inflammatory response is initiated that promotes healing and scar formation. As the myocardium does 
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not possess a proliferative cardiomyocyte population the injured tissue is replaced with a collagenous 
scar6, 7. The replacement of healthy, contractile myocardium with non-contractile, stiff scar tissue 
ultimately decreases cardiac output, putting the patient at risk of severe heart failure.  
Current treatments for patients who have survived an MI are palliative in nature and only treat the 
symptoms. These treatments occur after the initial MI event and include aspirin, β-adrenergic blockers, 
and angiotensin-converting enzyme (ACE) inhibitors8. Further management of symptoms can be done 
through cholesterol and weight management along with exercise routines 8. These treatments may 
improve immediate symptoms, however they are unable to restore functional tissue lost during the injury.   
Consequently, researchers have investigated other therapeutic options for heart failure, such as cellular 
therapy. There are two main paradigms regarding cellular therapy for cardiac regeneration, the first is 
that the delivered cell, such as a mesenchymal stem cell, can provide a pro-healing environment for the 
heart to heal4. The second is the delivery of a contractile cell, such as a stem cell derived cardiomyocyte, 
could provide an integrative restoration in contractile function lost after an MI4. Clinical trials delivering 
bone marrow mononuclear cells, CD34+ cells, and mesenchymal stem cells have demonstrated efficacy in 
increasing cardiac function after a myocardial infarction 9. However, all cell delivery methods suffer from 
low retention (0-19%)10, 11.  
Previously, we have developed a fibrin microthread suture that can be used for efficient cell delivery to 
the myocardium12. We have shown that human mesenchymal stem cells (hMSCs) can be seeded onto the 
fibrin suture, with a loading efficiency of up to 70%, and successfully implanted into the rat heart with a 
63.6±10.6% retention12. Delivering hMSCs to an infarct area with higher efficiency may improve 
mechanical function post-infarct. Other cell types being investigated for myocardial regeneration include 
human pluripotent stem cell derived cardiomyocytes (hPS-CM). The hPS-CM is not a mature 
cardiomyocyte; however, this cell type offers more similarities to the host tissue than a MSC, which may 
allow for better functional restoration of the infarcted region13. Herein, we deliver hMSCs using the fibrin 
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microthread platform to an infarcted rat heart and assess the effect on mechanical function. Additionally, 
we examine hPS-CM seeding onto the fibrin microthreads and examine the function of seeded cells over 
time in culture. Finally, we deliver the hPS-CM seeded microthreads to an uninjured rat heart and examine 
cell retention.  
1.2 Overall goal and hypothesis 
The overall goal of this dissertation is to develop a cell seeded fiber for cardiac cellular therapy. Utilizing 
the fibrin microthread technology, we hypothesize that a fibrin suture can support human mesenchymal 
stem cell and pluripotent stem cell derived cardiomyocyte attachment and subsequent delivery to cardiac 
tissue. The expected outcome of this dissertation work is to understand the conditions necessary to seed 
hMSCs and hPS-CM onto fibrin microthreads, how the fibrin microthread mediated delivery of hMSCs 
affects mechanical function in a rat model of myocardial infarction, and to characterize the contractile 
behavior of hPS-CM seeded microthreads and their ability to be delivered to healthy cardiac tissue. The 
first portion of the dissertation work seeks to create a pro-healing environment by delivering hMSCs to 
the infarct via fibrin sutures. The second portion will assess if the fibrin microthreads are capable of 
supporting hPS-CM attachment and delivery in such a fashion that in the correct environment the cells 
can integrate into the damaged tissue and restore contractile function.  
To test this hypothesis, this proposal was divided into three specific aims comprising five objectives. We 
aim to understand hMSC attachment to fibrin sutures and subsequently deliver hMSC seeded fibrin 
sutures to a rat infarct model and examine the effects on regional mechanical function. Next, we aim to 
develop a method with high spatial and temporal resolution to concurrently measure mechanical 
contraction and calcium transient activity of hPS-CM. We aim to determine seeding parameters to allow 
hPS-CM attachment on fibrin microthreads and characterize their contractile behavior when attached to 
the fibrin microthreads. Finally, we aim to deliver hPS-CM to healthy cardiac tissue to examine retention 
of hPS-CM delivered via fibrin microthread sutures.  
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1.3 Specific Aim 1. Determine the effects of hMSCs delivered via a fibrin suture on mechanical function of 
an infarcted heart. 
Recent findings in clinical trials suggest the delivery of MSCs to an infarct will promote myocardial repair. 
However, these studies used cell delivery methods that inefficiently delivered cells to the infarcted tissue. 
In this aim we propose that the efficient delivery of hMSCs via fibrin sutures to an infarcted rat model will 
impact mechanical function post infarct.  
1.3.1 Objective 1a: Investigate cell seeding conditions to improve attachment of hMSCs onto fibrin 
microthread sutures. 
In this objective, we investigated varying seeding concentrations and seeding times of hMSCs onto the 
fibrin sutures to understand how seeding conditions affect the numbers of hMSC attached to the suture. 
The ideal seeding conditions were found to occur using 100,000 cells per suture seeded for 12-24 hours.  
1.3.2 Objective 1b: Evaluate changes in mechanical function when hMSC seeded fibrin sutures are 
implanted in the infarct zone. 
In this objective we employed fibrin sutures to deliver hMSCs to the infarct zone in a rat infarct model. 
We hypothesized that delivering hMSCs with high efficiency and targeted localization would improve 
regional mechanical function compared to the delivery of unseeded sutures and infarct alone. The results 
of the objective indicate that the delivery of hMSC seeded biological sutures exert a trend towards 
increased regional mechanical function compared to infarct alone. Additionally, histology demonstrated 
that Quantum dot loaded hMSCs remained present in the infarcted myocardium after one week and 
migrated off of the suture. The remaining suture area after 1 week was significantly increased for hMSC-
seeded sutures over unseeded sutures. As both the unseeded and hMSC-seeded suture groups had similar 
infarct sizes, the suture area being significantly increased for the hMSC-seeded group may explain the 
improvement in regional mechanical function for the hMSC-seeded group, compared to the unseeded 
group. 
1.4 Specific Aim 2. Produce and characterize contractile hPS-CM seeded fibrin microthreads.  
The discovery of iPS cells and their subsequent ability to be differentiated into contractile 
cardiomyocytes presents a new cell type to be explored for cardiovascular regeneration endeavors. In this 
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aim, we hypothesized that hPS-CM would attach to fibrin microthreads in a manner that would not inhibit 
mechanical contraction or calcium transients. In order to test this hypothesis, in objective 2a we created 
a method to near simultaneously measure and quantify mechanical contraction and calcium transients by 
applying HDM to contracting hPS-CM. In objective 2b we examined seeding conditions to allow hPS-CM 
attachment on fibrin microthreads and applied the quantification method developed in objective 2a to 
characterize the contractile behavior of hPS-CM seeded on fibrin microthreads over 21 days in culture. 
The results of this aim suggest that hPS-CM can readily adhere to fibrin microthreads, align along the 
microthreads, and maintain the ability to contract over several weeks in culture. 
1.4.1 Objective 2a: Develop a method to characterize the contractile behavior of hPS-CM  
Currently there are no existing systems to measure the simultaneous mechanical contraction and 
calcium transients of clusters of hPS-CM. In this objective we developed a method combining light and 
fluorescent microscopy to near simultaneously record brightfield and fluorescent images. Analysis of 
these high speed videos allow us to determine contractile behavior of hPS-CM in terms of contractile 
strain, beat frequency, and calcium transient waveforms. We applied our speckle tracking algorithm to 
contracting clusters of hPS-CM to determine the parameters needed to quantify contractile strain 
produced by hPS-CM. By analyzing the fluorescent channel, we are capable of producing the calcium 
transient waveform, which can be overlaid with the contractile strain waveform to examine their temporal 
relationship. 
1.4.2 Objective 2b: Produce and characterize contractile hPS-CM seeded microthreads. 
In this objective we demonstrated that higher numbers of hPS-CM attached to collagen IV coated 
microthreads, but that hPS-CM attached and contracted on fibrin only, fibronectin, and collagen IV coated 
microthreads. Next, using the method developed in objective 2a, we sought to characterize hPS-CM 
contractile behavior, in terms of contractile strain, beat frequency, contractile direction, and conduction 
velocity when adhered to the fibrin suture. No major differences were found in the contractile behaviour 
of hPS-CM seeded on coated or uncoated microthreads. Cells seeded on tissue culture plastic increased 
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beat frequency, but decreased contractile and maximum strains over 21 days. The contractile strains 
produced by hPS-CM on TCP at day 21 were significantly reduced compared to the strains hPS-CM seeded 
on microthreads produced. hPS-CM seeded on the microthreads increased beat frequency and contractile 
and maximum strains over 21 days in culture. In regards to alignment, both immunohistochemical staining 
and contraction angle indicated that the cells contracted in a manner that was more aligned to the 
microthread at later time points. Cell seeded on tissue culture plastic did not exhibit a dominate 
contraction angle over 21 days indicating that they remained unaligned in culture. Additionally, calcium 
transient analysis demonstrated a significant increase in conduction velocities of hPS-CM seeded 
microthreads up to 24.26±8.42cm/s by day 21. 
 These data indicate that major differences in contractile behaviour do not exist between cell 
seeded TCP and fibrin microthreads; however the microthread provided a scaffold for the hPS-CM to align 
along and subsequently produce higher strains over 21 days. Additionally, the contraction and alignment 
data would suggest that delivery of hPS-CM seeded microthreads to cardiac tissue should occur 14-21 
days after seeding in order to deliver a higher functioning suture. 
1.5 Specific Aim 3. Evaluate the use of fibrin microthread sutures to deliver hPS-CM to healthy cardiac 
tissue. 
In this aim we will deliver hPS-CM seeded on fibrin microthreads to cardiac tissue and assess cell 
retention at 1 hour, 8 hours, 1 day, and 3 days post-delivery. Cells were seeded and cultured for 14 days 
as described in objective 2b and delivered to an uninjured rat heart using the surgical procedure described 
in objective1b without the induction of an infarct. After the given time points, the hearts were removed, 
fixed, sectioned, stained for Ku80, and analyzed for cell retention by counting the cells in a set number of 
sections. At 1 hour, we delivered an average of 7602±2382 cells with a delivery efficiency of 67±17%, 
which was significantly higher than the average number of cells delivered at 3 days which was 185±403 
with a delivery efficiency of 1.3±3.9% (p<0.05). To understand why retention significantly decreased out 
to 3 days post-delivery sections were stained for H&E to examine cell morphology; additionally an in vitro 
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delivery assay was developed to examine apoptosis. The H&E stained sections indicated hyperchromatic 
cells and nuclear debris after 1 hour with high neutrophil infiltration after 8 hours. The apoptosis assay 
utilizing Annexin V demonstrated some apoptotic cells on control threads, however when the cell seeded 
sutures were passed through a fibrin gel the seeded cells expressed Annexin V as early as 30 minutes post-
delivery. These results indicate that the cells may be undergoing apoptosis after being stitched through 
cardiac tissue and as such, fewer cells are being retained at later time points after cell delivery. 
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2 Background  
2.1 Introduction 
2.1.1 The cardiovascular system 
The cardiovascular system is responsible for carrying nutrients and oxygen to the body while removing 
carbon dioxide and other waste products. The primary components of the cardiovascular system are the 
heart and the blood vessels. The heart is a multichamber muscular organ that serves as an 
electromechanical pump to deliver blood through the body’s vascular network. It is a dynamic organ that 
beats over 100,000 times a day resulting in over 2 billion beats in a humans lifetime1.  
There are four chambers within the human heart, the two atria are positioned superior to the two 
ventricles. An atria and a ventricle each compose the left and right side of the heart, which serve separate 
functions. The primary responsibility of the right side is to carry deoxygenated blood from the body to the 
lungs to be re-oxygenated. The left side of the heart then receives oxygenated blood from the lungs and 
delivers it to the rest of the body. Ventricular tissue is thicker than atrial tissue as atrial myocardium only 
acts to pass blood a relatively short distance to the ventricles. The left ventricle (LV) is more muscular than 
the right ventricle as the left ventricle must drive blood throughout the body, whereas the right ventricle 
pumps blood only to the lungs. 
The heart pumps blood through the body over the 
cardiac cycle, which is composed of two phases: 
diastole and systole. In diastole the ventricles fill with 
blood from the left and right atria, pressures are low 
and the volume within the ventricle increases over 
diastole as seen in part 1 of the pressure volume work 
loop in Figure 2-1. During systole pressure rises within 
the ventricles until the valves open (Figure 2-1) and 
blood is ejected out of the ventricles to the body 
Figure 2-1. Pressure volume work loop. 1- diastolic filling. 
2- isovolumic contraction, 3- ejection, 4 – isovolumic 
relaxation. Red indicates systole and blue indicates diastole. 
Arrows indicate loop direction. 
Chapter 2: Background                                                                                                                                          10 
 
(Figure 2-1). As the pressure and volume decrease in the ventricles after systole (Figure 2-1), the valves 
close until pressures are low enough to allow the valves to reopen enabling the ventricles to refill. 
The heart itself is a muscular organ that has a high metabolic demand required to sustain normal cardiac 
function. It is served by the coronary arteries that branch from the aorta. The left side of the heart is 
supplied from the left anterior descending coronary artery (LAD) and the circumflex coronary artery that 
branch from the left coronary artery. The right coronary artery supplies blood to the right side of the 
heart. 
There are several type of cells that make up cardiac tissue such as, cardiomyocytes, endothelial cells, 
smooth muscle cells, and pacemaker cells, which lie within an extracellular matrix comprised of collagen 
(types I,III, and IV), fibronectin, elastin and laminin, which serve to provide structure for cardiac cells. The 
workhorse of cardiac tissue is the cardiac muscle cell, or cardiomyocyte. Cardiomyocytes form branched 
muscle fibers that are electrically coupled at their intercalated disks, which are made of gap junctions 
comprised of connexin proteins. Gap junctions facilitate rapid action potential conduction through the 
entire myocardium. When the action potential is initiated, calcium is released into the cardiomyocyte. 
Calcium then binds troponin resulting in a conformational change allowing actin to be bound by myosin. 
Subsequent ATP hydrolysis induces cross-bridge formation between actin and myosin and results in the 
power stroke, which moves actin. As cardiomyocytes are electrically coupled, they act as a syncytium that 
results in a synchronized contraction. This synchronized contraction allows atrial and ventricular 
contraction which pumps blood through the body.  
2.2 Cardiovascular disease 
The AHA reported that in 2015 85.6 million Americans, over 33% of the population, exhibit a form of 
cardiovascular disease (CVD)2. Of the 85.6 million Americans who suffer from CVD, 7.6 million will suffer 
a myocardial infarction (MI) resulting in 5.7 million Americans suffering from heart failure (HF), a condition 
characterized by the inability of the heart to pump enough blood to support other organs 2, 3.  
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2.2.1 Myocardial infarction  
A myocardial infarction generally occurs from narrowing of the coronary arteries resulting in complete 
or partial occlusion causing ischemia to downstream cardiac tissue. If treatment is not immediately 
obtained, the ischemia results in myocyte death. Infarcts primarily occur in the left ventricle; it has been 
suggested that over a quarter (1 billion) of a patient’s left ventricular myocytes can die during an MI4. Not 
only do infarcts cause massive cardiomyocyte death, thus decreasing the available number of contractile 
units, but an inflammatory cascade is triggered that results in infarct expansion and the formation of scar 
tissue5. 
During the inflammatory process post-infarct, initially neutrophils infiltrate the infarct regions and 
recruit resident monocytes and lymphocytes6, 7. These cells remove necrotic myocardium, but 
inflammatory cytokines are secreted in the process. The release of inflammatory cytokines and increased 
infiltration of inflammatory cells causes infarct expansion and further damages the myocardium. The end 
of the inflammatory phase is characterized by the presence of anti-inflammatory cytokines and growth 
factors, released by apoptotic neutrophils and anti-inflammatory macrophages, that promote fibroblast 
proliferation and neovascularization8. As there is a less than 1% self-renewal of cardiomyocytes the 
injured tissue is replaced with scar tissue9.  
The scar tissue that replaces healthy contractile myocardium after an infarct negatively affects the 
active mechanical function of the heart. Contraction is inhibited as the scar tissue creates a stiff region, 
which works against the active contraction of cardiac tissue. Additionally, myocardial ischemia decreases 
the number of contractile units resulting in reduced active contraction. All together, these changes result 
in a reduced cardiac output that is detrimental to a patient’s quality of life. The impairment of the left 
ventricular myocardial function resulting from a MI can cause the patient to suffer from HF. HF from MI is 
a progressive disorder where the heart remodels and weakens over time to the point where the heart 
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cannot deliver a sufficient amount of blood to sustain the rest of the bodies organs10 There are currently 
915,000 new cases of HF annually, with a 5 year mortality rate of 50%11. 
2.2.2 Therapeutic treatment strategies for MI  
Despite medical advances, there have been few improvements in treatment options for patients who 
have suffered an MI. Options for treating patients in HF are limited, however current treatments have 
been attributed to a decline in mortality associated with HF11. These treatment options include 
pharmacological treatments such as ACE inhibitors and beta-blockers, as well as more aggressive 
techniques such as coronary revascularization, implantation of cardioverter-defibrillators, and cardiac 
resynchronization strategies12. The utilization of these treatments have increased survival rates for 
patients in HF, however these treatments only treat the symptoms of heart failure and do not treat or 
restore the damaged myocardium12. Without treating the damaged myocardium the patient’s heart 
disease may progress to end stage HF, for which the only treatment is a full heart transplant. However, as 
there are less than 2,700 donor hearts available each year, and over 4,100 patients needing a heart 
transplant, not all patients in HF will be adequately treated11. Additionally, donor mismatches and the 
chances for organ rejection make heart transplants a less than ideal treatment option. A left ventricular 
assist device is an option for extending the time for a patient to receive a heart transplant, however it only 
serves as a bridge to transplant.    
2.2.3 Techniques to measure and assess cardiovascular function 
In order to appropriately assess and treat a patient who has suffered from an MI it is important to obtain 
measurements of cardiovascular function. Measurements of cardiac function include left ventricular end 
diastolic and systolic volumes and diameters (LEDV- left ventricular end diastolic volume, LESV- left 
ventricular end systolic volume, LEDD- left ventricular end diastolic diameter, LESD – left ventricular end 
systolic volume). These measurements are used to obtain ejection fraction (EF) and fractional shortening 
(FS), two major benchmarks for cardiac function. EF is determined by the equation: (𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿)
𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿
∗ 100 and 
fractional shortening is determined by the equation:(𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿−𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿)
𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿
∗ 100. Stroke volume (SV) is determined 
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by (𝐿𝐿𝐸𝐸𝐸𝐸𝐸𝐸 − 𝐿𝐿𝐸𝐸𝐿𝐿𝐸𝐸) and gives the volume of blood ejected during systole. Other parameters for cardiac 
function include left ventricular systolic and diastolic pressure, maximum and minimum pressure 
development, diastolic relaxation time constant (τ), heart rate, stroke work, and cardiac output (SV*heart 
rate).  
There are numerous methods for measuring cardiac function. Echocardiography is a widely used 
system in animal models and humans as it is minimally invasive and can measure ejection fraction and 
fractional shortening 13. Cardiac computed tomography and magnetic resonance imaging are two other 
modalities that can be used to measure left ventricle end points such as FS, EF, and wall thickening 13. 
These two modalities are less invasive than echocardiography, but have a higher cost due to the needed 
imaging machinery. These imaging modalities obtain global cardiac function with little to no ability to 
decipher functional changes that occur on a regional level.   
A method to determine regional cardiac function is the use of a high resolution speckle tracking 
system – high density mapping (HDM, Figure 2-2)14. HDM is a phase correlation technique used to measure 
sub-pixel displacement fields14, 15. For the heart14, 16, a mixture of silicon carbide and retroreflective micro 
particles are applied to the heart wall to create a random light intensity distribution (Figure 2-2) and a 3.5 
French size catheter tipped micro manometer is inserted into the left ventricle through the apex to record 
left ventricular pressures. Then, a high speed (250 frames/second), high resolution (1696x1730 pixels) 
video of the contracting heart wall is taken simultaneously with pressure measurements. Using the 
pressure measurements, maximum and minimum rate of pressure change, and the diastolic relaxation 
time constant are determined. HDM is applied to determine regional changes in the mechanics of the 
heart wall (Figure 2-2B, C) including regional stroke work (RSW) and systolic area of contraction (SAC) 
(Figure 2-2D). RSW is an analog to stroke work and is calculated by taking the integral of left ventricular 
pressure (P) with respect to regional area of interest (A), normalized over end diastolic area and maximum 
pressure developed (RSW = ∫PdA/Pdev). SAC is an analog to SV and is defined as the difference between 
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regional end diastolic area (EDA) and regional end systolic area (ESA) (SAC = EDA-EDS). While the use of 
HDM is invasive, its high spatial resolution provides a powerful measurement tool as it determines 
regional cardiac function. Measurement of regional function is important in MI studies which usually 
result in regional dysfunction as well as in cell based therapies to determine changes in mechanics where 
the cells where delivered. The contribution of the cells may be washed out on a global scale, but may 
impart significant changes on a regional level. As such, this method will be utilized in this dissertation to 
determine changes in regional cardiac function. 
Figure 2-2. Description of HDM method. A region of interest is selected across the infarct area and is divided 
into 32x32 pixel subimages (A). HDM applies a phase correlation to measure displacement fields from frame to 
frame (B). HDM can measure sub-pixel displacements to obtain changes in area across the cardiac cycle (C).By 
using corresponding pressure data and area changes regional stroke work (RSW) and systolic area contraction 
(SAC) can be measured (D). P=pressure, A= area, EDA= end diastolic area, ESA= end systolic area 
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2.3 Cardiovascular regeneration 
When damage occurs in many systems in the body there is an endogenous system in place to repair the 
damage. This allows that system to continue to function with little to no impairment, depending on the 
severity of the damage. For example, skeletal muscle can regenerate through the activation of resident 
satellite cells, which have the ability to form functional mature myotubes allowing muscle to return to its 
pre-injured state17. Cardiac muscle tissue however is different as it lacks the ability to endogenously repair 
itself after injury, such as an MI, and restore function to pre-injury levels18, 19. Unlike skeletal muscle, 
cardiac muscle does not contain a resident stem cell population that will repopulate the damaged area 
after injury. Additionally, cardiomyocytes have a very limited self-renewal, around 1% a year, which 
decreases even further with age9. Over a billion myocytes can be lost after an MI, as the heart does not 
have the capacity to replace dead myocytes the heart instead replaces functioning myocytes with scar 
tissue20. The remaining cardiac myocytes can compensate to the injury by hypertrophy, however 
prolonged cardiac hypertrophy can lead to HF21, 22. As described above, there are limited options to treat 
an MI and subsequent HF, which has led researchers to investigate other therapeutic options to improve 
cardiac function post MI such as cell transplantation and tissue engineering techniques (Figure 2-3). 
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2.3.1 Material based 
A number of material based therapies have been proposed for cardiac regeneration including injectable 
materials and synthetic and natural polymer based cardiac patches. Injectable materials were first 
explored as a mechanism to increase cell retention and a number of materials have been utilized including 
fibrin, collagen, chitosan, gelatin, alginate, matrigel, and PEG based polymers23. Exploring the potential of 
injectable materials for MI has been primarily driven by Dr. Christman’s group. Her group has injected 
fibrin into the infarct zone, but more recently has been focused on decellularized extracellular matrix 
(ECM) as an injectable. By injecting fibrin into the infarct zone Christman et al. demonstrated prevention 
of LV wall thinning and maintenance of cardiac function post MI, additionally fibrin improves blood flow 
to the area of injury by increasing the arteriole density24, 25. With the discovery and improvement of 
decellularization techniques the group sought to decellularize cardiac tissue and create an injectable 
material from the remaining ECM26. Safety and efficacy studies using rat and porcine MI models with 
catheter based myocardial matrix delivery indicate that the material is biocompatible and can improve 
Figure 2-3. Schematic of cardiovascular regeneration techniques. Various options to improve cardiac function 
post infarction including cell transplantation and tissue engineering methods. 
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cardiac function post-MI27, 28. Additionally Masson’s Trichrome staining indicated decreased collagen and 
an increased muscle layer within the infarct zone for animals treated with the myocardial matrix28. These 
findings indicate the safety and efficacy of using injectable biomaterials for the treatment of MI. When 
combined with the appropriate cell type the use of biomaterials may have an even greater impact on 
functional cardiac improvement post-MI. 
The use of biomaterials for cardiac regeneration strategies has also been explored in the context of 
creating a patch that can be placed on the epicardial surface of the heart to improve function. Materials 
used for cardiac patches have ranged from fibrin, alginate, urinary bladder matrix, and small intestine 
submucosa, to PTFE and polyurethane23. Cell seeded and acellular patches have been delivered to infarct 
zone and studies have demonstrated improved LV wall thickness and improvements in cardiac function in 
terms of FS and EF29-31. Mesenchymal stem cells have predominately been used, however recent studies 
have explored the use of human pluripotent stem cell derived cardiomyocytes (hPS-CM) seeded patches32-
37. The hPS-CM patches have utilized fibrin as a base in addition to creating scaffold free cell sheets. 
Transplantation of hPS-CM patches onto porcine and rat MIs have demonstrated the ability for the patch 
to attenuate cardiac remodeling as well as improve cardiac performance34-36. In the case of Kawamura et 
al. and Wendel et al., functional gains in EF were seen initially, however they were diminished at later 
time points34, 36. Additionally, cardiac patch implantation studies found that the patches have an 
angiogenic potential, which may contribute to the increase in cardiac function. However, these studies 
found that the cells either did not survive at later time points or did not migrate from the patch into the 
host myocardium indicating that these cells did not integrate with the host myocardium to contribute to 
increases in function.  
2.3.2 Cell based 
 There are two main paradigms regarding cellular therapy for cardiac regeneration, the first is that a 
delivered cell type can provide a pro-healing environment for the heart to heal38. The second is that the 
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delivery of a contractile cell would provide an integrative restoration in contractile function lost after an 
MI38. The cell types used for cardiac based cellular therapy primarily include skeletal myoblasts, 
mesenchymal stem cells (MSCs), cardiac progenitor cells, and pluripotent stem cells38-42. Many of these 
cells types have been explored in pre-clinical MI animal models as well as in human patients38, 39, 43, 44. The 
following sections describe previous and current cell based efforts for cardiac regeneration. 
2.3.2.1 Skeletal myoblasts 
Skeletal myoblasts were one of the first cell types explored for cardiac regeneration, as they are a 
contractile cell type researchers believed they may integrate with the host myocardium to improve 
function. In early studies, skeletal myoblasts were delivered to rabbit and sheep models of MI45-47. These 
studies demonstrated that skeletal myoblasts could engraft in the infarcted tissue as well as provide 
improvements to cardiac function post-MI. Due to the initial success of these studies, skeletal myoblasts 
were examined in clinical trials for MI. The transplantation of skeletal myoblasts in human patients 
resulted in proarrhythmic events and as such have been deemed an inappropriate cell type for cardiac 
regeneration purposes48.  
2.3.2.2 Cardiac progenitor cells 
There is a controversial set of data suggesting the existence of cardiac progenitors within cardiac 
tissue that are capable of dividing and differentiating into cardiac cells. These cells have been isolated 
from cardiac tissue and identified based on their positive expression of tyrosine kinase c-kit, a cell 
surface receptor49-51. Studies where these cells were delivered to animal models of MI indicated their 
potential to improve cardiac function post injury42, 52. These pre-clinical studies laid the ground work for 
a clinical trial where autologous c-kit positive cells were delivered to patients with ischemic 
cardiomyopathy in the SCIPIO trial53. While the results of this trial were encouraging, reports of 
misconduct and subsequent paper retractions54 have called into question the results of this clinical trial 
and the overall existence and potential for c-kit positive cardiac progenitor cells. Many follow up studies 
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have indicated that c-kit positive cells cannot contribute enough cardiomyocytes to be considered 
functionally significant55, 56. 
2.3.2.3 Bone marrow derived cells 
Cells derived from the bone marrow (BMC) and used for myocardial repair strategies typically include 
bone marrow mononuclear cells (BM-MNC) and mesenchymal stem cells (MSCs). BM-MNCs consist of a 
variety of cell lineages including hematopoietic cells, monocytes, lymphocytes, and progenitor cells38, 57. 
A sub-population of BM-MNCs are MSCs which are a multipotent cell capable of differentiating into many 
types of cells, notably adipocytes, chondrocytes, and osteoblasts58-60. As MSCs possess the capacity to 
enhance endogenous repair systems through immunomodulation and paracrine effects they became an 
excellent cell source for cell based therapies targeting a range of diseases including graft versus host, 
diabetes, bone and cartilage diseases, and neurological diseases61-66. BMCs have been explored for 
myocardial infarction treatment for nearly two decades; a study Orlic et al. suggested that the delivery of 
bone marrow cells to an infarct could create de novo cardiac tissue and promote functional repair67. The 
cells delivered were lin-, c-kit+ GFP labeled cells that were delivered after ischemia was established. The 
author’s results demonstrated that 9 days after injury over 60% of the infarcted tissue was occupied by 
newly formed cardiomyocytes and left ventricular function has been significantly improved. This study 
was the first to show promise for BMCs to induce myocardial repair, however many follow up studies 
were not able to reproduce their results indicating that these stem cells cannot transdifferentiate into 
cardiomyocytes68-70. 
However, as BMCs present a promising autologous cell source many studies have continued to explore 
their potential for myocardial repair. Follow up studies delivering MSCs to animal models of MI indicated 
that the MSCs participate in angiogenesis and provide an immunomodulatory effect through the secretion 
of paracrine factors, which helps diminish the pro-inflammatory environment found post-infarct, resulting 
in decreased infarct expansion and reduction of scar tissue formation38, 41, 71-73. These preclinical successes 
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gave way to the initiation of many clinical trials delivering BMCs to patients who had survived an MI. The 
initial clinical trials indicated that the delivery of BMCs to a patient’s heart was a safe process and showed 
improvement in left-ventricular function74-76. Future studies examined the effect of allogeneic versus 
autologous cell delivery, different doses of cells, and the effect of cell delivery early or late after an MI75, 
77-80. The POSIEDON trial examined autologous vs allogeneic MSC delivery and found similar functional 
improvements after MI with little immune reactions from the allogeneic MSCs78. An unexpected finding 
of this study also indicated that the delivery of smaller numbers (20 million) of MSCs was superior to the 
delivery of larger numbers (100 million)78. The SWISS-AMI, TIME, and LateTIME trials all conducted studies 
to examine the effect of delivery time on BM-MNC injection after Percutaneous Coronary Intervention 
(PCI) post-MI. In the SWISS-AMI study, cells were delivered 3-4 days or 5-7 weeks after PCI, in the TIME 
trial cells were delivered 3 or 7 days after PCI, and in the LateTIME trials cells were delivered 2-3 weeks 
after PCI77, 79, 81. The major findings from these studies were similar, that the timing of cell delivery does 
not significantly affect global function. Due to the safety profile and therapeutic efficacy demonstrated in 
the initial clinical trials there are many ongoing clinical trials continuing to investigate the functional 
effects of MSCs on myocardial repair post-infarction. 
2.3.2.4 Pluripotent stem cells 
The generation of embryonic stem cells (ESC) by Thomson in 1998 82 and induced pluripotent stem 
cells (iPS) by Yamanaka in 2006 provides a potential new source of cells for cardiac regeneration 83. Human 
derived ESC and iPS cells exhibit many of the same characteristics including morphology, proliferation, 
pluripotency, and gene expression 84. Both cell types have the ability to provide a large cell source with 
cardiac differentiation potential for cell replacement strategies84, 85.  
Differentiation of ESCs into cardiomyocytes has been achieved by co-culture with mouse visceral 
endoderm-like (END-2) cells 86 as well as by culturing in embryoid bodies (EB) in the presence of serum87, 
but this results in batch to batch variability with poor differentiation efficiency (<22% contractile 
population) 88. More advanced techniques using monolayer culture, instead of EB formation, allow cells 
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to be cultured under fully defined conditions and have produced cardiomyocytes with a higher 
differentiation efficiency. One method developed by Lian et al. utilized small molecules to regulate 
canonical Wnt signaling, yielding a 98% (cTnT+) pure cardiomyocyte population from ESC and iPS cells89. 
Another method developed by Laflamme et al. regulated differentiation by the addition of activin A and 
bone morphogenetic protein 4 to a monolayer of ESC or iPS cells, which results in cardiomyocyte purity 
of greater than 95% (βMHC+)90, 91. These ESC and iPS derived cardiomyocytes (hPS-CM) exhibited down 
regulation of pluripotent stem cell markers such as NANOG and OCT4, stained positive for cardiac markers 
cardiac troponin T (cTnT) and α-actinin, and exhibited ventricular-, atrial-, and nodal-type cardiac 
electrophysiology91-93. cTnT and α-actinin are regulatory and cytoskeletal proteins, respectively, present 
in cardiomyocytes and are routinely used to characterize differentiation of hPS-CM89, 93-95. Despite the 
success of cardiac differentiation, these hPS-CM cannot be considered a mature adult cardiomyocyte as 
they lack the morphology, gap junction expression, contractile apparatus, and functionality of an adult 
cardiomyocyte93, 96, 97.  
 Many ongoing research efforts are focusing on enhancing the maturity of hPS-CM98, 99, however, 
in the interim, studies have delivered these cells to animal infarct models to assess their regenerative 
capacity100, 101. Initial studies delivered hPS-CM to models of mouse and rat infarctions and demonstrated 
improved cardiac function in terms of LV dimensions and fractional shortening, attenuated cardiac 
remodeling, improved vascularization as well as the formation of nascent myocardium90, 102-106. 
Interestingly, the studies by van Laake and Carpenter showed only transient improvement in LV function 
with improvements being diminished by 10 and 12 weeks, respectively102, 104. Additionally, while most 
studies found that grafts persisted past 4 weeks most studies only found few instances where connections 
between host and graft tissue were present90, 103, 104. Only a few connections between host and graft 
tissues may have been formed due to the inherent mismatch in beat frequency between graft cells 
(human, 60-100 beats per minute (bpm)) and host tissue (rodent, 300-600 bpm). Due to these 
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physiological discrepancies, larger animal studies have been employed to understand hPS-CMs effects on 
myocardial function in a heart that more closely mimics that of a human heart. 
One of the initial larger animal studies was conducted by Menasché and Pucéat where they 
delivered ESC derived progenitors to the infarcted myocardium of a nonhuman primate107. While they did 
not include any functional endpoints, this study demonstrated that the implanted cardiac progenitors 
reconstituted 20% of the scar tissue while undifferentiated cells formed teratomas. In 2012, Sawa’s group 
used hPS-CM derived cardiomyocytes to create cell sheets that were delivered to the epicardial surface 
of a porcine infarct model36. This study demonstrated significantly improved systolic function with 
attenuated ventricular remodeling, however very few cells survived at the 8 week time point. Templin et 
al. developed a sodium iodide symporter (NIS) transgene to improve iPSC cell tracking post-delivery108. 
iPSC-NISpos cells were delivered to a porcine model of infarction, and while no functional endpoints were 
used, the study was able to demonstrate retention of cells up to the study endpoint at 15 weeks. 
Additionally these cells were capable of contributing to the vascularization of the infarcted myocardium. 
A study by the Murry group delivered hPS-CM to a nonhuman primate model of infarction and 
demonstrated substantial remuscularization of the infarct zone with host vasculature perfusing the 
grafts101. Additionally, calcium transients indicated a 1:1 coupling between host and grafted tissue, but 
there was evidence on non-fatal ventricular arrhythmias. Further larger studies will need to be done to 
understand the potential for arrhythmias, however the remuscularization and electrical coupling results 
are encouraging and support the continued development of hPS-CM for cardiac repair. 
2.3.3 Cell delivery methods 
Substantial progress has been made for cell based therapies, however one inherent limitation with all 
cell therapies is the method used to deliver the cells to the injured tissue. There are several methods by 
which researchers have chosen to deliver cells, but none have resulted in the efficient delivery of cells 
localized to the injured region. Various delivery platforms include systemic delivery by intravenous 
injection, but this results in cells getting trapped in the lungs and only 1% of these cells engraft in the 
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heart109. Intracoronary delivery, during angioplasty, results in a similarly low retention of about 1% 
because cells get washed away after blood flow is resumed109. The current gold standard for cell delivery 
is an intramyocardial (IM) injection of cells into and around the epicardial surface of the infarct, yet this 
only results in a 10% retention of the delivered cells109. A recently explored delivery method, 
transendocardial delivery, has shown promising clinical results with 19% cell retention, but is still relatively 
inefficient110. Such low retention rates result in massive cell loss and would require on the order of 10 
billion cells to be delivered, which is prohibitively expensive 111. This dissertation explores an alternative 
method for cell delivery using fibrin microthread sutures. 
2.3.4 Fibrin microthreads for cell delivery 
In the wound healing process fibrin is the first protein deposited in the provisional matrix and recruits 
the cells that regulate the wound healing cascade 112. Tissue engineering research has used fibrin to create 
fibrin glues, hydrogels, and scaffolds that can be used in a variety of applications, including wound 
sealants, cell delivery, and engineering of adipose, cardiac, bone, and cartilage tissues 113. Fibrin has been 
used as a three dimensional (3D) scaffold for cardiac tissue engineering and it supports the survival and 
contraction of neonatal rat ventricular myocytes and recently hPS-CM114-117. This dissertation exploits the 
natural, biodegradable properties of fibrin and utilizes fibrin as a cell delivery vehicle in the form of fibrin 
microthreads. Fibrin microthreads are generated by co-extruding fibrinogen and thrombin into a HEPES 
buffered bath to create discrete fibrin microthreads118. Proulx et al. demonstrated the ability for the 
discrete fibrin microthreads to be incorporated into a suture that can support the attachment of human 
mesenchymal stem cells (hMSCs)119. Guyette et al. utilized the fibrin suture as a delivery platform to 
deliver hMSCs to the normal rat heart120. A delivery efficiency of 63.6±10.6% to the normal rat heart at 
one hour was achieved by suturing an hMSC seeded fibrin suture into the myocardium (Figure 2-4.). This 
delivery vehicle presents a promising approach to cell delivery and will be employed in this dissertation. 
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Figure 2-4. Fibrin microthread suture delivery to the heart. Fibrin Microthread suture before seeding (A). Suture 
stitched through myocardium (B, C) Suture needle is removed before animal is closed (D, E). Masson’s Trichrome 
of a cross section of rat heart with a fibrin suture delivered (F). Black arrows indicates fibrin sutures in E and F.  
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3 Objective 1a: Investigate cell seeding conditions to improve attachment of hMSCs onto fibrin 
microthread sutures. 
The introduction (starting with section 3.1), methods, results, and discussion presented in this objective 
are published in BioResearch Open Access. These sections are published under the liberal CC-BY license 
and can be freely reused with the proper citation: Hansen et al. “Functional Effects of Delivering Human 
Mesenchymal Stem Cell-Seeded Biological Sutures to an Infarcted Heart.” BioResearch Open Access. 2016; 
5(1):249-260 (see Chapter 9: Appendix). 
3.1 Introduction 
A limitation of MSC based cell therapy is the inefficient retention associated with most cell delivery 
methods1. Current delivery methods achieve a small and inefficient 10-20% retention rate. In addition, 
targeting cell delivery to a specific region is also challenging. Biomaterials have been proposed for MSC 
delivery to ischemic tissue; many focus on the development of injectable biomaterials as well as cardiac 
patch materials. Both natural and synthetic injectable biomaterials that have been explored include 
alginate2, chitosan3, collagen4, fibrin5, 6, and poly(ethylene glycol)7 based biomaterials. All biomaterials, 
with the exception of collagen, were shown to support stem cell survival upon delivery and improve cell 
retention. Similar biomaterials, fibrin8, chitosan/alginate9, collagen10, and polyglycolic acid11, were used 
to create stem cell seeded cardiac patches. Consistent with injectable biomaterials, cardiac patches also 
improved cell survival in vivo, however, many studies have reported minimal migration of cells from the 
patch to the host tissue. Natural biomaterials have the added advantage of having innate biological 
activity, however, the material properties of synthetic biomaterials are more easily customizable to fit the 
application. 
Fibrin has been used as a glue, a hydrogel, and a scaffold for applications in tissue engineering of bone12, 
13, ocular14, 15, liver16, 17, muscle18, 19, cartilage20, 21, skin22-24, and cardiovascular tissue6, 25, 26. Many of these 
applications have incorporated mesenchymal stem cells into the fibrin either encapsulated within the 
substrate or seeded on top of the substrate. These studies have demonstrated fibrin to be capable of 
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supporting MSC attachment as well as growth and survival for extended culture duration. Fibrin provides 
a self-supporting, naturally biodegradable structure for MSC survival and will be investigated in this 
dissertation as a vehicle to deliver hMSCs. 
To overcome issues of poor cell retention while simultaneously providing a delivery method that allows 
for targeted cell delivery, we developed fibrin based biological sutures. These sutures have been 
demonstrated to support hMSC attachment and survival and does not impact the potential of the hMSCs 
to differentiate27. Using this delivery method, previous studies have shown a 64% retention of hMSCs to 
cardiac tissue28. Herein, we use this delivery method to deliver of hMSCs to infarcted myocardium and 
determine if these cells lead to improved active mechanical function. In this objective we aim to 
understand and tune the seeding conditions to promote hMSC attachment onto the biological sutures. 
Previous work in our lab developed a seeding method to allow attachment of hMSCs to the biological 
sutures; however, how different seeding concentrations and seeding times affect hMSC attachment has 
not been examined. 
3.2 Materials and methods 
3.2.1 Fibrin microthread production 
Discrete fibrin microthreads were produced as described previously27. Briefly, fibrinogen (70mg/mL; MP 
Biomedical) and thrombin (8U/mL; Sigma) were coextruded using a blending tip connector in a 10mM 
HEPES (Calbiochem) buffered bath (pH 7.4). A custom built extrusion system was used to extrude 
microthreads at a flow rate of 0.23 mL/min through 0.38 mm polyethylene tubing. After extrusion, the 
microthreads were allowed to polymerize before being removed and air dried.  
To create biological sutures, 12 individual microthreads were arranged parallel to one another, hydrated 
with distilled water, and twisted together (Figure 3-1A, B). After drying, each bundle was cut to 4 cm 
lengths. The 4 cm bundles were threaded through the eye of a surgical needle (size 26, Havel’s Inc.), 
hydrated with distilled water, and the free ends of the bundle were twisted together to form a 2cm long 
suture (Figure 3-1C, D). Once dried, each suture was placed in a 4cm long piece of silastic tubing (1.98mm 
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ID, Dow Corning) with a 27-gauge ½ inch needle (Becton Dickinson) and secured with a slide clamp across 
the needles (Figure 3-1E). Suture constructs were ethylene-oxide sterilized for a 12 hour period and stored 
in a desiccator before cell seeding.  
3.2.2 Human MSC culture 
hMSCs (Lonza Inc.) were cultured in T75 flasks incubated at 37°C in 5% CO2. Passage 4-8 hMSCs were 
grown in monolayer culture in growth medium (MSCGM; Lonza Inc.) until cells reached 80-90% 
confluence. All implanted hMSCs were treated with MSCGM supplemented with 8.2 nM Qdot 655 ITK 
carboxyl quantum dots (Qdots; Invitrogen) to allow for cell tracking. Qdots were added to 70-80% 
confluent layers of hMSCs and were allowed to incubate for 24 hours at 37°C in 5% CO2. Quantum dot 
loading was verified using fluorescent microscopy. After 24 hours, Qdot media was replaced and cells 
were maintained until further use.  
3.2.3 Biological suture seeding 
Prior to cell seeding, sutures were hydrated with 100 µL of dPBS for 20 minutes within the seeding 
construct; dPBS is expelled before cells were introduced. For cell seeding, 100 µL of a 2.5x105, 5x105, 1x106 
hMSC/mL solution was drawn into a 1ml syringe (Becton Dickinson). The syringe was attached to the 27-
gauge needle and dispensed into the silastic tubing containing the suture. The 27-gauge needle and 
Figure 3-1. Fibrin suture seeding. 12 individual fibrin microthreads are placed together (A) and hydrated and twisted together 
to form a bundle (B). Each bundle is cut to 4 cm lengths and placed through the eye of a suture needle (C) and hydrated and 
twisted together form a suture (D). Each suture is placed into a piece of silastic tubing with a 27G needle to facilitate seeding (E). 
hMSCs in media are injected into the tubing and clamped off and then placed in a vented conical tube in a rotator in the incubator 
for seeding. 
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syringe were removed and a slide clamp was added to the free end of the tubing to seal both ends. The 
seeding construct was placed in a vented 50mL conical tube and placed in a portable MACsmix rotator 
(Miltenyi Biotech, Figure 3-1F). The rotator was set to 4 rotations per minute and placed into a 37°C 
incubator in 5% CO2. To determine the role of incubation time, sutures were allowed to seed for 1, 3, 6, 
12, and 24 hours.  
3.2.4 hMSC cell attachment quantification 
After seeding, hMSC-seeded sutures were removed from the seeding construct and either fixed in 4% 
paraformaldehyde for staining or prepped for a CyQuant DNA assay. For CyQuant DNA assays, sutures 
were placed in a 1.5mL Eppendorf tube with 100uL of phosphate buffered saline (PBS) in a -80°C freezer 
for cell lysis. Sutures were allowed to freeze for 1 hour to 4 weeks before use in the CyQuant assay. The 
CyQuant assay was run according to manufacturer’s specifications. Briefly, sutures were removed from 
freezer, allowed to thaw, and 400 µL of cell lysis buffer with GR dye was added to the Eppendorf tube. 
Four, 100 µL aliquots of the cell suspension were added to a 96 well plate along with an independent 
standard curve. Fluorescent measurements were taken using a plate reader (Victor 3, Perkin Elmer) at an 
excitation of 480nm and absorption of 520nm. Values are reported as mean±SEM cell count per linear 
centimeter of suture. 
3.2.5 Histological data 
Sutures not prepared for CyQuant were fixed in 4% paraformaldehyde for 10 minutes and stained for 
F-actin. Briefly, sutures were washed in PBS, blocked for 30 minutes in 1% albumin from bovine serum, 
and stained with 488 phalloidin (Invitrogen) for 30 minutes. Sutures were washed in PBS and then 
counterstained with Hoechst 33342 (0.5ug/mL, Invitrogen) for 5 minutes at room temperature. Images 
were acquired at 200x with a Leica Upright DMLB2 or a Leica TCP SP5 confocal laser scanning microscope. 
3.2.6 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). 
Results are represented as mean±SEM. Comparisons between seeding conditions were analyzed using a 
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one-way analysis of variance (ANOVA), with a post-hoc Tukey test for multiple comparisons. All conditions 
were considered significant at a value of p<0.05. 
3.3 Results 
3.3.1 Effect of cell seeding concentration on hMSC attachment to biological sutures 
Three different concentrations of hMSCs (2.5x105, 5x105, 1x106 hMSCs/mL solution) of human MSCs 
were seeded onto 2 cm long biological sutures. There were significantly more hMSCs attached to the 
sutures seeded with the higher concentrations (5x105, 1x106 hMSC/mL) compared to a concentration of 
2.5x105 (n=10; p<0.05) (Figure 3-2A), a finding which was further supported by F-actin staining (Figure 
3-2B, C, and D).  
3.3.2 Effect of incubation time on hMSC attachment to biological sutures 
To determine the effect of incubation time of cell attachment on biological sutures, five different 
incubation times were examined (1, 3, 6, 12, and 24 hours). Seeding for 12 and 24 hours significantly 
increased cell attachment compared to 1 and 3 hours (p<0.05) (Figure 3-3A). There was no significant 
Figure 3-2. Effect of cell seeding concentration on hMSC attachment to biological suture. Biological sutures were seeded 
with three different concentrations of hMSCs: 25, 50, and 100K cells per suture. Highest attachment was found for the 
higher concentrations (A) with no statistical difference found between the 50 and 100K. F-actin staining for 25K (B), 50K 
(C), and 100K (D) revealed similar cell attachment for the 50 and 100K conditions. Some blue autofluorescence seen in B 
and D is due to the suture. Mean±SEM, - p<0.05, n=10 per group. 
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difference in the number of hMSCs attached at 6, 12 or 24 hours. F-actin staining shows cell attachment 
beginning at 1 hour (Figure 3-3B), more cells attached at 6 and 12 hours (Figure 3-3C and D) with cells 
appearing to elongate along the length of the suture at 12 and 24 hours.  
3.4 Discussion 
Concerns remain when cells are delivered to the heart. Current delivery methods exhibit retention rates 
of only 10-20%, which are inefficient for delivering clinically relevant numbers of cells. Fibrin based 
biological sutures are able to efficiently (64% retention) deliver hMSCs to targeted areas of ischemic 
myocardium. While previous studies have developed methods to seed hMSCs onto biological sutures, no 
study has examined the effect of seeding concentration and seeding time on hMSC attachment. 
In this study, we demonstrated the ability for cell seeding concentration and seeding times to affect the 
numbers of hMSCs seeded onto the biological suture. The highest hMSC attachment occurred using higher 
concentrations (5x105, 1x106 hMSC/mL) compared to a concentration of 2.5x105. There was only a small 
Figure 3-3. Effect of seeding time on hMSC attachment to biological suture. hMSC attachment for 5 different 
time points (1, 3, 6, 12, and 24 hours) was examined. Seeding times of 1 and 3 hours resulted in significantly 
fewer cells attached compared to 12 and 24 hours, where there was no significant differences in attachment 
at 6, 12 and 24 hours (A). F-actin staining shows cells attached at 1 hour (B), but with higher numbers of cells 
attached at 6 and 12 hours (C, D). Mean±SEM, - p<0.05, n=10 per group. 
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increase in cell attachment between the 5x105 and 1x106 hMSC/mL seeded groups, thus we do not believe 
that increasing the number of cells seeded beyond 1x106 hMSC/mL would lead to improved cell 
attachment as the surface area available for cell attachment has been maximized. In regard to seeding 
time, there was no significant difference in hMSC attachment at 6, 12, or 24 hours. F-actin staining 
revealed cells beginning to attach a 1 hour, however at 12 and 24 hours cells were more elongated along 
the suture. As there was no significant difference in cell numbers attached at 6, 12, or 24 hour this suggests 
that a range of times could be used when delivering hMSCs on biological sutures which may be 
advantageous in a clinical setting. For consistency and due to time considerations, the 24 hour time point 
using a 1x106 hMSC/mL seeding concentration was used in objective 1b.  
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4 Objective 1b: Evaluate changes in mechanical function when hMSC seeded fibrin sutures are implanted 
in the infarct zone. 
The introduction (starting with section 4.1), methods, results, and discussion presented in this objective 
are published in BioResearch Open Access. These sections are published under the liberal CC-BY license 
and can be freely reused with the proper citation: Hansen et al. “Functional Effects of Delivering Human 
Mesenchymal Stem Cell-Seeded Biological Sutures to an Infarcted Heart.” BioResearch Open Access. 2016; 
5(1):249-260 (see Chapter 9: Appendix). 
4.1 Introduction 
Cell based therapies have been proposed as a treatment for MI. Multiple cell types have shown 
promising pre-clinical and clinical results1-4. Human mesenchymal stem cells (hMSCs) were initially shown 
to improve ejection fraction and regional function in pre-clinical animal models5, 6. Importantly for the 
clinical use of these cells, Hare and colleagues demonstrated no deleterious effects of hMSCs when 
delivered intravenously to patients7. While several clinical trials have demonstrated promising initial 
results with short term improvements in ejection fraction, longer term studies have shown that functional 
benefits dissipate within one year8. A limiting factor to the success of all studies was the method in which 
cells were delivered such that all studies fail to deliver cells in an efficient manner (<19% retention).Fibrin 
microthreads have previously demonstrated the ability to deliver hMSCs to cardiac tissue with a 64% 
delivery efficiency9. This objective seeks to build upon that work by using the fibrin suture to deliver 
hMSCs to an acute rat infarct model to examine changes in regional function. 
4.2 Materials and methods 
hMSCs were cultured and seeded as done in objective 1a. All implanted sutures were seeded with 100uL 
of a 1x106 hMSC/mL solution for 24 hours. 
4.2.1 Infarct model 
Male nude rats (NIH nude, Taconic) were used for all procedures. Animals were anesthetized using 5% 
inhaled isoflurane in oxygen, intubated, and mechanically ventilated with anesthesia maintained with 3% 
isoflurane. A 2cm incision along the fourth intercostal space and subsequent blunt dissection of the 
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muscle was used to expose the heart. To induce an infarct, the left anterior descending (LAD) artery was 
ligated for 1 hour using 5-0 Prolene (Ethicon) suture. After 1 hour, the ligature was cut to restore blood 
flow and the chest was either closed or the suture was implanted and the chest was closed. The suture 
was implanted from the base of the heart towards the apex of the heart and excess suture was cut and 
removed from the entry and exit points (Figure 4-1). Sham operations underwent the same procedure 
described above without the ligation of the LAD and suture implantation. Animals were allowed to recover 
for 1 week.   
4.2.2 Terminal surgery 
One week post operation, animals were once again anesthetized, intubated and placed on a respirator 
as described above. The heart was exposed through the original suture lines and retractors were placed 
into the intercostal space to expose the left ventricle of the heart. The infarcted muscle tissue was 
identified based on the darkened color of infarcted heart tissue compared to bright red healthy heart 
tissue, as well as lack off contractility. A 3.5 French size micro tip catheter (Millar) was inserted into the 
left ventricle of the heart through the apex and sutured in place. A high speed video camera (Fastec 
Figure 4-1. Implanted hMSC seeded suture. Male athymic rat heart was exposed and the LAD was ligated to induce infarct. 1 hour 
post ligation, ligature was cut and blood flow was resumed. The hMSC seeded fibrin suture was implanted from the base to the 
apex such that suture entered in the ischemic zone (i), passed through the infarcted myocardium (ii), and exited through the 
ischemic zone at the apex (iii) (A). Implantation of fibrin suture in rat heart (B). Excess suture was removed.  
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HiSpec4, Fastec Inc.) was used to record high speed videos (250 frames/second, 8 bit depth, 1696x1710 
pixels) of the contracting ventricular muscle. Pressure data was synchronized to video frame acquisition 
via a DAQ board (National Instruments) and a LabVIEW-based controller. Videos were acquired from 
multiple different angles and video and pressure data were saved for offline data analysis. After video 
acquisition, a 0.3mg/kg dose of Beuthanasia-D (VetOne) was injected into the left atrium to arrest the 
heart. The heart tissue was then carefully removed for histological processing and analysis. 
4.2.3 Assessment of global and regional mechanical function 
Global mechanical function was assessed using the collected pressure waveforms as described 
previously10. Maximum developed pressure was determined by averaging the difference between the 
maximum and minimum pressure for each beat. Minimum rate of pressure decline and maximum rate of 
pressure development were determined by applying a 5 point linear averaging filter to the pressure wave 
form and finding the maximum and minimum of the discrete derivative of the signal for each beat. Finally, 
the diastolic relaxation time constant was determined by applying a 3 parameter least squared fitting 
method to pressure data from its negative inflection point to its minimum for each beat 11. All global 
function data are averaged over at least 5 beats per animal and reported as mean±SEM. 
High density mapping (HDM) was used to assess regional mechanical function as previously described9, 
10, 12. HDM is an image tracking algorithm based on Fourier domain phase correlation with the subpixel 
registration algorithm described by Foroosh et al. 13. Using this method, a region of interest was defined 
on the rat heart over the thread and/or infarct region. The region was subsequently divided into small 
(32x32 pixel) windows. Individual windows were tracked from frame to frame across several cardiac cycles 
to yield a displacement field. Displacement fields were used to quantify systolic area of contraction (SAC) 
and regional stroke work (RSW), as described previously12. 
4.2.4 Histological data 
After terminal surgery, hearts were removed and cut in half to produce cross-sections, bisecting the 
infarct and biological suture, and fixed in 4% paraformaldehyde overnight. After fixation, heart sections 
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were moved to a 30% sucrose solution for 24 hours. Each half was embedded in a Peel-a-Way disposable 
embedding mold (Polysciences, Inc.) with OCT and placed in a -20°C freezer. Once the OCT has solidified 
the heart block was removed from the block and placed in a Leica CM 3050 cryostat (Leica Microsystems) 
and cut into 10 µm thick sections and placed on charged glass microscope slides (Globe Scientific, Inc.) 
Sections were stained with Masson’s Trichrome reagents according to manufacturer’s instruction. 
Adjacent sections were used for immunofluorescence staining. Briefly, sections were fixed in acetone at -
20°C for 10 minutes, and blocked with 5% goat serum for 45 minutes. The sections were incubated in 
mouse anti-α-actinin monoclonal antibody (1:100; Abcam) overnight at 4°C. Subsequently, sections were 
treated in goat anti-mouse secondary antibody (1:400; Alexa Fluor 488, Thermo Fisher Scientific) for 1 
hour at room temperature. Sections were then counterstained with Hoechst 33342 (0.5 µg/mL) for 5 
minutes at room temperature. Fluorescence images were obtained using a Leica Upright DMLB2 or Leica 
TCP SP5 confocal laser scanning microscope.   
4.2.5 Infarct region and suture area quantification 
Images (taken at 50x magnification) from sections stained with Masson’s Trichrome were stitched 
together using Microsoft Image Composite Editor to generate composite images of the full cross-sections. 
Images were uploaded into a custom MATLAB image analysis program (Mathworks) that evaluates color 
of individual pixels in the image, and from this information extrapolates the location of the lumen and 
outer boundary of the section. Image regions outside the boundary of the heart and within the lumen 
(white space) are removed, leaving the image region corresponding to heart tissue intact. As Masson’s 
Trichrome stains viable cardiac muscle tissue red and fibrosis blue, blue regions of the image were 
programmatically identified and used to determine infarct size.  The program approximates and outputs 
total section area and total area of the infarct. Sectional area was calculated by the sum of squared pixel 
lengths, and converted to microns. Total area of the infarct was calculated with the same method, and 
used to determine the percentage of the section that is infarcted.  
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For suture area measurement, images with Masson’s Trichrome staining were uploaded to ImageJ 
(NIH). Manual tracings around the remaining suture in each cross-section were obtained to give the area 
of the suture. Every section containing a suture was used for the measurements to give an average area. 
4.2.6 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). 
Results are represented as mean±SEM. Comparisons between in vivo treatments were analyzed using a 
Kruskal-Wallis test with a Dunn’s test for multiple comparisons. An unpaired t-test was used to determine 
significance between suture areas. All conditions were considered significant at a value of P<0.05.  
4.3 Results 
4.3.1 hMSC seeded biological sutures do not improve global function after infarction 
After the model was successfully developed, five sham, two infarct, one unseeded, and three animals 
from the hMSC-seeded group died prior to successful completion of all data acquisition. These animals 
were not included in this study.   
Figure 4-2. Global function is not impacted by hMSC seeded biological suture treatment after infarct. No significant 
changes were noted for any of the following measurements: minimum dP/dt (A),maximum dP/dt (B), end diastolic pressure 
(C), heart rate (D), or diastolic time relaxation constant (E). Mean±SEM. n=6 per group. 
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No differences were noted in the maximum or minimum rate of pressure development or end diastolic 
pressures between groups (sham, MI, MI with unseeded sutures, and MI with hMSC-seeded sutures, n=6 
per group; Figure 4-2A-C). There were no significant differences in the heart rates in all groups at the time 
of terminal surgery (Figure 4-2D). Similarly, no significant differences were seen in diastolic relaxation 
time constant, although sham operated hearts had the shortest relaxation time (8.6±1.1 ms) and infarcted 
hearts had the longest time (14.1±4.3 ms) (Figure 4-2E).  
4.3.2 hMSC seeded biological sutures improve regional mechanical function after infarction 
In order to assess regional mechanical function, a particle tracking algorithm, HDM, was used to 
determine epicardial displacement of multiple regions within the infarcted tissue. From the two-
dimensional displacement, changes in regional area were determined, which when combined with left 
ventricular pressure, allowed for determination of regional stroke work (Figure 4-3A). The average region 
in which function was determined was similar in all groups. Creation of an MI resulted in significant 
decrease in RSW (0.026 ± 0.011) and SAC (0.022 ± 0.015) compared to sham operated animals (RSW 0.141 
Figure 4-3. hMSC seeded biological sutures improve regional mechanical function after infarct. RSW and SAC were 
significantly decreased for infarct and unseeded suture groups compared to the sham group (A, B). Representative 
pressure area work loop (C) shows improved function for seeded group compared to infarct and unseeded groups. 
Arrows indicate direction of all work loops over time. Mean±SEM, - p<-0.05, n=6 per group. 
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± 0.009; SAC: 0.166 ± 0.005) (n=6, p=0.0027 RSW and SAC) (Figure 4-3A and B). Delivery of unseeded 
sutures to the infarcted regions also resulted in statistically reduced RSW (0.037 ± 0.005) and SAC (0.039 
± 0.009) compared to sham operated animals (n=6, p=0.012 RSW; p=0.026 SAC). hMSC-seeded sutures 
had a lower RSW (0.057 ± 0.011) and SAC (0.051 ± 0.014) than sham operated hearts, although statistical 
significance was not achieved (n=6, p=0.165 RSW; p=0.086 SAC). There were no significant differences in 
regional mechanical function between infarct, unseeded and seeded groups, however infarcted hearts 
treated with cell-seeded sutures showed a trend toward increase of RSW when compared to infarcted 
hearts (p=0.07). Pressure area work loops (Figure 4-3C) indicate improved function in hMSC seeded group 
over unseeded and infarcted groups.  
4.3.3 Cells delivered via the suture remain in the heart at least one week after delivery 
Numerous Qdot-loaded cells were detected in the seeded group. Cells were found in regions close to 
the biological sutures (Figure 4-4), but not on the suture suggesting migration into surrounding tissue. 
 
Figure 4-4. hMSCs persist in myocardium 1 week after delivery. Masson’s Trichrome stained cross-sections show 
successful delivery of biological suture (pink; black arrows in A, white lines in B and C) to myocardium. The black boxes 
(B, C) show the location of serial sections stained for alpha-actinin and Hoechst relative to (A). The arrows in B and C 
indicate quantum dot positive hMSCs that have migrated off the suture into fibrotic tissue. The cell identified by the 
yellow arrow in C is shown in the insert. 
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When stained to visualize α-actinin, no quantum dot loaded cells visualized exhibited positive α-actinin 
expression.  
4.3.4 Infarct size is reduced using unseeded and hMSC seeded sutures 
Serial sections of Masson’s Trichrome stained sections were analyzed to determine infarct size, denoted 
as a percentage of the cross section. No infarcted tissue was detected by Masson’s Trichrome staining in 
sham operated hearts, whereas the MI, unseeded suture, and seeded suture groups all appeared to have 
similarly sized infarct regions (Figure 4-5A). Infarcted hearts without suture delivery had the greatest 
infarct size of 7.0±2.2%. Unseeded and hMSC-seeded groups had comparable infarct sizes of 3.8±0.6 and 
3.7±0.8%, respectively, but were not significantly different from MI alone (p>0.05, Figure 4-5 B). Due to 
the automated method used to calculate infarct size, the sham group had a small infarct size of 1.6±0.1% 
(likely due to inherent collagen structure in the healthy heart).  
Figure 4-5. Infarct size and suture area. Masson’s Trichrome staining shows infarcted area in blue and healthy muscle in 
red (A). Quantification of infarct size from serial trichrome stained sections indicates an increase in infarct size for infarct 
only group with a similar reduction in infarct size shown for seeded and unseeded groups (n=6) (B). Quantification of 
persisting suture area after 1 week shows significantly smaller suture area for unseeded sutures (n=6) (C). Mean±SEM, 
*P<0.05.  
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4.3.5 hMSCs preserve suture area in infarct  
Serial sections of Masson’s trichrome stained sections were analyzed for suture area. An average suture 
area of 0.027±0.01mm2 and 0.041±0.01mm2 was found for unseeded and seeded groups, respectively 
(Figure 4-5C). The group with hMSCs had a significantly greater suture area (p<0.05) indicating that the 
hMSCs preserved suture area at 1 week after delivery in the infarcted heart.  
4.4 Discussion 
Cell therapy continues to hold tremendous potential to treat millions of patients living with MIs and 
heart failure. However, the full benefits of cell therapy have yet to be realized. The past decade has seen 
the emergence of dozens of clinical trials aimed at improving cardiac output. These studies have examined 
different cell types including bone marrow mononuclear cells 2, MSCs 7, 14, and cardiosphere derived cells 
4, effect of timing on cell delivery 15-17, chronic 18, 19 and acute 20 MI, and cell delivery methods: 
intracoronary 4, 20, intravenous 7, intramyocardial 21, and transendocardial 22, 23. Despite numerous trials 
investigating extensive variables, these clinical trials demonstrated only limited improvements in ejection 
fraction without restoring cardiovascular function to baseline values. All studies failed to efficiently deliver 
the chosen cell type to infarcted tissue, further underscoring the value of investigating new delivery 
methods that improve cell retention. 
Current cell delivery methods to the heart exhibit retention rates of only 10-20%, which are inefficient 
for delivering clinically relevant numbers of cells23-25. Previously, we demonstrated cell-seeded biological 
sutures capable of efficiently delivering cells to a targeted area (64% retention)9 Additionally, we reported 
that delivering unseeded sutures to a healthy heart demonstrated a small fibrotic reaction that was 
significantly reduced with hMSC-seeded sutures10. In terms of regional function, unseeded sutures 
decreased SAC, where hMSC-seeded sutures dampened the decrease in SAC10. Similar values for RSW and 
SAC were reported for sham animals in the previous study and our current study. In this study, we 
investigated the functional effects of delivering hMSCs via a biological suture to an infarcted heart. When 
combined with our method for evaluating regional mechanical function with high spatial resolution, we 
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are uniquely able to determine changes in regional mechanical function that occur directly in the region 
of cell delivery. This combination allows for targeted cell delivery followed by targeted evaluation of 
regional mechanical function.  
No changes between conditions were found for global parameters including pressure changes, 
diastolic relaxation constant, or heart rate. The MI created in the rat may not have been large enough to 
result in a detectable change in global function. In addition, rat ventricular remodeling after an MI can 
take 4-8 weeks to manifest such that changes on a global level may not be seen at 1 week26. This finding 
further necessitates the use of HDM, which images the region of damage and cell delivery to determine 
on a regional level if improvements in mechanical function were found that may have been negated at a 
global level.  
Using HDM to analyze myocardial function in infarcted rat hearts we demonstrated decreased 
regional mechanical function in animals with an induced MI, using metrics of RSW and SAC. Delivering 
unseeded-sutures demonstrated improvements in regional mechanical function over the MI group, the 
hMSC-seeded sutures demonstrated slightly higher function, however not statistically significant. This 
suggests that the biological suture alone has the ability to improve regional mechanical function in the 
infarct zone. Studies have demonstrated that acellular biomaterial delivery to an infarct can improve 
mechanical function by stabilizing the infarct, thickening the left ventricle, and decreasing infarct 
expansion27-29. As both the unseeded and hMSC-seeded suture groups had similar infarct sizes, the 
significantly increased suture area for the hMSC-seeded group may explain the improvement in regional 
mechanical function for the hMSC-seeded group, compared to the unseeded group. A similar trend of 
increased suture area for hMSC-seeded sutures was also found in studies in a healthy heart, suggesting 
the ability for the hMSCs to decrease the in vivo degradation time, by modulating the inflammatory 
response and decreasing the number of cells present that may contribute to fibrin degradation, of 
biological sutures compared to unseeded sutures10. 
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It has been established that MSCs act transiently and die off within days to weeks of being delivered to 
the infarct30. As such, we chose not to examine cell retention as hMSC retention may be altered by the 
infarct environment at 1 week independent of the method used for delivery. However, hMSCs were found 
to persist in the myocardium for 1 week and were found in regions away from the suture, suggesting their 
propensity to migrate from the suture into the damaged tissue. Delivered cells were tracked using Qdots, 
which have previously been shown to be taken up by hMSCs and remain in the cells for several passages 
in vitro31.  
Despite the emergence of many clinical trials focused on the delivery of MSCs to injured cardiac tissue, 
none of these trials have found significant findings to suggest the robust ability for MSCs to improve 
contractile cardiac function. Many of these studies used delivery methods with low delivery efficiencies. 
In this study, we describe findings using a biological suture based method to efficiently deliver cells to 
infarcted tissue. While we did not see statistically improved function when seeded sutures were delivered 
over infarct alone, we do remain optimistic about the use of the biological suture for cell delivery. Many 
studies have demonstrated the immunomodulatory effects of delivered MSCs. While this cell type may 
not be the most appropriate cell to use in regeneration of contractile cardiomyocytes, they may still have 
beneficial effects in the infarcted heart32, 33. Recent advances in induced pluripotent and embryonic stem 
cell technology have enabled the development of a cardiomyocyte that has demonstrated the in vitro 
contractile properties that may be ideal for cell replacement strategies34, 35. Objectives 2 and 3 will focus 
on delivering cardiomyocytes differentiated from pluripotent stem cells using our fibrin based suture 
technology. 
 
 
 
 
 
 
 
Chapter 4: Objective 1B                                                                                                                                         53 
 
4.5 References 
1. Jakob P and Landmesser U. Current status of cell-based therapy for heart failure. Current heart 
failure reports. 2013;10:165-76. 
2. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Cort R, 
Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S and Zeiher AM. Intracoronary Bone 
Marrow–Derived Progenitor Cells in Acute Myocardial Infarction. The New England journal of medicine. 
2006;355:1210-21. 
3. Hare JM, Fishman JE, Gerstenblith G and et al. Comparison of allogeneic vs autologous bone 
marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with 
ischemic cardiomyopathy: The poseidon randomized trial. JAMA : the journal of the American Medical 
Association. 2012;308:2369-2379. 
4. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, Marban L, Mendizabal A, Cingolani 
E, Johnston PV, Gerstenblith G, Schuleri KH, Lardo AC and Marban E. Intracoronary cardiosphere-derived 
cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the 
CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). Journal 
of the American College of Cardiology. 2014;63:110-22. 
5. Tang J, Xie Q, Pan G, Wang J and Wang M. Mesenchymal stem cells participate in angiogenesis 
and improve heart function in rat model of myocardial ischemia with reperfusion. European journal of 
cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 
2006;30:353-61. 
6. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, Pittenger MF and 
Martin BJ. Mesenchymal stem cell implantation in a swine myocardial infarct model engraftment and 
functional effects. The Society of Thoracic Surgeons. 2002;73:1919-26. 
7. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, 
Denktas AE, Gammon RS, Hermiller JB, Jr., Reisman MA, Schaer GL and Sherman W. A randomized, double-
blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells 
(prochymal) after acute myocardial infarction. Journal of the American College of Cardiology. 
2009;54:2277-86. 
8. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, 
Hertenstein B, Ganser A and Drexler H. Intracoronary bone marrow cell transfer after myocardial 
infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw 
transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113:1287-94. 
9. Guyette JP, Fakharzadeh M, Burford EJ, Tao ZW, Pins GD, Rolle MW and Gaudette GR. A novel 
suture-based method for efficient transplantation of stem cells. Journal of biomedical materials research 
Part A. 2013;101:809-18. 
10. Tao ZW, Favreau JT, Guyette JP, Hansen KJ, Lessard J, Burford E, Pins GD and Gaudette GR. 
Delivering stem cells to the healthy heart on biological sutures: effects on regional mechanical function. 
Journal of tissue engineering and regenerative medicine. 2014. 
11. De Mey S, De Sutter J, Vierendeels J and Verdonck P. Diastolic filling and pressure imaging: taking 
advantage of the information in a colour M-mode Doppler image. Eur J Echocardiogr. 2001;2:219-33. 
12. Kelly DJ, Azeloglu EU, Kochupura PV, Sharma GS and Gaudette GR. Accuracy and reproducibility 
of a subpixel extended phase correlation method to determine micron level displacements in the heart. 
Medical engineering & physics. 2007;29:154-62. 
13. Foroosh H, Zerubia JB and Berthod M. Extension of phase correlation to subpixel registration. IEEE 
transactions on image processing : a publication of the IEEE Signal Processing Society. 2002;11:188-200. 
14. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S and Sun JP. 
Effect on left ventricular function of intracoronary transplantation of autologous bone marrow 
mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004;94:92-5. 
Chapter 4: Objective 1B                                                                                                                                         54 
 
15. Traverse JH, Henry TD, Ellis SG and et al. Effect of intracoronary delivery of autologous bone 
marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: 
The latetime randomized trial. JAMA : the journal of the American Medical Association. 2011;306:2110-
2119. 
16. Traverse JH, Henry TD, Pepine CJ and et al. Effect of the use and timing of bone marrow 
mononuclear cell delivery on left ventricular function after acute myocardial infarction: The time 
randomized trial. JAMA : the journal of the American Medical Association. 2012;308:2380-2389. 
17. Surder D, Manka R, Lo Cicero V, Moccetti T, Rufibach K, Soncin S, Turchetto L, Radrizzani M, Astori 
G, Schwitter J, Erne P, Zuber M, Auf der Maur C, Jamshidi P, Gaemperli O, Windecker S, Moschovitis A, 
Wahl A, Buhler I, Wyss C, Kozerke S, Landmesser U, Luscher TF and Corti R. Intracoronary injection of bone 
marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left 
ventricular function. Circulation. 2013;127:1968-79. 
18. Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, Haack-Sørensen 
M, Ekblond A and Kastrup J. Bone marrow-derived mesenchymal stromal cell treatment in patients with 
severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). European heart 
journal. 2015;36:1744-1753. 
19. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, 
Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman 
S, Wijns W and Terzic A. Cardiopoietic Stem Cell Therapy in Heart Failure: The C-CURE (Cardiopoietic stem 
Cell therapy in heart failURE) Multicenter Randomized Trial With Lineage-Specified Biologics. Journal of 
the American College of Cardiology. 2013;61:2329-2338. 
20. Wollert KC, Meyer GP, Lotz J, Ringes Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, 
Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A and Drexler H. Intracoronary autologous bone-
marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. The 
Lancet. 2004;364:141-148. 
21. Hamano K, Nishida M, Hirata K, Mikamo A, Li T-S, Masahiko Harada M, Miura T, Matsuzaki M and 
Esato K. Local Implantation of Autologous Bone Marrow Cells for Therapeutic Angiongenesis in Patients 
with Ischemic Heart Disease. Japanese Circulation Journal. 2001;65:845-47. 
22. Perin EC, Willerson JT, Pepine CJ and et al. Effect of transendocardial delivery of autologous bone 
marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart 
failure: The focus-cctrn trial. JAMA : the journal of the American Medical Association. 2012;307:1717-
1726. 
23. Vrtovec B, Poglajen G, Lezaic L, Sever M, Socan A, Domanovic D, Cernelc P, Torre-Amione G, 
Haddad F and Wu JC. Comparison of transendocardial and intracoronary CD34+ cell transplantation in 
patients with nonischemic dilated cardiomyopathy. Circulation. 2013;128:S42-9. 
24. Laflamme MA and Murry CE. Regenerating the heart. Nat Biotech. 2005;23:845-856. 
25. Hou D, Youssef EA, Brinton TJ, Zhang P, Rogers P, Price ET, Yeung AC, Johnstone BH, Yock PG and 
March KL. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde 
coronary venous delivery: implications for current clinical trials. Circulation. 2005;112:I150-6. 
26. Krzeminski TF, Nozynski JK, Grzyb J and Porc M. Wide-spread myocardial remodeling after acute 
myocardial infarction in rat. Features for heart failure progression. Vascular pharmacology. 2008;48:100-
8. 
27. Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH and Lee RJ. Injectable fibrin scaffold 
improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in 
ischemic myocardium. Journal of the American College of Cardiology. 2004;44:654-60. 
28. Dai W, Wold LE, Dow JS and Kloner RA. Thickening of the Infarcted Wall by Collagen Injection 
Improves Left Ventricular Function in Rats: A Novel Approach to Preserve Cardiac Function After 
Myocardial Infarction. Journal of the American College of Cardiology. 2005;46:714-719. 
Chapter 4: Objective 1B                                                                                                                                         55 
 
29. Rane AA and Christman KL. Biomaterials for the Treatment of Myocardial InfarctionA 5-Year 
Update. Journal of the American College of Cardiology. 2011;58:2615-2629. 
30. Laflamme MA and Murry CE. Heart regeneration. Nature. 2011;473:326-35. 
31. Rosen AB, Kelly DJ, Schuldt AJ, Lu J, Potapova IA, Doronin SV, Robichaud KJ, Robinson RB, Rosen 
MR, Brink PR, Gaudette GR and Cohen IS. Finding fluorescent needles in the cardiac haystack: tracking 
human mesenchymal stem cells labeled with quantum dots for quantitative in vivo three-dimensional 
fluorescence analysis. Stem cells. 2007;25:2128-38. 
32. Behfar A, Yamada S, Crespo-Diaz R, Nesbitt JJ, Rowe LA, Perez-Terzic C, Gaussin V, Homsy C, 
Bartunek J and Terzic A. Guided Cardiopoiesis Enhances Therapeutic Benefit of Bone Marrow Human 
Mesenchymal Stem Cells in Chronic Myocardial Infarction. Journal of the American College of Cardiology. 
2010;56:721-734. 
33. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, Koc ON and Penn MS. SDF-1 
expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial 
infarction. FASEB journal : official publication of the Federation of American Societies for Experimental 
Biology. 2007;21:3197-207. 
34. Takahashi K and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult 
fibroblast cultures by defined factors. Cell. 2006;126:663-76. 
35. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, 
Hassanipour M, Police S, O'Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J and Murry 
CE. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of 
infarcted rat hearts. Nature biotechnology. 2007;25:1015-24. 
Chapter 5: Objective 2A                                                                                                                                         56 
 
5 Objective 2a: Develop a method to characterize the contractile behavior of hPS-CM 
The introduction (starting with section 5.1), methods, results, and discussion presented in this objective 
are reprinted with permission from TISSUE ENGINEERING: Part C, Volume 23[8], pp. 445-454, published 
by Mary Ann Liebert, Inc., New Rochelle, NY (see Chapter 9: Appendix). 
5.1 Introduction 
Investigation within the past decade has yielded the ability to reprogram somatic cells into induced 
pluripotent stem cells (iPS)1, 2. iPS cells can be differentiated into a multitude of cellular phenotypes while 
maintaining the original genetic blueprint from the donor3. Maintaining the donor’s genetic information 
within these reprogrammable cells allows investigators to model disease states4, many of which focus on 
cardiac specific pathologies5. Generation of cardiomyocytes from iPS and embryonic stem cells (ESC)1, 6-8 
presents great promise for the generation of patient-specific cardiac disease models, myocardial 
regeneration therapies, and drug discovery9-11. However, human pluripotent stem cell-derived 
cardiomyocytes (hPS-CMs) are most phenotypically similar to fetal cardiomyocytes in terms of force 
production, adrenergic response, and sarcomere organization12, which may not be ideal for drug 
development or regenerative therapies. Therefore, recent research has focused on improving the 
maturation of hPS-CM to yield a more adult-like phenotype13-15. However, there are limited tools available 
to effectively measure the cellular physiological response to different stimuli over time, which would 
significantly aid investigations seeking to mature hPS-CM and utilize them in disease modeling and 
regenerative therapies.   
Many cardiac diseases manifest themselves as changes in cardiac tissue which directly affect mechanical 
strain, electrical propagation, beat frequency, beat consistency (arrhythmia), and delays between calcium 
flux and initiation of mechanical contraction16. Current techniques to monitor these changes in single cells 
or clusters of hPS-CM include integrating microelectrode arrays (MEA), flexible posts, force transducers, 
incorporation of fluorescent beads into the culture platform, patch-clamping techniques, and calcium 
sensitive dyes17-21. However, the incorporation of these devices into a culture platform is costly, low-
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throughput, time consuming, and may have secondary effects on cell performance, such as changes in 
beat frequency or magnitude of contraction22, 23. Thereby, the development of cost-effective and less-
invasive modalities able to concurrently measure mechanical and electrical components of contraction 
are needed for long-term experimentation.   
In this study, we describe a method to study the physiology of cardiomyocyte contractility with high 
spatial and temporal resolution using an image capture system. The system works by rapidly alternating 
between brightfield and epifluorescent illumination for each frame, to record mechanical contraction and 
calcium transients of contracting cardiomyocytes, respectively. A speckle tracking algorithm24 applied to 
the sequence of brightfield images determines the deformation of sub-pixel regions of cells and clusters 
in the field of view. From this information, the contractile strain and beat frequency can be calculated for 
the cell or cluster of interest that corresponds to the calcium transient frame that lies in between. As a 
result, the temporal relationship between the calcium transients and mechanical components leading to 
the contraction of a cardiomyocyte can be investigated. This technique can be applied aseptically and 
without the need to alter the culture platform, allowing for determination of cardiomyocyte behavior over 
time for use in drug discovery and functional tissues for myocardial regeneration strategies. 
5.2 Materials and methods 
5.2.1 Generation and culture of pluripotent stem cell derived cardiomyocytes 
Human induced pluripotent (iPS-CM) and embryonic (hES-CM) stem cells were differentiated into 
cardiomyocytes using a previously described guided differentiation protocol involving the serial 
application of activin-A and bone morphogenetic protein-47, 9, 25 and were cryopreserved as previously 
reported26. hES-CMs modified to express the genetically encoded protein calcium sensor, GCaMP, were 
used27. All employed cell preparations were confirmed to contain >70% cardiac troponin T+ 
cardiomyocytes by flow cytometry. hPS-CM cells were thawed and seeded at a density of 150,000 
cells/cm2 onto collagen IV coated 96 well plates (Sigma, 10 µg/mL). Cells were cultured at 37oC at 5% CO2 
and media (RPMI-B27, Pen Strep, L-Glutamine) was changed every 2-3 days. Upon thawing, cells adhered 
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to the coated plates within 24 hours. After three days in culture, regions within the monolayer of cells 
appeared to form clusters of cells, which began to spontaneously contract. Over the next 18 days, clusters 
did not appear to change in size, although some of the clusters detached from the surface of the culture 
plate. 
5.2.2 High density mapping analysis of cardiomyocyte contraction  
A high speed camera (HiSpec4, Fastec Inc.) attached to an inverted microscope (Leica, DMIL) was used 
to record contracting myocytes at 60 frames per second. HDM (high density mapping), a speckle tracking 
algorithm previously developed to measure strains on cardiac tissues24 was applied to the raw images to 
calculate strain fields and beat frequency (Figure 5-1). Briefly, HDM divides a selected region of interest 
(ROI) into variable window sizes (e.g. 16x16 pixel windows) (Figure 5-1B) and tracks displacements of each 
window between two sequential frames over a series of images. Displacement calculations are based on 
the phase correlation algorithm with subpixel accuracy first described by Foroosh et al.28 and are 
theoretically accurate to within 0.2 pixels24. Briefly, a hamming window is applied to the pixel windows, 
which are then transformed to the Fourier domain and combined via a cross power spectrum function 
(Figure 5-1C, D). Computation of the inverse Fourier transform of the cross power spectrum yields an 
impulse function marking the x and y displacement of the region between the two frames (Figure 5-1D,E). 
This process is repeated across the entire ROI with windows overlapping in both directions by a spacing 
equal to half the window size (e.g., 8 pixels for a 16x16 window, see Figure 5-1B) for each pair of frames 
yielding displacement fields over time. From displacement fields, regional strain tensors were computed 
via the Green-Lagrange definition29 using the start of contraction as a reference state. All strain fields 
reported herein are the maximum contractile strain (minimum E2) from the initiation of contraction to 
peak contraction. To isolate regions with significant contraction from noise, only regions contracting with 
greater than 0.5% strain were analyzed. Overlapping windows were applied to obtain a spatial map of 
contractile strain across the cardiomyocyte cluster for each contraction cycle. From these data, heatmaps 
were generated to indicate the location and magnitude of contractile strain spatially within a cluster at 
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peak contraction (Figure 5-3A). From this map, the spatial average (reported as contractile strain) and 
maximum contractile strains were calculated across a cluster, and plotted over time (Figure 5-5, Figure 
5-6). Finally, to compare effects of culture duration on cardiomyocyte contractility, these spatial average 
and maximum strains were temporally averaged over three contraction cycles (Figure 5-5). For display of 
strain waveforms, baseline drift (due to frame-to-frame error propagation in the HDM algorithm) was 
removed by subtracting a spline curve fit to the minimum (spatial average) strain just prior to each 
contraction beat. Average principal strain across the entire ROI over time was used to determine beat 
frequency via Fourier analysis. To determine the parameters to be used for HDM analysis, different 
window sizes (8x8, 16x16, and 32x32 pixels), each with a spacing equal to half of the window width, and 
different number of averaging windows (3 - 9) were examined. 
 
5.2.3 Brightfield and fluorescent imaging acquisition 
Dual brightfield and fluorescent cardiomyocyte imaging was performed using a Zeiss AxioObserver.A1 
inverted microscope with Zeiss Fluar objective lens (20x, Numerical Aperture: 0.5) and a Hamamatsu Orca 
Flash 4.0 sCMOS camera with CameraLink board mounted with a 1.0x c-Mount adapter. A digital 
Figure 5-1 Use of High Density Mapping to determine displacement fields of contracting hPS-CM. HDM 
was applied by acquiring a high speed video of contracting hPS-CM to obtain a stack of images (A) from 
which a region of interest could be selected (B) and subdivided into 16x16 pixel windows. Each 16x16 pixel 
window is transformed to the Fourier domain (C) where phase correlation between frames is applied (D) 
and an inverse Fourier transform is taken resulting in the peak displacement between the two frames (E). 
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illumination controller (Nobska Imaging) synchronized image capture with alternating pulses of either (1) 
epifluorescence excitation illumination from a 50W blue LED (Mightex) coupled to the microscope by a 
liquid light guide, or (2) brightfield illumination from a green 3W LED (Luxeon Rebel with Spot optics, 
LEDsupply) mounted above the stage in place of the condenser. MicroManager software controlled image 
streaming parameters and illumination timing (pulse duration and delay relative to start of frame capture)   
via programmable TTL logic from the camera (Figure 5-2A). The controller activated either the 
epifluorescence LED (blue), for a pulse duration as specified by the user in MicroManager, or the 
brightfield LED (green) for a fixed 16 µs pulse (Figure 5-2B). Time-series videos were acquired in free-
running streaming mode with a minimum exposure time defined by:  
readout
v
pulse t
Ntt
2exp
+≥
 
where tpulse is the excitation pulse duration, Nv is the vertical images size (pixels), and treadout is the readout 
time per vertical line = 9.744 µs. For a typical 2048(h) x 1024(v) pixel image, the readout time is ~5 ms, 
limiting total framerate to ~200 fps and rate of brightfield/fluorescent frame pairs to ~100 fps. Reducing 
Figure 5-2. Image acquisition schematic with temporal control of fluorescence or brightfield illumination. Microscope 
schematic, a digital microscope controller for image capture of contracting cardiomyocytes using an Orca Flash 4.0 sCMOS 
camera with alternating pulses of fluorescence and brightfield illumination (A). Timing chart indicating sensor readout and 
the start of pixel exposure; when all lines are exposed the controller initiates a pulse of fluorescent (blue) or brightfield 
(green) illumination (B). The cycle is started over after the total exposure time (7ms) with alternating brightfield and 
fluorescent illuminations. 
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vertical pixel number proportionally increases framerate, 
with 1000 fps possible with a narrowed vertical image 
size (Table 5-1). Image stacks were de-interlaced using 
ImageJ.  
5.2.4 Loading iPS-CM with fluo-4 AM 
Fluo-4 AM dye (Invitrogen) was loaded into iPS-CM for 
calcium transient analysis. Cells were incubated with 
Fluo-4 AM (5µM dissolved in Pluronic F-127 (20% 
solution in DMSO; Invitrogen) in RPMI-B27 medium) for 
10 minutes at 37°C. Before recordings were obtained, 
fresh pre-warmed RPMI-B27 medium was added and 
cells were allowed to sit for 20 minutes to allow the dye 
to de-esterify inside the cells. All fluorescence imaging of calcium transients were recorded at 71 frames 
per second within 2 hours of dye addition. After recording, cells were rinsed in RPMI-B27 medium and 
returned to incubator for continued culture in RPMI-B27 medium. To assess if the calcium signal occurred 
independently of the mechanical contraction, cells were treated with 10µM Cytochalasin-D (Sigma) for 10 
minutes prior to imaging. 
5.2.5 Calcium transient analysis 
Intracellular calcium levels were quantified using a custom MATLAB code that determined average 
fluorescent intensity change with respect to baseline intensity values across a selected ROI and reported 
as ∆F/F0. F0, the baseline fluorescent value, was defined as the minimum intensity value in the region, 
while ∆F is the average change in intensity for the selected region at each given time point. A 
deconvolution algorithm was implemented in MATLAB (‘deconv’ function with exponential decay kernel) 
to correct for the dynamics of the fluorescent calcium reporters, using time constants of 4 ms for the fluo-
4 AM indicator 30 and 50 ms for GCaMP (representing the ‘on’-kinetics) 31.   
Table 5-1. Table showing possible combinations of 
optical system parameters and each resultant frame 
rate. Column labeled “typical” shows the parameters 
chosen for this study. 
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5.2.6 Infusion of chemical stimulation via epinephrine 
Isoproterenol hydrochloride (Sigma) was used to examine the cardiomyocytes response to an 
adrenergic stimulant. Baseline recordings were taken with cells cultured in normal medium, medium was 
then removed and a recording was obtained with cells incubated in medium supplemented with 
isoproterenol at 0.1, 1, and 10µM. The same contracting region was analyzed for each increasing drug 
addition with a total of 5 regions analyzed.  
5.2.7 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). 
Comparisons for contractile parameters of hPS-CM between time points were done using a one-way 
ANOVA with a Tukey post-hoc analysis for multiple comparisons. All measurements were averaged over 
the entire selected region and then averaged over three contraction cycles. All data is reported as 
mean±SEM, with the exception of strain data (Figure 5-3B), and frequency data (Figure 5-5A and Figure 
5-6B) reported as mean±SD. Significance was considered at p<0.05.  
5.3 Results 
5.3.1 Effect of spatial resolution on determining contraction in hPS-CM 
Using the dual image acquisition system, high-speed videos were captured of regions of beating hPS-
CMs at 142 fps (71 frame pairs/s). A computational algorithm based on Fourier transforms (HDM) was 
applied to the recorded image sequences to determine contractile strain. Different window sizes (8 - 32 
pixels), window spacing (half of window size), and number of windows (3 - 9; used to obtain an averaged 
contractile strain) were examined to determine how these parameters affected contractile strain 
quantification across a cluster of contracting hPS-CM (Figure 5-3). The smallest window size (8x8 pixels) 
gave the widest range of contractile strains (4.5 - 11.3%) and highest standard deviation using 3 or 5 
averaging windows (Figure 5-3B), and the finest spatial resolution and largest strain map (Figure 5-3C), 
but also the longest computation time (Figure 5-3D). The largest window size (32x32 pixels), resulted in a 
coarser and smaller map of the strain distribution due to overlapping window regions, showed no 
difference in the contractile strain output when averaged over a range of windows, and was computed 5 
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times faster than an 8x8 window for the same region. Overall, the number of windows used to calculate 
strain did not have a significant effect on computational time. A 16x16 pixel window with 8 pixel window 
spacing and 5-window averaging was chosen for further applications of HDM, based on its narrower range 
of contractile strain values (4.5 - 7.6%), subcellular spatial resolution, and reasonable computation time. 
Additionally, spatial distribution of strain for 
four independent contracting clusters was 
examined and was found to follow a normal 
distribution (Figure 5-4).  
5.3.2 Contractile mechanics of hPS-
CM can be monitored over 21 days  
In order to test the ability for the HDM 
algorithm to evaluate cardiac contractile 
mechanics over time, hPS-CMs were cultured 
on collagen type IV coated plates and high 
Figure 5-3. The effect of window size and window spacing on reported contractile strain values. The resulting strain 
magnitude and location was used to generate heatmaps (A) with increasing average spatial contractile strain at peak 
contraction in red. Pixel width for boxes in (A) was 325 wide and 272 pixels in height. Using different window sizes and 
spacings (1/2 window size) can affect reported contractile strain values (B), area used for contractile strain calculations 
reported as a change from the original selected ROI (C), and computing times (D). A 16x16 pixel window spacing with an 
8 pixel window shift and an average contractile strain calculated over 5 windows was used to report contractile strain (A, 
B). Mean±SD. 
Figure 5-4. Representative distribution of strain within clusters. 
Spatial distribution of strain for four independent contracting clusters 
was examined. Strain values were placed in 2-4% bins from -4 to 10% 
strain and plotted as a histogram with the average value in the upper 
left. Black arrow indicates values used for average strain calculation. 
All histograms followed a normal distribution. 
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speed videos of contracting hPS-CM were taken on days 7, 14, and 21. Three clusters of contracting cells 
within two wells were analyzed for contraction over three contraction cycles per cluster (n=6). HDM was 
applied to the cluster using a window size of 16x16 pixels, an 8 pixel window spacing, and 5 averaging 
windows. Beat frequency, contractile strain, and maximum strain were computed for each time point. 
hPS-CMs showed increased beating frequency over-time, where cells exhibited a significantly higher 
(p<0.001) beat frequency on day 21 (1.52±0.09 Hz) when compared to day 7 (1.06±0.09 Hz; Figure 5-5A). 
Cells seeded on collagen IV coated plates had a contractile strain on day 7 of 4.5±0.4%, which significantly 
decreased (p<0.05) to 2.9±0.3% strain at day 21 (Figure 5-5B). Maximum contractile strain calculated on 
day 7 for hPS-CMs was found to be 19.9±1.4%, which decreased significantly (p<0.001) to 10.8±1.5% strain 
at day 21 (Figure 5-5C). These results indicate the ability for the HDM algorithm to detect and quantify 
changes in cardiomyocyte contractility over 21 days.  
5.3.3 Measurements of calcium transients and mechanical contraction in hPS-CM 
iPS-CM calcium transients were visualized by loading the cells with 5µM Fluo-4 AM, a calcium indicator 
dye that changes fluorescence in proportion to intracellular free calcium. In addition, calcium transients 
were observed in ES-derived cardiomyocytes (ES-CMs) differentiated from a reporter line expressing the 
Figure 5-5. HDM can be used to quantify contraction of hPS-CM seeded on collagen IV coated 
plates over 21 days. hPS-CM significantly increased beat frequency by 1.5x between day 7 and 
day 21(A). A significant decrease between day 7 and day 21 was observed for contractile strain 
(B) and maximum contractile strain (C). Mean±SD for frequency, Mean±SEM for contractile and 
maximum strain, n=6, *p<0.05. 
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genetically-encoded calcium indicator GCaMP39. The same image acquisition system was able to detect 
calcium changes over the contractile cycle via Fluo-4 AM in iPS-CMs (Figure 5-6) and GCaMP in ES-CMs 
(Figure 5-7). A 1ms fluorescent light pulse with 2x2 binning allowed for recordings at a frame rate of 142fps 
Figure 5-6. Overlay of mechanical contraction and calcium transients in iPS-CM. Alternating brightfield and fluorescent 
images of contracting iPS-CM loaded with fluo-4 AM at day 21 resulted in spatial heatmaps for peak mechanical 
contraction (A) and peak calcium flux (B). The location of peak calcium intensity did not correspond with location of peak 
contractile strains. (A, B white arrows) The resulting cyclic contractile strain and calcium signal is presented over 8 seconds 
(C) with an isolated cycle indicated by the red box in C (E). Cells treated with Cytochalasin-D exhibit loss of mechanical 
contraction while calcium transients are maintained (D). 
Figure 5-7. Overlay of mechanical contraction and calcium transients in ES-CM. Alternating brightfield and fluorescent 
images of contracting GCaMP3 ES-CM resulted in spatial heatmaps for peak mechanical contraction (A) and peak calcium 
flux (B). The resulting cyclic contractile strain and calcium signal is presented over 14 seconds (C) with an isolated cycle 
indicated by the red box in C (D). 
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(71fps for each channel, brightfield and fluorescent), spatial resolution of 0.65 µm/pixel, and field of view 
of 1024 x 512 pixels or 665 x 333 µm (Table 1). These settings yielded a calcium signal-to-noise ratio of 21 
dB as determined using MATLAB. Fluorescent traces were deconvolved to remove the effects of slow 
optical calcium sensor dynamics, using the “on”-kinetics of the Fluo-4 and GCaMP sensors. Whereas no 
difference was seen before and after deconvolution for the faster Fluo-4 sensor (data not shown), the 
deconvolved GCaMP trace rose faster than the original trace, however both traces began at the same time 
(Figure 5-8).  
Brightfield and fluorescent images were alternatively acquired to examine the spatial and temporal 
relationships between mechanical contraction and calcium transients of contracting hPS-CMs. Regions of 
peak contractile strain (Figure 5-6A) and peak calcium intensity change (Figure 5-6B) during the contractile 
beat cycle were not well correlated across the iPS-CM cluster. The mechanical contraction and calcium 
transient tracings across were plotted together in order to examine their temporal relationship (Figure 
5-6C). Calcium levels rose before the onset of mechanical contraction for Fluo-4 AM loaded iPS-CM (Figure 
5-6) and GCaMP-expressing ES-CM (Figure 5-7), following expectations for cardiomyocyte physiology. 
Fluo-4 calcium traces peaked before peak strain in iPS-CM, whereas GCaMP calcium traces peaked after 
peak ES-CM strain, reflecting differences in calcium sensor or cardiomyocyte dynamics. Cells treated with 
Cytochalasin-D, which eliminate mechanical function by inhibiting actin polymerization, retained similar 
Figure 5-8. Deconvolved GCaMP calcium transient traces. Deconvolved (blue) and non-deconvolved (orange) 
GCaMP calcium traces (A). Expanded portion of the traces from A, black box indicates region shown (B). 
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calcium signal cycles (Figure 5-6D), demonstrating that the calcium signal was due to calcium transients 
and not mechanical interferences. 
5.3.4 Isoproterenol simulation increases contractile strain and beat frequency  
Adrenergic stimulation (isoproterenol) was applied to Fluo-4 AM loaded iPS-CM to evaluate the ability 
of the algorithm to detect simultaneous changes in contractility in terms of contractile strain, beat 
frequency, and calcium transients. Isoproterenol, a β-adrenergic agonist, was chosen as it has been shown 
to increase beat frequency for adult cardiomyocytes32. Isoproterenol was applied at concentrations of 0.1, 
1, and 10µM with recordings taken immediately after each addition (n=5). Beat frequency was found to 
be 0.66±0.13Hz with cells cultured in RPMI-B27 media without isoproterenol (Figure 5-9A, B). The addition 
of isoproterenol at concentrations up to 10µM significantly increased beat frequency to 0.88±0.09Hz 
(Figure 5-9A, B, p<0.05). Contractile strain began at 3.1±0.45% with RPMI-B27 media (Figure 5-9). The 
addition of isoproterenol did not significantly change strain levels as all strain levels for stimulated cells 
were between 3.2-3.6% (Figure 5-9C, p>0.05). These results indicate that this system is capable of 
Figure 5-9. Isoproterenol stimulation of hPS-CM. Adding isoproterenol to hPS-CM increased beat frequency (A,B) up to the 
addition of 10µM isoproterenol, with representative traces of Fluo-4 AM loaded contracting hPS-CM (A) and frequency data 
averaged in (B). Addition of isoproterenol did not affect contractile strain for any condition compared to baseline (C). Mean±SD 
for frequency, Mean±SEM for contractile strain, n=3, *p<0.05. 
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detecting changes in the contractile properties of cells when isoproterenol is applied, which may be 
helpful for drug screening studies. 
5.4 Discussion 
Recent advances in stem cell technology have yielded high purity (>90%) populations of contracting 
cardiomyocytes derived from both ES and iPS cells7, 8. These cardiomyocytes have the potential to be used 
in a wide variety of applications including myocardial regeneration therapies, disease modeling, drug 
screening, and development. To fulfill the potential of these applications, cost-effective, high-throughput 
techniques to concurrently monitor contractile and calcium transient changes in single cells or clusters of 
hPS-CM are needed. By concurrently monitoring the relationship between contractile and ionic changes 
overtime, physiological relationships can be better understood, which is valuable for applications such as 
drug screening for off target changes in cardiomyocyte contractility.  
Current techniques to monitor cardiomyocyte electrophysiological function include the use of 
microelectrode arrays, patch clamping, and voltage or ion sensitive fluorescent dyes. Microelectrode 
arrays give measurements of beat frequency and field potential, but require cells to be cultured on a 
specific surface connected to the appropriate data acquisition system33. Patch clamping records action 
potential and ion channel information of single cells, and is low-throughput, time consuming, and requires 
expertise34. Voltage and ionic dyes, such as di-8-ANEPPS and Fluo-4 AM, or their genetically-encoded 
counterparts, such as ArcLight and GCaMP, are good for non-invasive measurements of cardiomyocyte 
electrophysiology or intracellular calcium concentrations at the single-cell level or in multicellular 
preparations35, 36.  
Contractile force can be evaluated using force transducers or traction force microscopy (TFM)37-39. Both 
of these techniques require known substrate mechanical properties and necessitate changes to the 
culture platform that may have secondary effects on cell function22, 23. Force transducers are best suited 
for measurements on the macro tissue scale, which is not appropriate for studies investigating cellular 
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contractility. TFM can measure contractility on the cellular level, but requires cells to be cultured on a 
substrate with incorporated microbeads. Bead displacement is used to quantify cell contraction; however, 
microbead incorporation can severely limit measurements by having random bead distributions and 
densities that might not accurately depict cellular contractility.  
Optical methods can be used to overcome the challenges of integrative culture platforms for monitoring 
cardiomyocyte function. Current image processing techniques focus on edge detection techniques, such 
as with laser diffraction and microscopic cell images to obtain information about cell contractility40, 41. 
However, these methods are limited to the spatial resolution of the imaging systems, as well as to changes 
in cardiomyocyte contraction from unexpected movement, asynchronous contraction, or cardiomyocyte 
rotation, which would result in an inaccurate contractile output. Imaging methods that focus on changes 
in sarcomere striations42 are limited to single isolated cardiomyocytes with well-defined striated patterns. 
However, hPS-CM are comparatively immature43, exhibit less defined sarcomere patterns, and are 
cultured in monolayers instead of single cells; thus, these imaging techniques may not be sufficient to 
measure contractile mechanics of hPS-CM. 
More recent techniques to monitor contraction apply an optical flow algorithm with macroblocks to 
estimate motion of a set of images of contracting cardiomyocytes22, or particle image velocimetry (PIV), a 
cross-correlation procedure to determine displacement fields of cardiomyocytes visualized using video 
microscopy23. Both methods quantify beating speed, beating velocity and beat pattern, but not the 
magnitude of contraction. Neither technique gives quantitative information about cardiomyocyte 
contraction combined with information about calcium signaling. While calcium signaling alone has been 
shown to predict in vitro cardiotoxicity19, the combination of calcium signaling and mechanical contraction 
provides a more robust method to detect cardiotoxicities that may affect mechanical contraction apart 
from calcium signaling. 
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Here, we describe a technique for concurrent monitoring of mechanical contraction and calcium 
transients of hPS-CM over several weeks using a system that alternates high speed imaging of brightfield 
and fluorescence. The system allows frames to be captured at >60fps over a 1024x512pixel region of 
interest (ROI), or up to 1000fps by decreasing the ROI to 96 vertical pixels. Our results demonstrate the 
ability to characterize mechanical contraction by applying HDM, a speckle tracking algorithm, to 
brightfield images to calculate beat frequency as well as quantitative information about the magnitude of 
contraction (contractile strain). Calcium transients were calculated by analyzing the acquired fluorescent 
signals from Fluo-4 AM or GCaMP calcium reporters. Calcium transients and contractile strain waveforms 
were plotted together; for Fluo-4 AM loaded iPS-CM, the calcium waveform was initiated and peaked 
before strain, as expected for cardiomyocyte physiology44. For GCaMP ES-CM, the calcium signal began 
before the strain signal, but the calcium signal peaked after strain began to decline, highlighting the 
differences between the cardiomyocyte sources and kinetics of the calcium reporters36, 45. Deconvolution 
was performed on both Fluo-4 and GCaMP fluorescent traces to attempt to remove any sensor-induced 
delays. At the frame rates used (14 ms interval), deconvolution had little effect on Fluo-4 traces (time 
constant 4 ms), but resulted in GCaMP traces that rose faster than the original traces (“on” time constant 
50 ms). However, “off” kinetics of GCaMP sensors are often much slower than “on” kinetics31. 
Deconvolution algorithms that address different on- and off-kinetics can better correct for these effects.  
Due to the aseptic nature of this analysis technique, recordings were obtained for several time points 
over a period of 21 days. Mechanical contraction of hPS-CM clusters was quantified using HDM in terms 
of beat frequency, contractile strain, and maximum contractile strain. Over 21 days, hPS-CM exhibited a 
significant increase in beat frequency, similar to reports from other groups46, 47, accompanied by a 
significant decrease in contractile strain. Isoproterenol stimulation demonstrated the system’s ability to 
capture chemically induced changes in mechanical contraction, which may be valuable for drug screening 
studies. With the addition of isoproterenol, we demonstrated a significant increase in beat frequency 
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along a similar order reported by others14, 20, 48, but no significant changes in contractile strain. While 
isoproterenol has been shown to increase twitch forces in mature adult cardiomyocytes, predicting an 
increase in contractile strain levels, studies have shown that immature cardiomyocytes, such as the hPS-
CM used in this study, have different responses to drug additions than adult cardiomyocytes. For example, 
immature hPS-CMs produce less force in response to isoproterenol compared with adult 
cardiomyocytes49, this may describe why no significant change in strain was demonstrated with 
isoproterenol addition. 
Another application of this system could be to measure functional differentiation of cultures over time. 
Although cardiac differentiation is a well-established technique, purity remains a major issue. Our system 
may be able to elucidate changes due to differentiation protocols or batch variability. In a computational 
model of fibroblasts and cardiomyocytes, Zhan and colleagues demonstrated changes in deformation 
resulting from changes in the ratio of fibroblasts to cardiomyocytes 50. A lower purity of cardiomyocytes 
may result in decreased contraction. Additionally, the whole-field property of our system could be used 
to determine if regions of cells are not contracting under whole field stimulation, suggesting 
undifferentiated or dysfunctional cells. Together, this information may continuously inform investigators 
on the functional differentiation of their cultures. 
The system developed here allows brightfield and fluorescent images to be acquired in rapid succession, 
for concurrent measurements of strain and intracellular calcium. Strain data is generated by analyzing the 
displacement between two brightfield images, which span each fluorescent image used to quantify 
calcium levels. Thus, the calcium information is obtained temporally at the midpoint of strain information, 
and the temporal relationship between calcium activity and the corresponding mechanical contraction 
can be obtained by overlaying the two waveforms. Additionally, by alternating image acquisition this 
system avoids the expense and alignment required by dual-view or dual-camera setups, which spectrally 
split fluorescence (blue-green) and brightfield (red or infrared), but capture both images simultaneously. 
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Another advantage of this system is that as it uses a 96 well cell culture plate, with the appropriate 
alterations the system could be automated to provide for real time information which would be ideal for 
high throughput screening.  
Different window sizes and spacings were used to compute contractile strain to determine if the 
calculated strain reached an optimum point, suggesting a minimum number of pixels needed for 
calculating strain. A 16x16 pixel window with an 8 pixel spacing averaged over 5 windows was used for 
strain calculations as these parameters maintained spatial information with less strain variance and 
decreased computation time. By averaging over 5 windows, strain calculations are likely not 
overestimated, as regions of strain artifacts are removed, or underestimated, as using 5 windows 
maintains spatial information. The 8x8 pixel window with a 4 pixel spacing maintained the most spatial 
information, but had the highest computation time and the largest degree of strain variance when fewer 
averaging windows were used (3 and 5) due to the small regions being analyzed. A 32x32 pixel window 
with a 16 pixel spacing had the fastest computation time; however spatial information was lost due to 
large regions being analyzed. One of the advantages of this method is spatial resolution, as the smaller 
pixel window sizes allow the regions analyzed to be on the size of a cell. The larger spacing results in 
displacement being determined in fewer locations, while the larger window size may miss inhomogeneous 
deformation that may occur within the window. A key benefit to this technique is that HDM enables 
different combinations of window sizes, window spacings, and number of windows averaged, which can 
be tailored to the desired application.  
The use of HDM provides high temporal resolution of quantitative information about cardiomyocyte 
contraction at a sub-pixel resolution. Here, this technique was demonstrated at a cellular level, but can 
also be applied at a tissue level as demonstrated on hPS-CM seeded myocardium fibers51. As this 
technique can be easily applied to high speed videos it is a powerful tool to examine cardiomyocyte 
contractility over time. This technique can be used to obtain information about how different drug 
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compounds affect cardiomyocyte contractility, both mechanically and at the intracellular calcium level, 
which would enhance the quality of current drug testing systems. Herein, we demonstrated the ability of 
the system to determine increased contractile frequencies with the administration of isoproterenol. 
Additionally, for hPS-CM potential to be realized for cell replacement strategies, hPS-CM should exhibit a 
more adult like phenotype in order to couple and contract with human myocardium. The use of this optical 
system to monitor contraction as an indicator for maturity, for example through adrenergic stimulation, 
would provide a convenient and economic solution to examine cell maturation without having to sacrifice 
cells for use in terminal analysis techniques.  
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6 Objective 2b: Produce and characterize contractile hPS-CM seeded microthreads. 
In this objective we will use the method developed in objective 2b to determine contractile behavior of 
hPS-CM seeded along the scaffold in terms of contractile strain, beat frequency, and conduction velocity 
from calcium transient waveforms. The same cell type from objective 2a will be used and all microthreads 
used in this objective were produced as described in objective 1a. 
6.1 Introduction 
Our fibrin suture has been shown to be an effective delivery vehicle for hMSCs1, we hypothesize that 
we will be able to similarly deliver hPS-CM to healthy cardiac tissue. The aim of objective 2b is to identify 
and implement strategies to seed hPS-CM onto fibrin microthreads and characterize how these cells 
function on the microthreads and understand how their contractile properties may change over time in 
culture.  
Fibrin microthreads have been previously shown to support hMSC attachment2, however it is unknown 
whether fibrin microthreads can support hPS-CM attachment. The ability of cells to bind to substrates is 
dependent on integrins, a family of cell surface receptors. Integrin’s are αβ heterodimeric transmembrane 
glycoproteins on a cells surface that can bind ligands found on ECM proteins. While hPS-CM can be 
maintained on tissue culture polystyrene they are better supported on an ECM that more closely 
resembles in vivo conditions3, 4. Cardiac muscle is comprised of collagen type I and III in the interstitium, 
collagen type IV and glycoproteins fibronectin and laminin in the basement membrane5. hMSCs have 
shown the ability to bind to fibrin as well as ECM proteins vitronectin and fibronectin, among others2, 4, 6. 
hMSCs and hPS-CM share some integrins namely α3, α5, αV, and β14, 7-9, which may suggest that hPS-CM 
can bind to fibrin; however, hPS-CM express many other integrins that may preferentially bind to other 
ECM proteins. Mummery et al. described the integrin expression profile for hESC-CM to be comprised of 
α3, α5, α6, α7, α11, αV, and β1 which bind laminins (α1β1, α3β1, α6β1, and α7β1) collagens (collagen IV; 
α1β1, α3β1, α10β1, α11β1), and fibronectin (α3β1, α5β1, αvβ1) with unknown specificity7, 10, 11. In adult 
cardiomyocytes, the same integrin expression with the addition of α1 (collagen IV, laminin), α9 
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(fibronectin) and α10 (collagen IV), has been reported12, 13. Additionally, studies have shown that ESC and 
iPS derived cardiomyocytes preferentially bind to substrates coated with fibronectin and collagen type IV 
over uncoated substrates11, 13. Based on the above evidence, in this objective we will investigate the effect 
of ECM coatings of fibronectin and collagen type IV on fibrin microthreads on hPS-CM attachment. 
hPS-CMs have the ability to spontaneously contract in a 2D environment in vitro after differentiation 14. 
Previous studies have indicated that fibrin is a suitable biomaterial to support hPS-CM contraction15, 16. 
Various groups have used fibrin based hydrogels to create cardiac patches for myocardial regeneration 
strategies as well as engineered heart tissue for initial screening of the cardiac effects of drugs15, 17, 18. Both 
patches and engineered heart tissue incorporate hPS-CM and been shown to assemble into a functional 
3D syncytium with measurable contractility. While these fibrin patches have been shown to be a 
competent scaffold for supporting hPS-CM contraction many studies implanting these patches onto the 
epicardial surface have found a collagen interface between the host myocardium and the graft limiting 
cell migration into the host myocardium15, 19. The use of a fibrin microthread suture may help over some 
these engraftment issues by delivering cells directly into the myocardium instead of on the epicardial 
surface, however, we must first examine if fibrin microthreads can also support hPS-CM attachment and 
contraction. 
Previous studies have indicated that fibrin microthreads are capable of supporting C2C12 myoblast 
attachment and survival as well as direct cellular alignment for myoblasts20. As cardiomyocytes exist in a 
highly aligned environment, improved alignment in vitro may provide enhanced functional contraction 
and improvement in integration when implanted in native myocardium. Several groups have used various 
techniques to examine how improved alignment of cardiomyocytes affects cell function21-24. These studies 
demonstrated that improved alignment using micropatterning or engineered tissues results in a greater 
degree of electrical anisotropy and higher production of contractile forces. Given the results of these 
studies it will be important to determine if the fibrin microthreads are capable of guiding hPS-CM 
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alignment along the threads and if improved alignment results in increased function in terms of higher 
contractile strains.  
As cardiovascular tissue is a highly aligned, contractile organ it will be important to determine if fibrin 
microthreads are capable of supporting hPS-CM attachment and cell contraction, and directing cellular 
alignment in a manner that will be beneficial for cell delivery via fibrin microthreads to cardiac tissue. To 
examine these properties, this objective will utilize different ECM proteins to examine cell attachment. 
Then, using the method developed and described in objective 2a, we will measure contractile strains, 
contractile orientation, beat frequency, and conduction velocity using calcium transients of hPS-CM 
seeded microthreads over three weeks in culture. Additionally, cell alignment will be examined using 
immunohistochemistry techniques and contractile orientation data. The results of this objective will 
define the ideal hPS-CM attachment conditions to fibrin microthread and will characterize hPS-CM 
alignment and mechanical contraction properties when seeded on fibrin microthreads over three weeks 
in culture. 
6.2 Materials and methods 
6.2.1 Seeding platform for hPS-CM attachment to fibrin microthreads 
To facilitate hPS-CM seeding individual fibrin microthreads were used and adhered in groups of three 
to custom polydimethylsiloxane (PDMS) washers (inner diameter: 1.2cm) using medical grade silicone 
Figure 6-1. Seeding schematic to seed hPS-CM onto fibrin microthreads. Individual 
fibrin microthreads are glued to a PDMS washer (A) and then placed over an elevated 
12mm coverslip (B). A 150µL suspension of cells is pipetted onto the coverslip with 
the threads for cell seeding. 
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adhesive (Figure 6-1). PDMS constructs with microthreads were placed in a six well plate for ethylene 
oxide (EtO) sterilization. Constructs were allowed to de-gas for 24 hours after EtO sterilization. 
Immediately before seeding, microthreads were allowed to rehydrate for 20 minutes in dPBS. Thread 
constructs were then placed over an elevated 12mm glass coverslip and coated with ECM protein 
(fibronectin or collagen IV, 10µg/mL) for 2 hours. For hPS-CM seeding, constructs were moved to new 
12mm glass coverslip platforms and a 150µL cell suspension (1.33x106 cells/mL) in aprotinin (50µg/mL) 
supplemented RPMI-B27 medium was added to the coverslip (Figure 6-1). Control TCP plates were coated 
with 0.1% gelatin, collagen IV, or fibronectin and were seeded with hPS-CM at a density of 150,000 
cells/cm2. Cells were allowed to attach for 18 hours in an incubator at 37oC, after which cell seeded 
microthreads were moved to a six well plate with fresh RPMI-B27 medium supplemented with aprotinin, 
medium was changed every 2-3 days. 
6.2.2 Effect of ECM surface coatings on hPS-CM attachment  
To examine the effect of different surface coatings on hPS-CM attachment to fibrin microthreads, ECM 
proteins collagen IV and fibronectin were used. The seeding methods from section 6.2.2 was adapted to 
allow for ECM coatings. After the threads were hydrated and moved to an elevated 12mm coverslip, 
threads were coated as described in 6.2.2. ECM coatings were allowed to adhere for 2 hours after which 
constructs were moved to another elevated 12mm coverslip for final cell seeding. Cells were seeded as 
done in section 6.2.2. 48 hours after seeding, constructs were moved to new wells with fresh medium for 
continued culture, or microthreads were prepared for a CyQuant assay. All threads from one construct 
were cut and placed in an eppendorf tube containing 1mL of dPBS. The remaining steps in the CyQuant 
assay were run as described in section 3.2.4. 
6.2.3 Viability of hPS-CM attachment on fibrin microthreads  
To characterize cell viability a LIVE/DEAD assay (Life Technologies) was conducted, according to 
manufactures recommendations, 48 hours after hPS-CM constructs were seeded. Briefly, medium was 
aspirated and replaced with 1mL of sterile RPMI containing a 4µM ethidium homodimer-1 and 2µM 
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calcein-AM working solution and plates were incubated at 37C for 15 minutes. The RPMI solution was 
aspirated and replaced with a 4µM ethidium homodimer-1 and 2µM calcein-AM working solution with 
Hoechst 33342 (0.5ug/mL; Life Technologies) and plates were incubated for an additional 15 minutes at 
37C. Calcein-AM (green Ex/em 495nm/515nm) is retained within the cytoplasm of living cells, while 
ethidium homodimer-1 (red, Ex/em 495nm/635nm) enters dead cells and binds nuclear DNA, but is 
excluded from living cells with intact plasma membrane activity. Microthreads were imaged using a Leica 
DMIL inverted microscope. 
6.2.4 Capturing contraction of hPS-CM seeded microthreads 
To record the contraction produced by seeded sutures a LEICA DMIL inverted microscope with a Fastec 
HiSpec4 camera mounted to record video at high magnifications. Video was recorded at 60 frames per 
second for 25 seconds at a magnification level of 200x at 4 different locations along the length of the 
thread. To determine the time course of contraction, microthreads were recorded at days 7, 14, and 21 
post seeding. Collagen IV, fibronectin, and fibrin only hPS-CM seeded sutures were analyzed. Parallel 
control experiments were run with hPS-CM plated on fibronectin (10µg/mL) and collagen IV (10µg/mL) 
coated TCP at a density of 150,000cells/cm2. The data was analyzed using HDM as described in chapter 5. 
For contractility alignment, the angle of the principal strain (E2) was calculated in MATLAB utilizing the 
following formula where Exx, Eyy, and Exy are the x, y, and shear components of strain:  
E1_angle (radians)=0.5*atan2(2*(Exy),Exx-Eyy) 
E1_angle (degrees)=E1_angle (radians)*180/pi() 
E2_angle (degrees)=E1_angle (degrees)-90 
     
The values of the E2 angle were calculated for zero to peak of E2, for each contraction cycle, and were 
compared to the angle of the microthread and the difference between the two was determined. The 
percent of total angle differences between 0-13 degrees were reported for days 7, 14, and 21. 0-13 
degrees was chosen as cardiomyocytes within human myocardium are aligned within 13 degrees25. 
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6.2.5 Immunocytochemistry  
At day 1, 4, 7, 14, and 21 hPS-CM seeded microthreads were fixed in 4% paraformaldehyde for 10 
minutes, rinsed with PBS and blocked in 5% goat serum or 1.5% rabbit serum in PBS for 45 minutes. 
Primary antibodies were applied at a dilution of 1:100 (mouse-anti-alpha actinin, Abcam; rabbit-anti-
connexin-43, Cell Signaling Technologies) at 4oC overnight. Cells were incubated for an hour in the 
appropriate secondary antibodies (AF488 anti-mouse 1:400, AF568 anti-rabbit, Invitrogen). Cells were 
counterstained using Hoechst 33342 (0.5ug/mL, Life Technologies) for 5 minutes. Images were obtained 
using a Leica laser scanning confocal microscope. 
6.2.6 Conduction velocity measurements 
hPS-CM seeded sutures were loaded with Fluo-4 AM and recorded at days 7, 14, and 21 as described in 
chapter 5 in sections 5.2.3 and 5.2.4. Calcium transient analysis was done as described in 5.2.5 with the 
exception that 2-3 regions along the thread were analyzed. Calcium transients for each region were then 
plotted together and the frame difference between the start frames of each calcium transient cycle for 
the different regions was recorded and the time delay was calculated. Next, the distance between the 
center points of each region was calculated using ImageJ. Conduction velocity was then calculated by 
dividing the distance between the regions by the time delay between the initiations of the calcium 
transients and is reported in cm/s.  
6.2.7 Alpha-actinin fiber alignment 
Confocal images of alpha-actinin stained hPS-CM seed on microthreads and TCP were uploaded to 
ImageJ (NIH) for actinin fiber alignment using OrientationJ. Briefly, each image was split into its green 
channel and each section of fibers were outlined and analyzed. Output angle data for each image was 
averaged and compared to the angle of the thread and reported as the difference between the thread 
angle and the average fiber angle.  
6.2.8 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.). Comparisons 
between seeding conditions, alignment data, and conduction velocities were analyzed using a one-way 
Chapter 6: Objective 2B                                                                                                                                         84 
 
analysis of variance (ANOVA), with a post-hoc Tukey test for multiple comparisons. Comparisons for 
contractile parameters of hPS-CM seeded on different surface coatings (threads and TCP) between time 
points were done using a two-way ANOVA with a Tukey post-hoc analysis for multiple comparisons. 
Comparisons were done including all data from threads and TCP, and separately with data from just plates 
groups and just threads groups to elucidate differences washed out when all groups across time and 
culture substrates were compared. A Pearson linear correlation coefficient was calculated in excel using 
the PEARSON function to assess the strength of correlation between contractile alignment and contractile 
strain. Cell attachment number, contractile strain, maximum strain, actinin alignment, and conduction 
velocity are reported as mean±SEM, frequency data is reported as mean±SD. Significance was considered 
at p<0.05.  
6.3 Results 
6.3.1 Collagen IV coating improves hPS-CM attachment to fibrin microthreads 
Fibronectin and collagen IV ECM protein 
coatings were evaluated against fibrin only 
to determine how ECM protein coating 
would affect hPS-CM attachment. 
Immunohistochemistry confirmed that 
both fibronectin and collagen IV proteins 
coatings resulted in positive expression of 
fibronectin and collagen IV on the surface 
of the microthread. Cell attachment was 
measured and quantified two days post 
seeding using a CyQuant DNA assay. hPS-
CM attachment was observed for all conditions, with significantly higher cells attached on the collagen IV 
coated microthreads (n=3-4, p<0.05, Figure 6-2). Increases in cell attachment and using different protein 
Figure 6-2. Collagen IV ECM coating enhances hPS-CM attachment to 
fibrin microthreads. Fibrin sutures were coated with collagen IV, 
fibronectin or no coating (fibrin) and were seeded with hPS-CM. A 
CyQuant DNA assay was used to quantify cell attachment per construct of 
three threads two days post seeding. Fibrin microthreads coated with 
collagen IV significantly improved hPS-CM attachment over fibronectin 
coated or non-coated fibrin microthreads. Mean±SEM. n=3-4, –p<0.05. 
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coatings did not appear to affect cell viability as indicated qualitatively by a LIVE/DEAD stain completed 2 
days post seeding (Figure 6-3).  
6.3.2 hPS-CM exhibit opposite temporal trends 
in contractile and maximum strains when 
cultured on TCP and fibrin microthreads 
To examine contractile behavior, contractile and 
maximum contractile strains were evaluated from 
hPS-CM seeded TCP (0.1% gelatin, collagen IV, and 
fibronectin coated) and microthreads (fibrin, 
fibronectin and collagen IV coated) at days 7, 14, 
and 21 post seeding. On TCP both contractile 
strains and maximum contractile strains followed 
similar trends such that cells cultured on TCP 
produced decreased strains over 21 days. Cells on 
TCP exhibit a significantly different decrease in 
contractile strain beginning at 4.23±0.23% on day 
7 and ending at 3.08±0.19% on day 21 (Figure 6-4A, 
n=18, p<0.05). Maximum strain followed a similar 
trend; cells on TCP had a maximum strain of 
Figure 6-3. hPS-CM seeded onto fibrin microthreads remain viable. hPS-CM were seeded onto Collagen IV, fibronectin, and non-
coated fibrin microthreads (fibrin). A LIVE/DEAD (live in green, dead in red) staining assay qualitatively confirmed cell viability 2 
days after seeding. Scale bar=0.1mm 
Figure 6-4. hPS-CM exhibit opposite trends in contractile 
and maximum strains when cultured on TCP and fibrin 
microthreads over 21 days. Contractile strain (A, C) and 
maximum contractile strain (B, D) was determined using 
HDM at days 7 (d7), 14 (d14), and 21 (d21). HPS-CM exhibit a 
significant decrease in contractile (A) and maximum strains 
(B) when cultured on TCP over 21 days. Conversely, hPS-CM 
cultured on fibrin microthreads exhibit an increase 
contractile (C) and maximum strains (D) over 21 days. 
Mean±SEM for contractile and maximum strain, n=18, –
p<0.05. 
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17.01±1.07% on day 7, which significantly decreased to 11.48±0.99% on day 21 (Figure 6-4B, n=18, 
p<0.05). hPS-CM seeded on microthreads increased contractile and maximum contractile strains over 21 
days. At day 7, hPS-CM seeded on microthreads begin at a contractile strain of  
3.56±0.22% and increased contractile strain to 4.47±0.29% on day 21 (Figure 6-4C, n=18, p<0.05). In terms 
of maximum contractile strain, hPS-CM seeded on microthreads produced a maximum strain on day 7 of 
12.70±0.94% which significantly increased to a maximum strain of 17.44±1.09% on day 21 (Figure 6-4D, 
n=18, p<0.05).  
Looking between culture substrate and over time, cells cultured on TCP and microthreads exhibited 
significantly different contractile strains on days 7, 14, and 21, and significantly different maximum strains 
on days 7 and 21 (Figure 6-5, n=18, p<0.05). Both contractile and maximum strains ended at higher values 
at day 21 for hPS-CM cultured on fibrin microthreads than the strains produced by hPS-CM cultured on 
TCP began at on day 7. Contractile and maximum strains followed similar trends between coating groups, 
on TCP and on microthreads over 21 days, with no significant differences between groups. 
Figure 6-5. hPS-CM exhibit significantly higher contractile and maximum strains when cultured on fibrin microthread 
compared to TCP by 21 days. Contractile strain (A) and maximum contractile strain (B) was determined using HDM at 
days 7 (d7), 14 (d14), and 21 (d21). hPS-CM cultured on fibrin microthreads exhibit significantly different contractile 
strains, at all-time points, and maximum strains, at days 7 and 21, than cells cultured on TCP. Mean±SEM, n=18,–
p<0.05. 
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6.3.3 Contractile frequency increases 
over 21 days for hPS-CM cultured 
on TCP and microthreads 
Beat frequency was examined to 
determine if there were any changes in 
beat rate for hPS-CM seeded on 
microthreads or TCP over 21 days (Figure 
6-6). Frequency significantly increased 
from day 7 to day 21 for both TCP and 
microthread groups; from 0.83±0.25Hz 
to 1.11±0.45Hz for the TCP group and 
from 0.84±0.15Hz to 1.03±0.19Hz for the 
microthread group (n=18, p<0.05). No differences were found between TCP and microthread groups for 
any time points. Frequency was found to increase over time for all surface coatings, on microthreads and 
TCP, with no differences between groups. 
Figure 6-6. Contractile frequency increased over 21 days for hPS-CM 
cultured on TCP and fibrin microthreads. Contractile frequency was 
determined on days 7 (d7), 14 (d14), and 21 (d21). hPS-CM 
significantly increased beat frequency between day 7 and day 21 for 
both culture conditions. Mean±SD, n=18,–p<0.05. 
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6.3.4 hPS-CM contraction direction becomes more aligned with the thread over 21 days in culture 
hPS-CM seeded on non-coated, collagen IV and fibronectin coated fibrin microthreads were used to 
examine changes in cellular alignment to the fibrin microthreads in terms of direction of principal 
contraction (n=17-18, Figure 6-7). Values reported are the percentage of cells that contracted within 0-13 
degrees of the direction of the fibrin 
microthread. At day 7 only 22% of cells 
contracted within 13 degrees of the 
direction the fibrin microthread, this 
increased to 53% by day 21. Additionally, 
hPS-CM seeded on TCP did not exhibit the 
same trend over 21 days in culture as cells 
had wide ranges of principal contraction 
angles at all-time points indicating that 
they remained unaligned over 21 days.  
Figure 6-7. hPS-CM contract with higher alignment to the microthread at 
later timepoints. The angle of contraction was determined for days 7, 14, 
and 21 and was calculated as the difference between the contraction 
angle and the angle of the thread. A histogram was plotted and the 
percentage aligned between 0-13 degrees is represented here. Over 21 
days in culture a higher percentage of hPS-CM contract in the same 
direction (within 13 degrees) as the microthread. n=17-18. 
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When contractile alignment was plotted together with changes in contractile strain over 21 days there 
was a linear relationship between contractile alignment and contractile strain for hPS-CM seeded on 
sutures (Figure 6-8). A Pearson linear correlation coefficient of 0.99 between variables was found 
indicating a strong correlation between increases in contractile alignment and contractile strain. For hPS-
CM cultured on TCP contractile strain decreased over 21 days with no major change in alignment as 
indicated by the flat orange trendline in Figure 6-8 and a Pearson linear correlation coefficient of -0.20. 
Figure 6-8 A linear relationship exists between contractile alignment and contractile strain for hPS-
CM seeded on fibrin sutures, not on TCP. Over 21 days in culture hPS-CM seeded on fibrin microthreads 
(grey line_ increased both alignment and contractile strain in a linear fashion with a Pearson correlation 
coefficient of 0.99. hPS-CM on TCP (black line) decreased contractile strain with no major change in 
alignment over 21 days. The grey dots with a blue trendline is representative of the suture group and 
follows the left y-axis. The black line with an orange trendline is representative of the TCP group and 
follows the right y-axis. Mean±SEM, n=18. Arrows indicate the direction of strain increase or decrease 
over time. 
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6.3.5 hPS-CM become more aligned along the microthread over 21 days in culture 
Alpha-actinin and connexin 43 staining were utilized to determine hPS-CM morphology up to 21 days in 
culture. hPS-CM were readily attached to microthreads at all-time points and exhibited positive alpha-
actinin and connexin 43 staining (Figure 6-9). 
Cells were less elongated at the earlier time 
points, 1 and 4 days. By day 7 cells had begun 
to elongate along the direction of the 
microthread and exhibited more organized 
sarcomere structure. Quantifying alignment 
demonstrated that hPS-CM at day 7 were 
aligned within 13.7±6.2 degrees to the 
thread, compared to 11.7±5.8 and 8.0±1.1 
degrees on days 14 and 21, respectively 
Figure 6-9. hPS-CM seeded onto fibrin microthreads express alpha-actinin and connexin 43. hPS-CM seeded onto 
Collagen IV coated fibrin microthreads express alpha-actinin and connexin 43 proteins at days 1, 4, 7, 14, and 21 in 
culture. Cells at later time points appeared more aligned along the length of the fibrin microthread with no major 
differences in alpha-actinin or connexin 43 expression patterns at any time point. 
Figure 6-10. hPS-CM demonstrate better alignment to the microthread 
at later timepoints. Alpha-actinin staining at days 7, 14, and 21 was 
used to calculate the angle of the cells and was compared to the angle 
of the microthread. A lower alignment angle indicated a better 
alignment to the thread. Over 21 days in culture alpha-actinin staining 
indicated hPS-CM were aligned more closely with the microthread 
direction. Average difference in fiber angle and thread angle is reported. 
Mean±SEM, n=4-28, NS. 
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(n=4-28 images, NS, Figure 6-10). 
Cells on TCP exhibited no dominate 
fiber alignment as indicated by a 
range of fiber angles from -86.6 to 
86.4 degrees (n=43 cell regions) Cells 
demonstrated positive connexin 43 
staining, however at all-time points 
the staining was diffuse through the 
cells with no evidence of organization 
and polarization to the intercalated 
disks (Figure 6-9 and Figure 6-11).  
6.3.6  hPS-CM seeded on microthreads increase conduction velocity over 21 days in culture 
Using the system developed in objective 2A we examined calcium transients in terms of conduction 
velocity of hPS-CM seeded on fibrin microthreads. High speed videos of hPS-CM seeded on microthreads 
loaded with fluo-4 dye were analyzed 
for calcium transient intensity over 2-
3 regions along the microthread to 
determine conduction velocity at days 
7, 14, and 21. Conduction velocities 
significantly increased from 
3.69±1.76cm/s at day 7 to 
24.26±8.42cm/s at day 21 (Figure 
6-12, n=5-6, p<0.05). 
Figure 6-12. Conduction velocity of hPS-CM seeded sutures. High speed 
videos of Fluo-4 loaded hPS-CM seeded on fibrin microthreads were analyzed 
for calcium transient intensity over different regions along the microthread 
and the time difference between regions was used to calculated conduction 
velocity. Conduction velocities were found to significantly increase from 
3.7cm.s to 24.3cm/s over 21 days in culture. Mean±SEM, n=5-6, -p<0.05. 
Figure 6-11. Representative images 
of connexin 43 at day 21. Connexin 
43 expression of hPS-CM were 
seeded onto fibrin microthreads at 
day 21 is punctate and poorly 
organized (A,B) does not mimic the 
end to end localization of Connexin 
43 expression expected for 
ventricular myocytes (C). 
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6.4 Discussion 
The goals of this objective were to define the seeding conditions and time to obtain a contractile hPS-
CM seeded microthread and characterize the cells contractile behavior when seeded on the microthreads. 
Different ECM surface coatings were used to improve cell attachment. Fibronectin and collagen IV were 
chosen due to their presence in cardiac basement membrane. Additionally, other studies seeding hPS-CM 
on various substrates have demonstrated successful hPS-CM attachment using fibronectin and collagen 
IV coatings11, 13. hPS-CM attached with higher quantities to collagen IV coated microthreads two days after 
seeding. All conditions did allow hPS-CM attachment, suggesting that hPS-CM preferentially attached to 
collagen IV coated microthreads, but a protein coating is not necessary to obtain hPS-CM attachment on 
fibrin microthreads. Qualitatively, protein coatings did not affect cell viability as the majority of cells 
attached were found to be viable for all conditions.  
In regards to contractility, hPS-CM seeded on microthreads began to contract within 7 days after 
seeding and cell contraction was observed for all conditions. Beat frequency increased over 21 days for 
hPS-CM seeded on microthreads and on TCP to above 1Hz, a similar finding to other groups26, 27. 
Contractile strain and maximum strain was found to increase over 21 days for hPS-CM seeded on 
microthreads. These values, at all-time points, were significantly different than the contractile strain and 
maximum strains produced by hPS-CM on TCP, which were found to decrease over 21 days. Maximum 
contractile strains produced by hPS-CM on the microthreads near the 19% strain that is produced by adult 
human myocardium28. Other tissue engineered constructs, such as the engineered heart tissue created 
by Eng et al. have demonstrated strains upwards of 17%, however these tissues needed to be electrically 
stimulated to produce higher strains where the unstimulated controls only produced strains of 10%27.  
Cardiomyocytes exist in an environment that requires them to be highly aligned and organized to 
produce efficient contractions. In order to investigate the relationship of alignment with strain changes 
over time we sought to quantify cell alignment to determine the effect cell alignment may have had on 
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changes in strain. Within a given layer of healthy myocardium, cardiomyocytes are aligned within 13 
degrees of each other25. The same would be expected of hPS derived cardiomyocytes. Additionally, 
previous studies have suggested the ability for fibrin microthreads to direct cell orientation along the 
microthread20. We demonstrated that over 21 days in culture the direction of cell contraction was more 
aligned along thread. Additionally, alignment was confirmed by immunohistochemical stains as cells 
aligned more closely to the thread over 21 days with a final alignment within 8 degrees of the thread. 
Studies in two and three dimensions have demonstrated the importance of cardiomyocyte alignment on 
improving contractility compared to unaligned controls24, 29. As contractile strains and maximum strains 
increased over 21 days for hPS-CM seeded on microthreads, this would suggest that these cells are able 
to produce higher strains because they are contract in a direction more aligned with the microthreads. 
No principal contraction alignment was found for cells cultured on TCP, which may explain the decrease 
in strains produced by these cells over time.  
Conduction velocity in a ventricular myocardial tissue is around to 50cm/s30, 31. Here, using calcium 
transient analysis we demonstrated conduction velocities that began at 3.7cm/s on day 7 and increased 
by day 21 to a mean of 24.2cm/s with some reaching 46.3cm/s. Not only do these conduction velocities 
near that of human myocardium, but increasing conduction velocities over time would suggest that this 
increase may be due to the higher alignment of hPS-CM over time. Other studies have indicated a similar 
trend in conduction velocities where aligned cultures of cardiomyocytes demonstrated a 1.6 increase in 
conduction velocity32.  
Alignment may not be the only contribution to changes in strain over time, substrate stiffness may also 
play a role in how much strain the cells can produce. We demonstrated that the hPS-CM seeded on the 
fibrin microthreads aligned along the thread and increased their contractile strains over 21 days whereas 
cells on tissue culture plastic had no dominate alignment and decreased contractile strains over time. 
While alignment may be driving this increase in contractile strain it is possible that substrate stiffness 
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plays a role. Hydrated fibrin microthreads have a modulus value around 2.2MPa20 whereas tissue culture 
plastic has a modulus value on the gigapascal range33 which is significantly stiffer than human myocardial 
tissue, which can range in stiffness from 20-500kPa34. It has been demonstrated that increased cell 
functionality may be a function of both substrate stiffness and alignment35-38.  McDevitt et al. 
demonstrated that cardiomyocytes patterned on glass coverslips lost their alignment over 10 days in 
culture suggesting that the stiff glass substrate is unfavorable to cardiomyocytes even though they had 
originally been patterned in an aligned manner37. Ribeiro et al. used matrigel micropatterns on 
physiologically relevant degrees of stiffness to constrain hPS-CMs into rectangular shapes that follow a 
physiological 7:1 aspect ratio24. These patterned hPS-CM were capable of producing higher contractile 
forces and improved myofibril alignment. The studies by McDevitt and Ribeiro were done on glass 
coverslips, however cardiomyocytes exist in a 3D environment and thus it is important to consider the 
effects of alignment and stiffness in an environment that better mimics myocardium. Chrobak et al. 
examined cardiomyocyte function using an unaligned fibrin gel with a modulus of approximately 
0.25kPa39. She demonstrated contractile strains that decreased over time suggesting that in a soft 
unaligned environment cardiomyocytes are unable to increase strains over time. Black et al. 
demonstrated that an aligned cardiomyocyte populated fibrin gel was capable of increased twitch forces 
at 2 weeks in culture over unaligned controls40. These results, in conjunction with the data presented here, 
suggest that neither an unaligned soft substrate or an aligned stiff substrate are enough to improve 
cardiomyocyte function, but that a soft substrate that promotes alignment may be ideal for 
cardiomyocyte function.  
When hPS-CM were seeded onto collagen IV coated tissue TCP, cells retained their contractile nature, 
but lacked a rod like phenotype with the organized sarcomere structure expected of mature 
cardiomyocyte. Connexin 43 is a protein found in cardiac connexons, which make up gap junctions that 
connect cardiomyocytes. To facilitate cardiac conduction, gap junctions are organized end-to-end at the 
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intercalated disks within cardiac tissue. Qualitatively, no organizational differences in connexin 43 staining 
was found for hPS-CM seeded on TCP or fibrin microthreads at any time points. However, we 
demonstrated that conduction velocity increased over 21 days, yet Connexin 43 expression did not appear 
to be more localized by 21 days. Studies have shown that increases in conduction velocity may not be 
solely Connexin 43 dependent. Cardiac conduction can be determined by several factors including 
membrane excitability, intercellular coupling, as well as the size, shape and orientation of the 
cardiomyocytes41, 42. de Boer et al. utilized a geometrically defined culture of immature cardiomyocytes 
and demonstrated that β-adrenergic induced increases in conduction velocity were due to changes in the 
intrinsic excitability of the cardiomyocytes and not alterations in gap junctional coupling. In adult mice 
with induced deletion of Connexin 43 a 50% decrease in the Connexin 43 protein did not have any impact 
on conduction velocity43. In a similar study, a 50% decrease in Scn5a, a gene that encodes sodium channel 
Nav1.5, demonstrated reduction in conduction velocity44. To examine this phenomenon at the cellular 
level strands of neonatal cardiac myocytes with a 43% reduction in Connexin 43 levels demonstrated no 
significant decrease in conduction velocity, but did demonstrate a significant increase in the action 
potential upstroke suggesting an increase in sodium channels. The data presented in these studies suggest 
that an increase in membrane excitability, plays an important role in conduction velocity. While not 
directly explored here, it is possible that Connexin 43 localization was not the main driver for the increase 
in conduction velocity and that increases in membrane excitability and alignment have a role. 
However, it is still important to note that many of these differences in alpha-actinin and Connexin 43 
organization and localization can be attributed to the immature phenotype of hPS-CM45. This suggests 
that further steps will be necessary for enhanced maturation of Connexin 43 localization and sarcomere 
organization of hPS-CM even given a substrate that promotes cell alignment. Others have shown that 
extended culture, as well incorporating electrical and mechanical stimulation can provide the cues 
necessary to impart maturation leading to improvements in cardiomyocytes functionality45-48.  
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The findings in this chapter suggest that hPS-CM are capable of attaching to fibrin microthreads, 
however a collagen IV protein coating improves hPS-CM attachment to fibrin microthreads. Additionally, 
hPS-CM were able to contract and align to the microthreads over 21 days in culture. By day 14 cells seeded 
sutures were contracting at a frequency of a human heart and were producing strains nearing those 
produced by human myocardium. These findings suggest that cell seeded sutures should be cultured on 
the microthreads beyond 7 days in order to deliver a more aligned, higher functioning contractile bundle 
for in vivo delivery. 
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7 Specific Aim 3: Evaluate the use of fibrin microthread sutures to deliver hPS-CM to healthy cardiac tissue.  
7.1 Introduction 
hMSCs have been widely used in pre-clinical animal infarct models and human clinical trials; however, 
results from the clinical studies have only demonstrated minimal improvement in left ventricular 
function1, 2. The improvement of embryonic and induced pluripotent stem cell differentiation to 
cardiomyocytes3-5 over the past decade have opened the doors to a new cell type that researchers can 
use for myocardial regeneration strategies5-11. Where an hMSC may reduce the harsh effect of the 
environment found post-infarct, an hMSC, which rarely differentiates into a cardiomyocyte12, will not be 
able to contribute to active mechanical function in a manner that an hPS-CM may, due to its contractile 
nature. Early studies using hPS-CM demonstrated that these cells are capable of engrafting in the heart 
and can attenuate infarct damage and improve function5, 7.  
Many studies utilizing hPS-CM have focused on cell sheet, cardiac patch technology, or an ECM base to 
deliver cells11, 13-15. Wendel et al. created a cardiac patch utilizing hPS-CM and human pericytes entrapped 
in a fibrin gel, these patches were sutured to the epicardial surface of the left ventricle of an acutely 
infarcted rat heart11. Data at 4 weeks post implantation suggested survival of implanted cells, reduction 
in infarct size, and improvements in cardiac function. However, a thin collagen rich interface between the 
patch and epicardial surface of the ventricle mitigated any electromechanical coupling and thus 
improvements in function were likely due to paracrine effects and infarct stabilization from the patch. Cell 
sheet technology for hPS-CM delivery has been explored most notably by Masumoto et al. in which hPS-
CM were used to create cardiac tissue sheets (hiPSC-CTS) that were transplanted onto the epicardial 
surface, without suturing, in a sub-acute rat infarct model13, 16. At 8 weeks post-implantation, viable cells 
were found with some evidence of neovascularization of host cells into grafts. Additionally, functional 
data indicated improvements in left ventricular systolic function by attenuating ventricular remodeling 
and improving fractional shortening. Ogasawara et al. delivered hPS-CM using a hyaluronan-based 
hydrogel (HyStem) or a pro-survival cocktail (PSC) combined with matrigel and injected the hydrogel/cell 
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combination into the infarct17. Graft sizes were significantly higher for cells delivered with PSC and 
matrigel rather than cells delivered with HyStem group alone. Additionally, no functional benefits were 
found for either group even given the larger graft sizes. These data suggest the need for improved 
methods to deliver hPS-CM without the use of matrigel or a PSC, due to the unregulated nature and high 
costs, or without a cell sheet or patch given the lack of cell migration into the damaged area. 
The above studies suggest that hPS-CM may have the potential to improve function via attenuated left 
ventricular remodeling by paracrine effects and improvements in neovascularization11, 13. However, as a 
method to improve cell retention many studies transplanting hPS-CM in infarct models have done so in a 
cardiac patch or cell sheet form11, 13. These cell delivery methods have limited success due to the formation 
of collagen interfaces between the host and graft tissue, which limits the ability for graft cells to migrate 
into host tissue thus, limiting the potential for electrical integration. Other studies have delivered hPS-CM 
using more traditional delivery methods including intramyocardial injection without matrigel, however, 
as discussed in chapter 2 there are limitations on the delivery efficiency using an intramyocardial 
injection9, 18, 19. These low delivery efficiencies and in combination with using matrigel could be 
prohibitively expensive when considering the cost of some of these hPS-CM based cell therapies. 
Previously, we have demonstrated that fibrin microthread based sutures can deliver cells with a 64% 
efficiency20 and are capable of delivering hMSCs to an infarct21. In chapter 6 we demonstrated that hPS-
CM are capable of attaching to and contracting on the fibrin microthread suture in a manner that does 
not impact functionality. In this objective, we aim to implant our hPS-CM seeded suture in healthy cardiac 
tissue and examine retention at 1 hour and 3 days post-delivery. The purpose of this aim is to determine 
the success of the fibrin suture delivery method on cell retention in healthy cardiac tissue. The cell type 
used in objective 2 will be used for aim 3; all microthreads used in this objective were produced as 
described in objective 1a and will be seeded as done for studies in objective 2b where individual threads 
were clamped into a bored out needle to facilitate implantation (Figure 7-1).  
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7.2 Materials and methods 
7.2.1 Implant model  
hPS-CM seeded microthreads were delivered to uninjured hearts for 1 
hour, 8 hours, 1 day, and 3 days. (n=6 for all groups). Uninjured animals 
were used to assess the in vivo fate of the hPS-CM in a healthy heart 
before cells are delivered to an infarcted heart. Surgeries were 
completed as described in objective 1b without the LAD ligation. For the 
1 hour time point animals were sacrificed 1 hour after hPS-CM 
implantation and the heart was extracted, bisected across the implanted 
suture and fixed overnight in 4% paraformaldehyde. For the 8 hour, 1 day, and 3 day time points, after 
hPS-CM are delivered, animals were closed and allowed to recover for the appropriate time. After 8 hours, 
1day, or 3 days animals were anesthetized, reopened along previous suture lines, a 0.3mg/kg dose of 
Beuthanasia-D (390mg/mL pentobarbital sodium) was injected into the left atrium to arrest the heart, the 
heart was extracted, bisected and fixed in 4% paraformaldehyde. The protocol was approved by the 
Worcester Polytechnic Institute Institutional Animal Care and Use Committee. 
7.2.2 Histological analysis  
Twenty-four hours after fixation, the hearts were placed in 30% sucrose overnight and subsequently 
embedded in OCT for cryosectioning. A cryostat was used to obtain 10µm transverse sections across the 
entire region of the heart containing the biological suture. To assess the retention of hPS-CM, serial 
sections 60µm apart were stained for human Ku80 (rabbit anti-Ku80, ab80592 Abcam) to identify and 
quantify the presence of hPS-CM in the myocardium. These sections were imaged using a Leica TCP SP5 
confocal laser scanning microscope. In each section imaged, the number of cells expressing Ku80 co-
localized with Hoechst staining were counted. By averaging adjacent sections and using linear 
interpolation a total number of cells delivered was calculated. Given these results and the number of cells 
attached to the suture prior to implantation a cell delivery efficiency was also calculated. Additional 
sections were stained with sarcomeric α-actinin (mouse anti-sarcomeric alpha actinin, Abcam) and 
Figure 7-1. Construct for 
implantation sutures. Three threads 
are clamped into a bored out needle 
and were individually glued to the 
PDMS washer to facilitate seeding. 
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Connexin-43 (goat anti-Connexin 43, Abcam), or Hematoxylin and Eosin, or Masson’s Trichrome according 
to the manufacturer’s instruction. 
7.2.3 In vitro cell delivery assay 
To determine the fate of the cells after being delivered for an hour, an in vitro delivery assay was 
developed to mimic the conditions of cell delivery.  The assay utilized a fibrin gel made by adding equal 
volumes of fibrinogen (70mg/mL) and thrombin (250U/mL) into a plastic mold (1.5x1.5x0.5cm)22. This 
formulation was chosen to mimic the stiffness of ventricular myocardium (>20kPa23) as the study using 
this formulation reported a Modulus of Elasticity of 27.5kPa22. 500µl of fibrinogen was added initially 
followed by 500µl of thrombin and a pipette tip was used to gently mix without the formation of air 
bubbles. After mixing, the gels were allowed to polymerize for 30 minutes and then were removed from 
the mold, placed in a petri dish and used in the assay. 
hPS-CM were seeded onto fibrin microthreads attached to a suture needle as described previously. 
After 14 days of culture sutures were treated with one of three conditions to mimic the conditions cells 
would experience upon delivery to ventricular myocardium. Condition one examined the environmental 
effects the sutures that had been brought to the operating room (OR) and then brought back to the 
incubator may have experienced.  Here, a 6 well plate containing the sutures was removed from the 
incubator and brought down one floor to the operating room, a process that takes around 2 minutes. The 
6 well plate was then placed on the surgical table for 2 minutes, the approximate time required to prepare 
the suture for delivery. After those two minutes the sutures were them returned to their original 
incubator. During this entire process the sutures were never moved from the 6-well plate and remained 
in their standard medium consisting of RPMI with B27. Condition two simulated the effect of cell delivery 
by removing the suture constructs from the incubator and placing them in a biosafety cabinet. The 
microthreads were then clipped off the PDMS construct and needle drivers were used to grab the suture 
needle and sutured the construct completely through the fibrin gel. After which, the suture construct was 
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placed in standard RPMI-B27medium in a 6 well plate and returned to the incubator for further 
incubation. Condition three simulated the effect of cell delivery in addition to the implantation effect. 
Here, the sutures were removed from the incubator, the threads were cut off the PDMS construct and 
were sutured through the gel. However, instead of being completely sutured through the gel as in 
condition two, sutures were left in the gel and were fully submerged in standard RPMI-B27 medium for 
further incubation. Controls included control seeded threads and control cells that were seeded on 
collagen IV coated tissue culture plastic, these controls were not exposed to any of the conditions. An 
additional control was used wherein cells seeded on collagen IV coated tissue culture plastic were exposed 
to the operating condition effects. 
 At 15 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours sutures from each condition were stained using 
Annexin V and Propidium Iodide (PI) to examine apoptosis. Cells in the control conditions were also 
stained using Annexin V and PI. The sutures from the OR condition were clipped off the PDMS post and 
placed on a microscope slide, the sutures that had been pulled through the gel were also placed on a 
microscope slide, and the sutures remaining in the gel were pulled the remaining distance through the gel 
and were placed on a microscope slide. The Annexin V assay (V13241, Thermo Fischer) was run according 
to the manufacturers specifications, briefly, sutures were washed with cold PBS, then Annexin V binding 
buffer, and were stained with Annexin V (1:10) and Propidium Iodide (1.5:100 of 100µg/mL) at room 
temperature for 15 minutes. Sutures were then rinsed with Annexin binding buffer and stained with 
Hoechst 33342 (0.5ug/mL) for 4 minutes and then returned to Annexin binding buffer. Sutures were 
imaged using a Leica TCP SP5 confocal laser scanning microscope. Images were quantified using ImageJ 
to count for Hoechst, Annexin V, and/or PI positive cells for each group at each time point. Counts were 
then averaged and plotted as a either a total number of cells or a percentage of the total cells present in 
each category: Annexin V + or PI + for each condition. 
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7.2.4 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.). Comparisons 
only between the 1 hour and 3 day delivery time points, due to low sample sizes in the 8 hour and 1 day 
group, were analyzed using an unpaired t-test. Cell retention is reported as mean±SEM. Significance was 
considered at p<0.05.  
7.3  Results 
7.3.1 Cell retention at 1 hour, 8 hours, 
1 day, and 3 days 
Cells expressing Ku80 co-localized 
with Hoechst staining were found around 
the suture area for all time points (Figure 
7-2). At the one hour time point cells were 
found directly in contact and localized next 
to the suture, where as with other time 
points cells were found close to the suture, 
but not always in direct contact. The 
numbers of cells delivered were quantified, 
using linear interpolation, through the 
entire section of the heart where the 
sutures were delivered. At 1 hour an average of 7602±2382 cells were delivered equating to a delivery 
efficiency of 67±17% which was significantly higher than the average number of cells delivered at 3 days 
which was 185±403 with a delivery efficiency of 1.3±3.9% (p<0.05, Figure 7-3). At 8 hours and 1 day an 
Figure 7-2 hPS-CM persist in ventricular myocardium up to 3 days after 
delivery via a fibrin microthread suture. PositiveKu80 staining (red) 
indicates cells persisting in the myocardium up to three days after 
delivery. Cells delivered at one hour were closely localized to the suture, 
however at later time points cells were found near the suture, but not as 
localized as in the one hour condition.  
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average of 1470±1470 and 256±196 were delivered with delivery efficiencies of 14±14%, and 1.9±2%, 
respectively (Figure 7-3).  
Figure 7-3. hPS-CM can be delivered to healthy myocardium with a 67% 
delivery efficiency. Cells were delivered with a 67% delivery efficiency one hour 
after delivery, however significantly fewer cells were retained at 3 days.  
Additionally, fewer cells were retained at 8 hours and 1 day post-delivery, 
however, significance was not reached due to a small sample size Mean±SEM, 
*p<0.05. n=2-5 
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7.3.2 Cell distribution across the delivered area 
Cell distribution was mapped along the entire delivery tract from entry to exit of the heart. For the 1 
hour cell delivery group cells were found throughout the entire delivery tract (Figure 7-4A). Two hearts 
had higher cell retention at the entry point, however most hearts had relatively similar numbers of cells 
in every section. For the hearts that contained cells in the 8 hour and 3 day groups cell distribution was 
even and present along the entire delivery tract (Figure 7-4B, D). For the 1 day group, cell were only found 
in the entry half of the heart and no cells were found in the portion where the thread exited the heart 
(Figure 7-4C). These data demonstrate, that initially cells are delivered and are well distributed along the 
entire delivery tract from entry to exit with little effect of shearing resulting in higher cell number at the 
Figure 7-4 Representative histograms indicate cells are distributed throughout the delivery track. Histograms tracking 
cell delivery from suture entry to suture exit demonstrate cells present through the entire delivery track (A,B,D) with the 
exception of the cells delivered for 1 day (C). Histograms are representative of each time point and do not quantitatively 
describe the average cell distribution for each time point.  
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entry. However, the decrease in cells present one 
hour after delivery compared to 3 days after 
delivery suggests a significant majority of cells are 
being retained in the heart for several days.  
7.3.3 Cell morphology after delivery 
Alpha actinin and Connexin 43 staining indicated 
limited positive signal between graft and host cells 
Figure 7-5) indicating that the implanted cells are 
not making connections to the host tissue at the 
three day time point. Hematoxylin and Eosin 
stained sections indicated hyperchromatic cells 
and nuclear debris after 1 hour with high 
Figure 7-5. Limited evidence of positive Connexin 43 staining 
between host tissue and graft tissue at 1 hour and 3 hours. 
Sections were stained with alpha-actinin and connexin 43 to 
examine the interface between host and graft tissue. Connexin 
43 stained sections show limited staining between graft tissue, 
stained with Ku80, and host tissue indicating limited connection 
occurring between the graft and host cells 
Figure 7-6. Representative Hematoxylin and Eosin staining. H&E stained sections indicate 
hyperchromatic cells with nuclear debris at 1 hour and neutrophil infiltration at 8 hours. Approximate 
location of delivered cells are outlined in black as determined by examining serial sections stained with 
Ku80. 
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neutrophil infiltration at 8 hours. These results indicate poor cell health post delivery and may explain 
why fewer cells were retained 8 hours to 3 days post-delivery (Figure 7-6). Additionally, Masson’s 
Trichrome staining indicated increased collagen deposition around the suture by day 3 (Figure 7-7). 
7.3.4 In vitro cell delivery assay indicates apoptotic cells as early as 30 minutes post-delivery 
We developed an in vitro cell delivery assay utilizing a fibrin gel which had a stiffness in the range of 
that of myocardium22. Cell seeded sutures were either brought to the operating room  or delivered to the 
gel where the suture was pulled through the gel or kept in the gel until the appropriate time point. Annexin 
V and PI staining was used to visualize cell health in each condition (Figure 7-8) and was quantified to 
determine the percentage of apoptotic (Annexin V) and dead cells (PI) (Figure 7-9).  
When examining the percentage of cells for Annexin V and PI expression we demonstrated that cells in 
control plates had low Annexin V and PI expression, however when the plate was brought to the OR, 
higher percentages of both apoptosis and PI positive cells were seen suggesting damaging effects of 
bringing the cells down to the OR (n=2, Figure 7-9A). Control sutures not exposed to any condition had 
Figure 7-7. Representative Masson’s Trichrome stained sections. Masson’s Trichrome stained sections 
qualitatively indicate increased collagen deposition beginning at day 1 and out to day 3. 
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higher percentages of Annexin V and PI positive cells than those found for the cells in the control plate, 
but had lower expression than the sutures going through simulated delivery (n=2, Figure 7-9). 
For the sutures that were brought to the OR there was a higher percentage of Annexin V cells at 30 
minutes compared to controls, however Annexin V expression increased over 3 hours with PI positive 
expression remained the same over 6 hours indicating higher apoptosis occurring at later time points (n=2, 
Figure 7-9A,B). Sutures that were pulled through the gel and allowed to sit demonstrated decreased 
Annexin V expression over 6 hours, however PI expression was greater than 60% at all-time points (n=2, 
Figure 7-9C). A similar trend was observed for sutures that stayed in the gel until the appropriate time 
point, where there was a decrease in Annexin V expression over 3 hours, but a greater than 60% PI 
expression at all-time points (n=2, Figure 7-9D).  
 When examining Annexin V and PI expression by the number of cells present on the suture,  we 
demonstrated that there were similar numbers of cells across all groups and all time points, such that no 
group had a higher number of cells which may have affected apoptosis. In the control groups, there were 
similar trends in Annexin V and PI expression compared to percentages where the control thread and 
Figure 7-8. In vitro cell delivery assay utilizing Annexin V to 
examine cell apoptosis. Cells were cultured for 14 days and 
then brought down to the operating room (OR), were pulled 
directly through a fibrin gel (pulled through gel), or were 
stitched through a fibrin gel but not pulled out (remained in 
gel). Annexin V staining indicates apoptosis occurring as early 
as 30 minutes post-delivery for all conditions and remained 
positive out to 6 hours. Control sutures demonstrate some 
Propidium Iodide staining, but very little Annexin V staining 
with Annexin V staining mostly localized to the center of the 
cell cluster on the suture. 
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control plate had higher PI expression compared to Annexin V (n=2, Figure 7-10A). Additionally, Annexin 
V and PI expression was higher in the control plate exposed to the OR conditions indicating that the OR 
conditions had an effect on cell health (n=2, Figure 7-10A). For the threads exposed to the OR conditions 
a similar trend, compared with percentages, was found with low Annexin V initially, but higher at 1 hour 
and then decreasing over 6 hours with higher PI expression at later time points (n=2, Figure 7-10B). Again 
indicating low apoptosis occurring within the first 30 minutes post exposure to the OR conditions. For the 
threads that were pulled through gel all time points had similar cell numbers and consistent Annexin V 
and PI expression, with higher PI expression towards the 3 and 6 hour time point (n=2, Figure 7-10C). For 
threads that stayed in the gel there was higher Annexin V expression at 30 minutes that decreased over 
time, which may be due to a loss of cells as the cells on the threads had died and were no longer present 
on the threads when they were pulled through the gel at later time points (n=2, Figure 7-10D). 
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7.4 Discussion 
These data demonstrate that hPS-CM are capable of being delivered with high efficiency to healthy 
cardiac tissue via a fibrin microthread suture. Other researchers have focused primarily on using cell sheet 
or cardiac patch technology to deliver hPS-CM, which have shown improved survival of grafted cells. 
However, these studies showed limited migration into host tissue because of a collagen interface that 
formed between graft and host tissue or because cells did not migrate from the graft11, 13. By using fibrin 
Figure 7-9. Percentage quantification of the in vitro cell delivery assay utilizing Annexin V to examine 
cell apoptosis. The percentage of Annexin V and PI positive cells were quantified for all conditions. Panel 
A indicated the control conditions where control threads and cells on a control plate with and without 
OR conditions exposure were used. Panel B indicated sutures exposed to the OR conditions, panel C 
indicated sutures that were pulled through the gel, and panel D indicated sutures that were stitched 
through a gel and were allowed to remain in the gel. The percentage of Annexin V or PI positive cells 
were plotted with respect to time. The controls indicate low Annexin V+ cells, however high PI positive 
percentages were demonstrated. Additionally, the OR cell plate control demonstrated higher Annexin V 
and PI positive cells over the non-exposed control plate alone.  The gel conditions demonstrates 
decreased Annexin V expression over time, while the OR conditions demonstrated increased Annexin V 
expression over time. With the exception of the 6 hour time point. All time points saw high PI positive 
expression of greater than 50%. n=2 for each condition and time point. 
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microthread sutures to deliver hPS-CM directly into the myocardium we aim to improve retention of the 
cells within the host tissue.  
We begin the aim by delivering cells into the uninjured animal to investigate how the hPS-CM delivery 
on fibrin sutures compared to hMSC delivery. Results from these studies demonstrated the ability to 
deliver hPS-CM using the fibrin suture with a 67% delivery efficiency at 1 hour. This delivery efficiency 
aligned well with our previous data where hMSCs were delivered with a 64% delivery efficiency at 1 hour 
using the fibrin sutures. Additionally, cells that were delivered were delivered along the entire delivery 
tract of the suture indicating that cells were well distributed within the tissue and a high number of cells 
were not sheared off and retained at the suture entry point.  
Figure 7-10. Cell number quantification of the in vitro cell delivery assay utilizing Annexin V to 
examine cell apoptosis. The number of Annexin V and PI positive cells were quantified for all 
conditions. Panel A indicated the control conditions where control threads and cells on a control plate 
with and without OP conditions exposure were used. Panel B indicated sutures exposed to the OR 
conditions, panel C indicated sutures that were pulled through the gel, and panel D indicated sutures 
that were stitched through a gel and were allowed to remain in the gel. The number of Annexin V or 
PI positive cells were plotted with respect to time. There were similar numbers of cells across all 
groups. In the control groups (A) there were similar trends compared to percentages with higher PI 
for control thread and control plate compared to Annexin V. Additionally, Annexin V and PI expression 
was higher in the OR plate. In the OR conditions (B) a similar trend, compared with percentages, was 
found with low Annexin V initially, but higher at 1 hour and then decreasing over 6 hours with higher 
PI expression at later time points. For the threads that were pulled through gel (C) all time points had 
similar cell numbers and had consistent Annexin V and PI expression at all-time points. For threads 
that stayed in the gel (D) there was higher Annexin V at 30 minutes that decreased over time. 
Additionally, over time there were fewer cells with the exception of high PI positive cells at 6 hours. 
n=2 for each condition and time point. 
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Next, we examined cell retention in host tissue 3 days after implantation in a non-infarcted 
environment. One hour was chosen in uninjured animals to look at immediate retention and viability in 
order to obtain an acute understanding of how the cells behave immediately after implantation. The 3 
day time point in healthy animals was chosen to look at changes in cell retention that may occur after 
implantation. After delivering cells for 3 days we found very few cells present, thus we expanded our time 
points to include 8 hours and 1 day, which also demonstrated decreased retention. Using a Masson’s 
Trichrome stain we indicated higher collagen deposition around the suture at day 3; a collagen interface 
between a biomaterial implant and the host myocardium has been demonstrated in other studies11. 
Moving forward, this collagen interface may be an issue, however as we only looked out to 3 days, further 
time points would be needed to elucidate the temporal progression, or regression, of further collagen 
deposition. While the suture was able to deliver hPS-CM with a high efficiency at 1 hour after 8 hours and 
out to 3 days post-delivery we saw a decrease in the number of cells that were retained. These data 
suggest that something is occurring to not allow sustained retention after the initial delivery period. 
In order to investigate what may be occurring to cause the decrease in cells post-delivery we examined 
cell morphology. Through H&E staining, we determined that the cells that were present at 1 hour were 
hyperchromatic and there was nuclear debris in the sections. H&E stained sections also revealed high 
neutrophil infiltration by 8 hours. To further investigate what could be causing the poor cell health we 
developed an in vitro delivery assay using a fibrin gel and Annexin V/PI staining to examine apoptosis and 
cell death. We sought to examine the effects of bringing the sutures down to the operating room as was 
done for all implants, as well as the effects the mechanical delivery of the cells may have imparted on cell 
health. A fibrin gel was chosen due to ease of production and the ability to formulate the gel such that 
the stiffness mimicked what could be expected of ventricular myocardium. hPS-CM seeded sutures were 
either brought to the OR or were delivered to a fibrin gel and allowed to be pulled through the gel or 
remained in the gel. As we saw the highest drop in cell retention by 8 hour we chose time points of 30 
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minutes to 6 hours to examine acute and later stage cell health. Staining with Annexin V and PI allows us 
to discern which cells are going through apoptosis and which cells are already dead.  
The results of the in vitro delivery assay indicated that a high number of cells on control sutures alone 
were already expressing PI. The decrease in Annexin V expression for both gel conditions suggest that the 
cells are apoptotic rather quickly after delivery and the cells either fall off the suture or are solely PI 
positive by 6 hours. The reverse is seen in the OR group where Annexin V expression increases, suggesting 
that the apoptotic effects of the OR take longer to occur in these cells. However, all groups did have high 
PI expression, over 60%, at all-time points, which may explain why the combination of bringing cells to 
the OR and then delivering them to cardiac tissue resulted in reduced retention 8 hours after delivery. 
While it is interesting to note the raw cell number data, the conclusions found remain the same as the 
conclusions drawn when examining the percentages of Annexin V and PI expression. All groups at all-time 
points had a similar range in the number of cells that were on the threads and showed positive Annexin 
V and PI expression indicating that cell number was not a major driver for apoptosis between the 
conditions. The controls and operating room conditions followed a similar trend when comparing cell 
number with the percentages. One interesting finding with the threads that remain in the gel is the higher 
Annexin V expression at the 30 minute time point that decreased over time. This finding indicates that as 
the cells are dying  they may no longer be present on the thread after the thread is pulled through the gel 
resulting in a decreased number of Annexin V positive cells at the later time points. One thing to note with 
this set of data is the small sample number (2) run for this experiment. While trends are capable of being 
described using these sets of data, it will be necessary to increase the sample size to draw statistically 
significant conclusions.   
This loss in viable cells is not unprecedented, several studies have demonstrated decreases in retention 
of hPS-CM over time24-28. A study by Funakoshi et al. delivered hPS-CM to healthy hearts using an 
intramyocardial injection and demonstrated up to a 75% decrease in retention 1 day and 3 days after 
Chapter 7: Aim 3                                                                                                                                                   116 
 
delivery25. They then tracked retention out to 56 days and saw increases in cell retention after 28 days 
suggesting a proliferative population in their delivered cells that was capable of surviving the initial cell 
delivery. Gao et al. delivered hPS-CM to infarcted cardiac tissue utilizing a scaffold patch approach; at 1 
week they reported a delivery efficiency of 24.5% which was reduced to 11.2% by week 426. A similar trend 
was observed by Rojas et al. when they delivered hPS-CM aggregates via intramyocardial injection to 
infarcted cardiac tissue; they reported a significantly reduced graft size from 7 to 28 days post-delivery27. 
Another study by Tachibana et al. saw very limited retention of hPS-CM at 2 weeks and even fewer cells 
at 4 weeks. These studies suggest that without a proliferative population, graft sizes of hPS-CM will 
decrease over time. Rojas et al. suggested that apoptosis due to weak cell-cell connections was a major 
driver for the decrease in cell retention. He attributed the weak cell-cell connections to the purity of the 
hPS-CM population in that there were limited fibroblasts that could improve structure and function of the 
delivered cells, as demonstrated by Kensah et al.,27, 29 which may result in enhanced graft survival. 
Even given limited and decreasing retention over time, all studies reported positive improvements in 
left ventricular function in terms of ejection fraction and decreases in infarct size. This suggests that high 
numbers of engrafted cells may not be necessary to obtain sustained improvements in left ventricular 
function post-infarct and that graft size may not correlate with functional improvements24. Additionally, 
studies did not demonstrate coupling between the host myocardium and the delivered cells suggesting 
that a paracrine effect from the remaining cells may be what is driving the improvement in LV function 
rather than regeneration and coupling from the delivered cells.  
Here, we demonstrated that the fibrin suture is capable of delivering hPS-CM with a 67% efficiency, 
which is a similar efficiency as what was previously published when hMSCs were delivered using a fibrin 
suture. While the retention found with the fibrin suture decreased on a much quicker time scale than the 
decrease in retention found in other studies, it is encouraging that the other studies that indicated 
decreased retention still demonstrated improvements in left ventricular function. These data suggest that 
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the improvements in function may be due to a paracrine effect instead of cell replacement indicating that 
there is still an opportunity to increase restoration of contractile function through cell therapy. It will be 
important moving forward to ensure that the hPS-CM delivered are capable of being retained over time 
to allow them to couple and properly engraft with the host tissue to aid in regeneration and 
remuscularization. Studies have indicated the possibility for remuscularization. Chong et al. delivered 
hESC-CM to a non-human primate infarct model and showed significant remuscularization that was 
electromechanically coupled to the host tissue9. However, non-fatal ventricular arrhythmias did occur in 
the larger animal model. The incidence of ventricular arrhythmias was also found in a study by Shiba et 
al. where they delivered hPS-CM and demonstrated improved cardiac contractile function out to 12 
weeks, however, this resulted in significantly higher incidences of ventricular arrhythmias compared to 
the control30. Future studies will need to be done to ensure the potential for the sustained retention of 
delivered cells as well as ensuring a low arrhythmogenic potential for these cell therapies.  
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8 Conclusions and future work  
8.1 Conclusions  
Heart disease continues to be a leading cause of death in the United States. Heart disease can lead to a 
myocardial infarction where a significant portion of the myocardium dies resulting in decreased 
cardiovascular function and an increased potential for heart failure. Cell based therapies have been 
proposed as a treatment strategy for myocardial infarction. Initial clinical data using human mesenchymal 
stem cells have shown the delivery of hMSCs to be safe, however no company has received FDA approval 
for hMSC cell therapy for MI due to the lack of efficacy data in late stage clinical trials1, 2. More recent 
studies have begun utilizing human pluripotent stem cell derived cardiomyocytes as a new cell source and 
have demonstrated their potential for improving cardiovascular function in pre-clinical animal models of 
MI3-5. While there is still significant excitement for cell based therapies to be a treatment strategy for 
cardiac disease, improvements in how cells are delivered to the damaged myocardium must be made. 
A limitation of cell based treatments for myocardial infarction is the inefficient retention of cells 
delivered to the infarcted tissue. A number of delivery methods have been used with intramyocardial 
injections6 and transendocardial7 delivery resulting in the highest retention rates of 10 and 19%, 
respectively. In this dissertation we sought to build upon a fibrin based scaffold that has been shown to 
support hMSC attachment and can deliver hMSCs with a 64% retention rate to cardiac tissue8, 9.  
This body of works aims to forward the use of the fibrin suture based delivery method for delivering 
hMSCs and hPS-CM which may aid in improving cardiovascular function post-MI by following two different 
paradigms. The first is that the hMSC will provide a pro-healing environment such that inflammation is 
decreased leading to a smaller infarct. The second is that a hPS-CM could provide a cell replacement 
strategy by coupling with the host myocardium and contributing to the active mechanical function lost 
after an infarct. This work explores both cell types and their potential for use in cardiovascular 
regeneration strategies.  
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Utilizing the fibrin based scaffold as a suture we further defined the seeding parameters of cell 
concentration and incubation time for hMSC attachment. A seeding concentration of 100µL of a 1.0x106 
cells/mL concentration allowed to incubate for 24 hours resulted in an attachment of 17,887±2,746 
hMSCs per linear centimeter of the fibrin suture. These seeding parameters were used to deliver hMSCs 
to a rat model of myocardial infarction to examine how the delivery of an hMSC affected regional 
mechanical function. Here, we demonstrated that hMSCs persisted in the myocardium for 1 week and 
were found in regions away from the suture, suggesting their propensity to migrate from the suture into 
the damaged tissue. Delivery of biological sutures seeded with hMSCs partially restored regional 
mechanical function, in terms of RSW, to the injured region compared to infarct alone (p=0.07). While the 
unseeded-suture group showed improvements in regional mechanical function over the MI group, the 
hMSC-seeded sutures demonstrated slightly higher function. This suggests that the biological suture alone 
has the ability to improve regional mechanical function in the infarct zone as supported by other studies 
demonstrating that biomaterial delivery, with no cells, to an infarct can improve mechanical function10-12.  
While we demonstrated limited improvement by delivering an hMSC to an infarct the paradigm 
behind the MSC is that this cell type will act to reduce inflammation and decrease scar size post-infarct, 
however this cell cannot contribute to active mechanical function as it does not transdifferentiate into a 
myocyte in vivo. A cell type that could contribute to the active mechanical function lost after an infarct is 
that of a hPS-CM. hPS-CM are capable of spontaneous contraction in culture and literature has suggested 
their ability to couple with host myocardium and contract in vivo13. Here, we sought to determine if the 
fibrin microthread suture would support hPS-CM attachment and contraction and if the fibrin suture could 
be utilized to deliver hPS-CM to healthy cardiac tissue with a delivery efficiency similar to what was 
published for hMSCs.  
To characterize the contractile behavior of hPS-CM we first developed a system in objective 2a that 
allowed us to quantify the mechanical contraction and calcium transients of hPS-CM over time. Systems 
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exist to measure and quantify contractile function, however many of these systems such as traction force 
or MEA arrays require a specific substrate for the cells to be cultured on which in turn imparts a secondary 
effect on the cells function14-16. Here, we sought to create an aseptic optical system where we could apply 
high density mapping (HDM), a speckle tracking algorithm used previously to examine regional cardiac 
function, to contracting clusters of hPS-CM to examine contractile behavior over time. We defined the 
analysis parameters of the HDM function and examined the techniques ability to quantify contractile 
behavior of hPS-CM seeded on TCP over 21 days in culture. Additionally, we developed an imaging 
technique capable of rapidly (>120fps) alternating bright field and fluorescence to capture mechanical 
contraction and calcium transient activity of fluo-4 AM dye loaded hPS-CM. While other optical systems 
exist to perform a similar function, many of the systems do not have the capability to simultaneous record 
brightfield and fluorescent channels, thus they only provide strain/force measurements or 
calcium/voltage measurements17. Additionally, many of the systems only examine beat velocity and do 
not provide quantitative information about the cells contractility over time14, 17.  
Once we had defined a system to measure contractility we focused on defining the seeding conditions 
necessary to seed hPS-CM onto fibrin microthreads. We found that a collagen IV protein coating assisted 
hPS-CM attachment and that hPS-CM were capable of contracting on the microthreads. We then applied 
HDM to high speed (60fps) videos of hPS-CM contracting on the fibrin microthreads and characterized 
their contractile behavior, in terms of contractile strain, maximum strain, and beat frequency, over 21 
days in culture. In terms of beat frequency, both cells on TCP and fibrin microthreads increased beat 
frequency over 21 days and up to physiologically relevant levels, a finding similar to other groups18, 19. 
Contractile strain and maximum strain were found to decrease over 21 days for hPS-CM seeded on TCP. 
hPS-CM seeded on fibrin microthread exhibited an opposite trend, where contractile and maximum 
strains increased over 21 days. By day 21, hPS-CM on fibrin microthreads produced maximum strains 
around 18%, which is near the strains found in ventricular myocardium (19%) suggesting that the cells 
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seeded on the microthreads are capable of contracting on a level found in vivo20. Over 21 days in culture 
it was found that cell contraction direction aligned more to the thread, suggesting that as these cells 
contract in a direction more aligned with the microthreads they are able to produce higher strains. Using 
the calcium transient activity we were able to calculate the conduction velocity of hPS-CM seeded sutures 
and found that conduction velocities increased over time. While the conduction velocity values were half 
of what is found in human ventricular myocardium, the values we reported are similar to other groups 
who are creating engineered cardiac tissue21. These findings suggest that the fibrin microthread is a 
suitable scaffold for hPS-CM attachment and contraction and that extended culture promotes cell 
alignment along the length of the suture as well as improvements in contractile function in terms of 
contractile strain and conduction velocity. 
In the final aim of this dissertation we utilized the fibrin suture to deliver hPS-CM to healthy 
myocardium and examined cell retention at 1 hour to 3 days post-delivery. We demonstrated that after 1 
hour post-delivery hPS-CM were delivered with a 67% delivery efficiency, an exciting finding as this 
matches very closely to the 64% delivery efficiency we found with hMSCs. However, when we examined 
retention after 8 hours and out to 3 days post-delivery we found that retention had significantly 
decreased. In order to determine why the cells were not being retained at later time points we developed 
an in vitro assay to simulate the conditions of delivery and examine at apoptosis. We demonstrated that 
the conditions of bringing cells to the OR as well as the delivery of cells through a gel increased the number 
of cells that were either undergoing apoptosis or were already dead as confirmed by Annexin V and 
Propidium Iodide staining. These results help elucidate the finding of reduced cell retention after the initial 
1 hour delivery period. While these results were unexpected, they are certainly not unprecedented with 
what has been demonstrated in literature. Many studies delivering hPS-CM to cardiac tissue have 
reported decreased cell retention within a couple days after delivery to a month after delivery22-24. While 
cell retention was decreased over time, these studies still indicated improvements in function post-infarct. 
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This would suggest that the cells are having a larger paracrine effect than integrating with the damaged 
tissue to contribute to active mechanical function that is lost post-infarct. 
8.2 Future work  
In this dissertation, we demonstrated that delivering hMSCs to a rat infarct model have the ability to 
improve regional function. We chose to only examine function 1 week after the infarct was created and 
the cells were delivered. We chose this time point to look at any acute functional effects the therapy 
imparted; however, many rodent studies delivering cells chose to examine function out to 1 month after 
infarct creation as remodeling is mostly complete by this time point in a rat model25. In future studies it 
will be important to examine function at longer time points to understand how the delivery of cells will 
impact function at later time points. The fibrin suture will degrade over time in the myocardium; however, 
we demonstrated that cell loaded sutures preserved the area of suture compared to unseeded sutures. It 
is then possible that the retention of the biomaterial in the infarct had an impact on function over the 
cells alone. By examining function out to 1 month the fibrin suture should be completely degraded and 
we would have a better understanding of functional outcomes without the prolonged presence of the 
biomaterial. In addition to functional benefits, more work could be done at the tissue level to understand 
the role of inflammation and angiogenesis, utilizing immunohistochemical techniques, at both the one 
week and one month time points. This would provide more information on how the hMSCs are functioning 
in the infarct environment and how they and the fibrin suture are resulting in improvements in function 
in terms of modulating inflammation and driving angiogenesis.  
For the studies utilizing hPS-CM, we demonstrated that the cells align along the suture and that 
contractile strains increase over 21 days. The cells seeded on tissue culture plastic did not have any 
dominate alignment and decreased strains over 21 days. It is possible that the stiffness differences alone 
led to the ability for the cells to generate greater strains on the fibrin microthreads over the very stiff TCP. 
While studies suggest that cells in an unaligned fibrin gel are not capable of generating higher strains and 
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that aligned softer substrates are more contractile, it remains important to examine the cells temporal 
contractile function in a softer environment26, 27. We chose to utilize collagen IV coated TCP as controls 
for our experiments, however a fibrin gel may have been a more relevant choice to examine functional 
contraction of the hPS-CM. Thus future studies will look at temporal changes in hPS-CM function when 
seeded in a fibrin gel.  
While we demonstrated that the hPS-CM were capable of aligning along the microthread and increasing 
contractile strain and conduction velocities over 21 days we did not see any changes in Connexin 43 
localization. In a mature adult cardiomyocyte Connexin 43 is polarized to the intercalated discs to allow 
for faster cardiac conduction. Many studies utilizing hPS-CM have suggested that hPS-CM are a relatively 
immature cell type in terms of sarcomere length, Connexin 43 localization, electrophysiology, and force 
production among other markers of maturity28, 29. One of the challenges within the field of regenerative 
medicine to utilize hPS-CM to their full potential is to create culture methods to mature hPS-CM. Studies 
have indicated that substrate stiffness, ECM incorporation, alignment, time in culture, and electrical and 
mechanical conditioning can mature hPS-CM16, 30-33. Future studies could use the fibrin suture as a 
maturation platform by integrating cardiac ECM into the suture, providing electrical and mechanical 
conditioning and examining functional maturation over time.  
One of the challenges of working with pluripotent stem cell derived cardiomyocytes is the batch-to-
batch variability that may occur due to the starting cell line or how the cells are differentiated. The 
differentiation process is a very sensitive process that even with the best, controlled methods can still 
lead to differences in differentiation efficiencies. It is possible that these changes in differentiation 
efficiencies can then affect how the cells respond out of cryopreservation in terms of viability, how they 
reattach to substrates, and how well they function. Thus, it will be important in future studies to ensure 
that similar levels of viability, attachment, and function are demonstrated with multiple batches. 
Additionally, it will be interesting to examine the effect of cryopreservation on cell attachment and 
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viability by examining freshly differentiated and dissociated cells from cells that came out of 
cryopreservation. We can repeat many of the same experiments done in objective 2a to determine the 
effects of different batches of cells as well as freshly dissociated cells on cell attachment, viability, and 
function. In order to truly consider stem cell therapy for myocardial infarction treatment it is necessary to 
create a highly controlled process that produces the same results time after time without having 
fluctuation in cell performance using different batches of cells.  
In this dissertation we demonstrated that the fibrin suture was capable of delivering hPS-CM to healthy 
cardiac tissue with a 67% delivery efficiency, very similar to that found for delivering hMSCs. While this is 
an exciting finding, when we examined retention at later time points we saw a decrease in the number of 
cells retained by 3 days. By using an Annexin V in vitro delivery assay we demonstrated that viability for 
the cells was low after simulated delivery conditions. Thus, future studies will need to address this issue 
and improve cell viability. Methods for improving cell viability could incorporate improving cell 
attachment as well as heat shock or treating with a type of pro-survival cocktail as has been done is 
previous studies delivering this cell type to myocardial tissue3, 34. Once the issue of cell viability is resolved 
and we have a system in place to ensure sustained cell retention, we can then begin delivering these cells 
to an infarct model. The rat infarct model is not an ideal model to study the regenerative effects of hPS-
CM due to the large mismatch in beating rates (60 vs 400 bpm). Thus, larger animal models such as a 
rabbit or guinea pig, which have slower heart rates, could be used to examine how the delivery of hPS-
CM seeded fibrin sutures affect functional regeneration post-infarct.  
 In order to use a larger animal model several questions regarding the delivery of the microthreads 
need to be addressed such as the number of threads that would be delivered. Larger animals have larger 
hearts than rats and thus higher numbers of cells delivered via more microthreads could be used in those 
systems. The number of microthreads that could be delivered could be determined by direct scale 
differences between the rat and the larger animal model, such that if a pig heart is five times larger than 
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a rat heart then five times more threads could be delivered. However, we have not examined the 
functional impact of the delivery of more than one suture to the ventricular myocardium of a rat and it is 
possible that the myocardium can support the delivery of more than one suture. Thus, future studies 
could be completed to examine the functional impact of delivering multiple sutures, as well as modulating 
the number of threads incorporated into the suture, to the rat heart and use the results to better inform 
how to scale up the technology for use in larger animal models. Additionally, future studies should take 
into consideration the depth into and length along the ventricular myocardium that the suture can 
penetrate in a larger heart. Finally, for true clinical translation a catheter based delivery system should be 
developed to allow the sutures to be delivered into the endocardial wall using a catheter lab instead of 
relying on using open heart surgery techniques for epicardial suture placement and cell delivery.  
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9 Appendix  
9.1 Reprint Permissions 
 
Reprint permission for work included in chapters 3 and 4, from the publisher’s website: 
“BioResearch Open Access publishes articles under the liberal CC-BY license. This means that articles can 
be freely redistributed and reused by the author and others as long as the article is properly cited. Published 
articles in BioResearch Open Access can be deposited immediately into an online repository or social 
network without an embargo. BioResearch Open Access articles can be emailed to colleagues, printed, 
archived in a collection, included in course-packs, and distributed without restrictions. Please read the 
full Creative Commons license for further information.” 
 
Reprint permission for work included in chapter 5: 
 
 
 
9.2 Protocols 
Protocols listed here: 
1.2.1. Seeding fibrin sutures with hMSCs 
1.2.2. Masson’s Trichrome 
1.2.3. Cardiac regional mechanics using HDM 
1.2.4. GCaMP Scope /GCaMP analysis 
1.2.5. Contractile strain analysis using HDM 
1.2.6. Seeding fibrin threads with hPS-CM  
1.2.7. Ku80 staining, Alpha-actinin and Connexin 43 
1.2.8. Annexin V assay 
9.2.1 Protocol for seeding fibrin sutures using rotator method 
Materials: 
• Sterile thread-bundle in Bioreactor 
• Sterile PBS 
• Sterile 1 mL syringe (3) 
• Cell Suspension (100,000 cells/100 µL or 50,000/100 µL, or 25,000/100 µL) 
• 50 mL vented conical tube 
• Tube rotator (fully charged!) 
Procedure: 
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1. Use a sterile syringe to inject sterile PBS into bioreactor (by attaching syringe to the already inserted 27G 
needle). 
2. Ensure all bubbles are eliminated from the bioreactor. 
3. Attach slide clamp and remove/discard syringe. (Keep syringe needle in the bioreactor). 
4. Allow 20 min for hydration 
5. While bundle hydrates prepare cell suspension according to cell passaging protocol 
6. Use new syringe to expel all sterile PBS from the bioreactor before seeding. For this, remove the slide 
clamp at the end opposite to the needle, draw air into a new sterile syringe and push the air into the 
bioreactor to expel all the PBS.  
7. Use a new syringe (1 cc maximum) to inject cell suspension into the bioreactor. For this, hold the 
bioreactor such that the open end of the bioreactor (one without slide clamp) remains elevated such that 
the cell suspension doesn’t spill out while being injected.  After 100 µL of cell suspension is injected into 
the bioreactor, close the end opposite the needle by sliding the clamp onto the tubing. 
8. After injecting the cell suspension and adding the slide clamp, remove the 27G needle from the 
bioreactor. 
9. Place the bioreactor into a gas permeable 50 mL conical tube. 
10. Place the bioreactor into the MACSmix tube rotator and rotate at 4 RPM (lowest setting) for 1-24 hours. 
For cells destined to be implanted make sure they are Quantum dot loaded 24 hours before hand. Sutures 
seeded for implants are seeded at a concentration of 100,000cells/100µL for 24 hour before implantation. 
 
9.2.2 Masson’s Trichrome staining 
Reagents: 
• Bouin’s Solution (sigma HT10-1-128) 
• Weigert Iron Hematoxylin 
o Solution A (sigma HT107-500mL) 
o Solution B (sigma HT109-500mL) 
o Working Solution: Mix equal parts of solutions A and B 
• Biebrich Scarlet-Acid Fuchsin Solution (HT151-250 mL) 
o 1% Biebrich Scarlet 
 Biebrich Scarlet-----2g 
 Distilled water ------198 mL 
o 1% Acid Fuchsin 
 Acid Fuchsin----------1g 
 Distilled Water-------99 mL 
o Working Solution: 
 1% Biebrich Scarlet ------180 mL 
 1% Acid Fuchsin ----------20 mL 
 Glacial acetic acid--------2 mL 
• Phosphomolybdic/phosphotungstic Acid Solution 
o Working Solution: 
Using Solutions: 
 1 Part Phosphomolybdic acid solution (HT156-250 mL) 
 1 Part Phosphotungstic acid solution (HT152-250 mL) 
 2 Parts Distilled Water 
-----or------ 
Using Powders: 
 Phosphomolybdic acid ----------5g 
 Phosphotungstic acid -----------5g 
 Distilled Water --------------------200 mL 
• Aniline Blue Solution 1% 
o Aniline Blue----------------5g 
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o Glacial Acetic Acid-------4 mL 
o Distilled Water-----------200 mL 
• Acetic Acid Solution 1% 
o 1 mL: Glacial Acetic Acid 
o 99 mL: Distilled Water 
 
For frozen sections: 
1. Rinse slides in distilled water (5 mins) 
2. Mordant the sections in Bouin solution for 1 hour at 60 degC 
3. Remove slides from oven, wash in running water (10min)  
4. Stain sections in Weigert hematoxylin for 10 minutes Discard solution 
5. Wash in warm running tap water for 10 minutes 
6. Stain sections in Biebrich Scarlet-Acid Fuchsin Solution for 10 minutes Reuse solution 
7. Rinse in distilled water (2 minutes) 
8. Place slides in Phosphomolybdic/phosphotungstic acid solution for 10 minutes, Reuse solution 
9. Stain sections in aniline blue solution for 10 minutes. (Increase time for greater blue color) Reuse solution 
10. Rinse slides in running water 2 minutes 
11. Place slides in 1% acetic acid solution for 5 minutes. Discard this solution 
12. Dehydrate through graded alcohols, clear in two changes of xylene and mount with cytoseal 
 
Results: 
Nuclei: Black 
Collagen and Mucus: Blue 
Cytoplasm, Keratin and Muscle fibers: Red 
 
9.2.3 High density mapping for regional cardiac function analysis 
All raw images should be saved in raw data folder under the experiment number for the animal (Eg Exp0404). All 
images and pressure files should be saved in a separate data set folder under the Experiment folder (Eg 
Exp0404_ds1). 
1. Open matlab under the Gaudette lab analysis environment (Session start is saved in projects under ~GCE 
folder and labeled GCE_sessionstart) 
2. Open to projects and the folder of the experiment you are analyzing 
3. Batch your tiffs into avis  
a. tiff2avi_batch([],250,250,20, 11) 
b. 250= frame rate and sample rate 
c. 20 = output frame rate 
d. 11=the minimum number of tiffs in the folder to run the avi function 
e. You will have to self-select the folder, by using the batch function you can select all data sets 
within one experiment and matlab will create avis for all of them 
4. Name your dataset 
a. ‘Exp0404ds1’ 
b. This names the data set you want to analyze 
5. Run heart mechanics code 
a. Heart_mechanics(ds, [beatgroups] , ‘camera’, ‘fastcam’) 
b. Beat groups = ]1, 2, 3, etc]…you will have to watch the video and select which beats you want to 
analyze. Don’t analyze beats with a lot of movement/when the animal is breathing. 
c. Only need to use ‘camera’ and ‘fastcam’ if you are analyzing videos taken with the old camera 
d. In this analysis function the automatic settings are subimage: 32, shift: 16 and roi: poly 
e. You will have to self-select the dataset folder where the tiff images are stored 
6. Once the figure comes up…select the region you want to analyze, then close the region, then close the 
figure 
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7. Matlab will run the analysis and will output all data (SAC, RSW, pressure, heart rate etc) into a 
‘heart_summary’ spreadsheet and will continue to add to it per data set you analyze 
9.2.4 Dual imaging scope/setup parameters and analysis 
Use the following specifications for 142 fps: 
• Bin 2 
• 1024x512 
• Pulse: 2 
• Exposure: 7ms 
1. Turn on camera (Hamamatsu orca flash 4) 
2. Turn on scope- in the back 
3. Turn on power bar – powers LED and digital controller 
4. Turn on fluorescence (camera (-), fluo (+)) 
5. Open micromanager 
  Make sure correct program is loaded (100fps program…) 
6. Go to device property browser in micromanager (under tools) 
 change to “programmable” (DCAM- output trigger) Trigger output 1-0.5us 
 make all polarity negative 
 
To change the region of interest…go live…then hit expand…then stop live…and drag the square all the way to the 
right and left…then go live again. Do all of this in Bin 1 and then change to Bin 2. 
 
For GCaMP analysis 
All videos taken will be saved as tiff stacks and inn order to use them you need to make substacks and separate 
out the tiffs. 
 
1. Split stacks into substacks. Drag stack into ImageJ 
 Image – stacks- tools – make substack 
If you have 1000 frames…do 1-1000-2….then next substack will be 2-1000-2 (this will separate out every other 
frame starting at 1 or 2) 
 
2. Open brightness and contract dialogue in ImageJ (Image – adjust – brightness/contract). Adjust brightness and 
contrast by sliding the frame slider to the brightest point and hit ‘auto’ on brightness/contract dialogue.  
3. Change to an 8 bit file type  
Image – type- 8 bit 
Hit Apply on Brightness/contract 
4. Save substack in a new folder (label one brightfield, label one fluo) 
 
In matlab: 
 
1. Split the stacks into tiffs 
 split_tiff_stack (‘name’, [], [0 1]) 
2. Run HDM on the brightfield images. 
 Pull rawhdm.mat file (under matlab folder) into the workspace to define the ROI for the GCaMP analysis. 
 
GCaMP analysis 
Run: gcamp_intensity2 (ds, roi, and x: y) 
 x:y eg 5:20- frames…they don’t matter at all, just pick random numbers 
Outputs are an intensity.xlsx spreadsheet which does DeltaF/Fo 
 
GCaMP heatmap production 
1. Run: edit gcamp_intensity2 
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2. hit debug at line 102 – this is at the end of intensity heatmap section, imwrite… 
3. Run:  gcamp_intensity2 (ds, roi, and x: y) 
 If done correctly, a bunch of variable should pop up in the workspace 
4. Run: colormap (jet), imagesc (perinc) 
 Your heatmap should come up as a figure…save this figure 
5. To change the scale and remove the border… 
run: set(gca, ‘position’, [0 0 1 1], ‘units’, ‘normalized’) 
 to scale down to ex. 1125x512 …. [0 0 0.46875 0.2843] 
6. Save 
 run: print (‘name’, ‘dtiff’, ‘-r300’) 
saves to your working directory 
 
9.2.5 High density mapping for contractile cell analysis 
All raw images should be saved in raw data folder under the experiment number for that cell thaw (Eg Exp4158). 
All images should be saved in a separate data set folder in a separate day folder (Eg D7) under the Experiment 
folder explaining the conditions examined (Eg Exp4158_thread1_1). 
1. Make tiffs into AVIs 
a. Save under projects folder 
For single AVIS use 
 tiff2avi (ds, record rate, sample rate, output rate) 
  eg. tiff2avi (ds,60,60,30) for 60 fps 
For batch code 
 tiff2avi_batch ([], record rate, sample rate, output rate, min tiffs) 
  eg. tiff2avi_batch ([], 60, 60, 30, 11) 
It will have you self-select the folder (in raw images) that contain the tiffs you want to make into 
avis 
2. If you need to split the tiffs use: 
a. split_tiff_stack (‘name’, [], [0 1]) 
i. 0 and 1 control for brightness 
3. Define your data set which is whatever the folder name is that you are analyzing 
4. **Run HDM 
a. hdm2(ds, frame rate, frames to use, subsize, shift) 
b. Eg hdm2(ds, 60, 3:500, 16, 8) 
c. It will have you self-select your folder (in raw data) that contains the tiff images you want to 
analyze  
d. **make sure you are analyzing in projects** 
5. To output to excel 
a. hdm2_avgstrain(ds,1) 
6. to rezero 
a. hdm2_cyclicstrain(ds, ‘E2’, ‘maxfreqmaxs’) 
i. this rezeroes it to your E2 strain 
7. For heatmaps 
a. hdm2_strainfield_beatavg(ds, resolution, ranges, scale, color) 
b. eg hdm2_strainfield_beatavg (ds, 5, {6:12, 40:47…}, [-0.1 0.1], ‘-jet’) 
i. always use 5 as your resolution if you use a 16, 8 subimage and shift 
ii. ranges are the zero to peak frame #s of a contraction 
iii. scale is the strains you want to visualize between (eg -10 and 10% = [-0.1 0.1] 
iv. color is the color map that will be output…’-jet’…blue is not contracting, red is 
contraction (for E2) 
8. to quantify strain values 
a. open heatmap folder…open beat avg folder…drag strain.mat into the workspace 
i. e2=straindata.E2 
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ii. Ic=e2<-0.05 (this is your “noise” threshold value…aka less than 0.5% strain) 
iii. mean(mean(e2(Ic)) this is your avg strain aka Contractile strain 
iv. min(e2(Ic)) this is your maximum contractile strain 
9. to find the percentage that the region is contracting 
a. percentcontract(threshold, straindata)  
i. eg percentcontract(-0.05, straindata.E2) 
Here E2= contraction 
E1= relaxation 
 
**for batch HDM analysis 
1. Have all your folders that you want to analyze in one master folder 
2. Hdm2_batch([], frame rate, subimage size, shift) 
a. It will have you self-select the folder that contains all folders with the tiffs you want to analyze. 
Just select all the folders and hit okay 
b. It will then analyze the folders and bring up the first images of each folder one by one 
c. Select the region of interest you want to analyze, close the region, then close the image…it will 
then bring up the next image… 
Then analyze folders for excel/quantifying as described above 
 
9.2.6 Protocol for seeding microthreads with hPS-CM 
Materials: 
• Sterile thread construct in 6 well plate with coating platform (sterilize using ETO) 
• Extra 6 well plate with seeding platform 
•  Sterile PBS 
• Sterile forceps 
• Cell Suspension (200,000 cells/150 µL) in 50ug/mL Aprotinin supplemented RPMI-B27 media +10% FBS + 
1% Rock inhibitor (Sigma, Y0503, 1mg) 
Procedure: 
11. Add 2 mL of sterile PBS to each 6 well that had a thread construct 
12. Allow 20 min for hydration 
13. While threads hydrate prepare your ECM coating solution 
a. Typically use Collagen IV (10ug/mL) 
14. Use sterile forceps to place construct on the coating platform making sure all threads are draped across 
the coverslip 
15. Add 150uL of Collagen IV solution onto coverslip ensuring all solution stays on the coverslip 
a. Also prepare a control 96 well plate with just cells (150,000 cells/cm2) 
16. Keep in biosafety cabinet for 2 hours 
17. During the coating period prepare your cell suspension by thawing a vial of cells and reconstituting in 
Aprotinin supplemented RPMI-B27 media 
18. Move constructs from coating platforms to seeding platforms 
19. Add 150uL of cell suspension to each thread construct 
20. Place the constructs with cell suspensions into the incubator at 37C with 5% CO2 for 18 hours 
21. After 18 hours, carefully remove constructs from seeding platform and place in a new 6 well plate with 1-
2mL of Aprotinin supplemented RPMI-B27 media, enough to cover all the threads 
22. Change media every 2-3 days 
9.2.7 Ku80, Alpha-actinin, and Connexin 43 staining  
Reagents 
• 5% Normal Donkey Serum 
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• In 5% donkey serum - primary 
o Rabbit monoclonal anti-Ku80 nuclei 1:250 (Abcam ab80592) in your blocking agent 
o Mouse anti-sarcomeric alpha actinin 1:100 (Abcam 9465) in blocking agent 
o Goat anti-connexin 43 1:100 (Abcam 87645) 
• In 5% donkey serum - secondary 
o 1:400 donkey anti-rabbit Alexa Fluor 488  
o 1:400 donkey anti-goat Alexa Fluor 568 
o 1:400 donkey anti-mouse Alexa Fluor 647 
• Hoechst 
o 0.0167% Hoechst dye in PBS 
o 0.5ul in 3000ul PBS 
Double boil antigen retrieval: 
1. Thaw slides in DiH20 
2. 2. Add 70ml DiH20 + 656ul vector antigen  to a big coplin jar 
3. Place coplin jar in a beaker with 400ml of DiH20 
4. Head to 95-98C without boiling 
5. Add slides and leave for 30 minutes 
6. Remove from heat for 20 min  
7. Resume staining 
Procedure (for fixed tissue samples) 
1. Thaw tissue in PBS 5 minutes (or after antigen retrieval)  
2. 0.25% Triton-X-100 10 minutes 
3. 3 washes PBS, 5 minutes each 
4. Block with 5%  Normal Donkey Serum  45 minutes 
5. Leave serum on negatives but aspirate serum off the positives 
6. Primary 1 hour room temp 
7. 3 washes in PBS, 5 minutes each 
8. Secondary antibody 1 hour at room temperature in the dark 
9. 3 washes PBS, 5 minutes each 
10. Hoechst – 1:6000 in PBS, 5 minutes 
11. 3 washes in PBS, 5 minutes each 
12. Coverslip 
Results: 
Human Nuclei: Green  
Alpha-actinin: Far red – have to use confocal to visualize  
Connexin 43: Red 
Nuclei: Blue 
 
9.2.8 Annexin V Assay 
Make Fibrin gels 1. Thaw fibrinogen (70mg/mL standard) and thrombin (250U/mL – have to make) 2. Add 500uL of fibrinogen to an embedding cassette then add 500uL of thrombin (100uL of 250U/ml 
thrombin + 425uL of 40mM CaCl2). Add quickly and carefully avoiding air bubbles 3. Let gels polymerize for 30 minutes 
*Don’t need to do aseptically…but you can filter both thrombin and fibrinogen using a 0.22um filter prior to gel 
formulation 
 
Annexin V staining 
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Prepare 1X Annexin-binding buffer. For example, to make 1 mL 1X buffer, add 200 µL 5X Annexin-binding buffer 
(Component C) to 800 µL deionized water. 
 
Protocol: 
1. Induce apoptosis using 10mM Staurosporine (Billiar lab) in cells cultured on TCP. Prepare a negative control by 
incubating cells in the absence of the inducing agent. 1 hour 
2. After the incubation period, wash the cells in cold PBS. 
3. Aspirate PBS and add 1X Annexin-binding buffer.  
4. Prepare a 100 µg/mL working solution of PI by diluting 5 µL 1 mg/mL PI stock solution (Component B) in 45 µL 
1X Annexin-binding buffer.  Store the unused portion of this working solution saved for future experiments 
5. Add 10µL of the Annexin V conjugate (Component A) and 1.5µL of the 100 µg/mL PI working solution 
(prepared in step 4) to each 100 µL cells in media.  
6. Incubate the cells at room temperature for 15 minutes. 
7. Wash the cells with 1X Annexin-Binding buffer. 
8. Observe the fluorescence using appropriate filters 
9. Fix using 4% PFA for 10 minutes 
 
The cells should separate into three groups: live, apoptotic, and dead. Live cells show only weak Annexin V 
staining of the cellular membrane, while apoptotic cells show a significantly higher degree of surface labeling. 
Dead cells show both membrane staining by Annexin V and strong nuclear staining from the Propidium iodide. 
 
 
 
